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Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is still a global health prob-
lem of immense proportion. Indeed, TB is considered the second most frequent cause of 
infectious disease-related death worldwide (after HIV-aIDS). The world Health Organization 
(wHO) is increasing its efforts to reduce the global threat of TB. nevertheless, the morbidity 
and mortality statistics for TB remain shocking. For example, the wHO estimates that the 
global burden of disease caused by TB in 2010 comprised 8.8 million incident cases, including 
1.1 million deaths from TB among HIV-negative individuals, and an additional 0.35 million 
deaths from HIV-associated TB.1
additional to these impressive figures is the underlying problem of latent TB infections, with 
as many as one-third of the world’s population being thought to be latently infected with 
this bacterium, an immense pool of potential patients around. Further, all current treatment 
programs tend to be specifically aimed towards the treatment of active TB infection, leaving 
the huge underlying problem of latent TB infections untouched, essentially meaning that the 
worldwide elimination of TB is still a distant dream.
The diagnosis of TB can be complex and challenging. Differentiating between latent TB 
infection and active TB is of vital importance, though not always easy for the clinician. The 
tools available for diagnosing TB infections are diverse and available in several different 
combinations. First and most important remains the direct detection of Mtb in sputum and 
other fluids, for example via the microscopic determination of bacilli, bacterial culture, or 
amplification of Mtb-specific genes, which are considered the “gold” standard techniques for 
TB diagnosis. Secondly, diagnosis can be made via the recognition of TB in terms of disease 
presentation e.g. patient anamnesis or chest radiography, or the detection of a TB-specific 
host immune response e.g. the tuberculin skin test (TST) or interferon gamma (IFn-γ) release 
assays (IGRa). Both TST and IGRa are based on detection and recognition of Mtb antigens by 
cells of the immune system and a subsequent immune response. unfortunately, one major 
limitation of the use of gold standard techniques for TB diagnosis is that these tests may take 
as long as 6 weeks to produce a result. This means that more rapid TB detection is urgently re-
quired in order to begin effective treatment as soon as possible. Several studies are currently 
ongoing to try to identify and validate biomarkers for the detection of active TB infection, 
among which IFn-γ (detected via the IGRa technique) is one of the most promising potential 
biomarkers. all these efforts to make a correct diagnosis are most important because if left 
untreated, TB can be a fast developing, lethal infection. However, it should be remembered 
that the treatment of TB is lengthy, complicated and not without side-effects, such that anti-
TB therapy should ideally only be given to those who need it.
The current six-month standard treatment of TB, as recommended by the wHO, and incor-
porated into numerous national and international guidelines, consists of an initial phase 
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of therapy which is then followed by a continuation phase of treatment.2 During the first 
two months (initial phase), the first-line anti-TB drugs; isoniazid, rifampicin, ethambutol 
and pyrazinamide are administered, whereas in the subsequent four months (continuation 
phase) only isoniazid and rifampicin are prescribed.
The mode of action of the anti-TB drugs is (in short); isoniazid inhibits the synthesis of mycolic 
acid, a component of the mycobacterial cell wall; rifampicin inhibits bacterial Dna-dependent 
Rna synthesis; ethambutol acts by obstructing the formation of the cell wall; pyrazinamide 
inhibits the enzyme fatty acid synthase, required to synthesize fatty acids.
Isoniazid, in the multidrug combination therapy, is regarded as the most potent drug avail-
able in reducing Mtb load and acts primarily by killing extracellular Mtb.3-4 The extraordinary 
killing capacity of isoniazid is clearly demonstrated by its high early bactericidal activity 
(EBa).5 In fact, the bacterial load is dramatically reduced in the first days of isoniazid treat-
ment, greatly decreasing the risk of selecting resistant bacteria. Rifampicin and pyrazinamide 
become more effective in their bactericidal activity after the first few days of therapy. The 
major role of rifampicin is to “sterilize” the infected tissues, helping to ensure that persistent 
(low active / slow dividing) Mtb is killed. These persistent Mtb are considered to be respon-
sible for relapses in infection, thus requiring lengthy duration of treatment to eliminate all 
infecting Mtb. The role of ethambutol is to prevent selection and/or growth of drug-resistant 
Mtb at the start of TB treatment when the susceptibility pattern of the infecting Mtb is still 
unknown and there exists the possibility of Mtb resistance to isoniazid, rifampicin or pyrazin-
amide. Once it is known that the Mtb is susceptible to isoniazid, rifampicin and pyrazinamide, 
the ethambutol can be stopped, since its use is then of no added value in the killing of a 
susceptible Mtb.
In cases of single- or multidrug resistance of Mtb towards the first-line anti-TB drugs, an alter-
native to the standard treatment regimen is required. These alternative treatments comprise 
a combination of any of the still active first-line anti-TB drugs, combined with additional 
second- or even third-line anti-TB drugs. among the second-line anti-TB drugs are: amino-
glycosides (e.g. streptomycin, amikacin or kanamycin), fluoroquinolones (e.g. moxifloxacin 
or levofloxacin), thioamides (e.g. ethioamide), para-aminosalicylic acid and polypeptides 
(e.g. capreomycin). The most prominent drugs in the group of third-line anti-TB drugs are 
linezolid, clarithromycin, amoxicillin-clavulanic acid and clofazimine. These anti-TB drugs are 
classified as second- or third-line choices of TB therapy rather than standard treatments per 
se, the reasons for this being the fact that; 1) there is (still) insufficient clinical experience 
when using these antibiotics; 2) these drugs possess a less potent pharmacokinetic profile 
in comparison to first-line drugs; and/or 3) there is an increased incidence and severity of 
adverse events or toxicity by these drugs.6 Crucially, as a consequence of the increased 
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treatment duration and expenses of these second- and third-line antibiotics, the total cost 
of treating multidrug resistant Mtb (MDR-TB) exceeds the costs of treating drug-sensitive TB 
therapy by 30-40 fold.7 It is clear that second- and third-line anti-TB drugs are only indicated 
when there is proven resistance towards first-line drugs.
attempts to realize shortening of treatment duration are of high importance as this will 
improve patient compliance and thereby reduce the risk of resistance selection. There is also 
an urgent need for new drugs that will enable (more effective) treatment of drug-resistant 
TB. Fortunately, after a gap of several years, there are currently several new promising anti-TB 
drugs in development.8 Currently, a promising anti-TB drugs is moxifloxacin, one of the newer 
fluoroquinolones. although at present not (yet) officially registered as a first-line anti-TB 
drug, moxifloxacin is already a prominent drug in the treatment of (MDR-) TB. Moxifloxacin 
is currently undergoing evaluation in a phase III trial, where its capacity as a replacement 
for either ethambutol or isoniazid in a first-line treatment regimen is being investigated. 
aim of these studies is to shorten treatment from 6 to 4 months.8-10 a second novel drug 
under development is called TMC207. TMC207 is a mycobacterial adenosine triphosphate 
(aTP) synthase proton pump inhibitor. Due to its unique mode of action of TMC207 on Mtb, 
no cross-resistance is expected. In vitro assays and in vivo models using this new drug have 
shown promising results.11-12 Other new drugs that are under investigation for the treatment 
of (MDR-) TB include; SQ-109 13, Pa-824 14-15, and Pnu-100480 16. However, even with the even-
tual introduction of these newly developed drugs, there will still be room for improvement 
in the use of the current range of anti-TB drugs. For example, the currently used therapeutic 
dose of rifampicin (10 mg/kg) may not actually be optimal for killing Mtb, and studies explor-
ing the use of higher dosages of rifampicin, or the use of rifamycin derivatives, are ongoing.17 
ultimately, the aim of all of these studies is to shorten TB treatment duration from 6 to less 
then 4 months.8-10 all of these new treatment approaches are extremely important in helping 
prevent the spread of (MDR-) TB. unfortunately however, more time, effort and funding are 
required before these new drugs become available to those who desperately need them, 
especially relevant for those individuals suffering from TB in poorer regions of the world.
The emergence of drug-resistant Mtb has greatly increased in the last decade 1, 18, with sev-
eral drug-resistant phenotypes now circulating globally. Multidrug resistant TB (MDR-TB) is 
defined as resistance to isoniazid and rifampicin, while extensively-drug resistant TB (XDR-TB) 
is defined as being resistance to both isoniazid, rifampicin, as well as additional resistance to 
at least one of the fluoroquinolones and at least one of the second-line injectable agents (e.g. 
aminoglycosides such as amikacin, kanamycin or capreomycin). Recently also, totally-drug 
resistant TB (TDR-TB) has been described in India. 19. Each of these different levels of resis-
tance have a dramatic effect on the expected therapeutic outcome of different antimicrobial 
treatment regimens.18.
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In fact, several factors promote the development of resistance to anti-TB drugs, including 
factors associated with patient therapy per se, and factors associated with the infecting Mtb 
genotype strain. The factors promoting the development of Mtb resistance and associated 
with individual patient therapy include: the unregulated availability of anti-TB drugs; unpro-
fessional prescribing practices, patient non-compliance; malabsorption of the anti-TB drugs; 
and inter-individual variability in the pharmacokinetics of anti-TB drugs. However, the extent 
of involvement of each of these various factors, or combinations of factors, in determining 
the selection of resistant Mtb isolates and the accompanying emergence of resistant TB is 
not well understood, though patient non-compliance is considered to be one of the leading 
factors.1, 20-21 Besides these different factors on the host side contributing to drug-resistance, 
there are also factors on the mycobacterial side that drive the development of drug-resistant 
Mtb. It is known that different Mtb genotype strains can exhibit different degrees of virulence, 
22 and that different genotype strains are particularly associated with treatment failures.23 For 
example, TB infection caused by the Beijing Mtb genotype strain is strongly correlated to the 
development and transmission of MDR-TB and even XDR-TB.24-27. The mechanism by which 
this Mtb genotype-associated resistance is regulated is unclear. Interestingly in this respect is 
also the geographical distribution of different genotype strains, since the majority of MDR-TB 
is currently found in the Former Soviet union States (FSu) and in asia.1.
a wide range of in vitro assays is currently used to elucidate the different mechanisms of Mtb 
resistance against anti-TB drugs. The frequently used assays, including the Minimal Inhibi-
tory Concentration determination (MIC) and Mycobacteria Growth Indicator Tube (MGIT, BD 
BaCTEC MGIT 960 System) assays, provide endpoint data that are obtained only after several 
weeks of Mtb exposure to anti-TB drugs; in addition these tests only determine the inhibi-
tion of Mtb growth.28 In comparison, the Time-kill kinetics assay used in the present thesis is 
performed over a 6-day period and is more informative with respect to the concentration-
dependent or time-dependent activity of anti-TB drugs, whilst also determining the killing of 
Mtb.29 another assay, the Hollow Fiber Model, allows investigation of the dynamics of drug 
activity by simulating the fluctuating drug concentrations likely to be achieved during anti-
biotic therapy in TB patients.30 additional to these in vitro assays, which investigate the action 
of drugs acting on extracellular Mtb, there are also assays available using in vitro macrophage 
systems harbouring Mtb that also mimic the intracellular behaviour of Mtb,31. These assays 
add an extra therapeutic dimension to the analysis of the activity of anti-TB drugs.
One of the key (translational) steps in anti-TB drug development and research is the use of 
animal models, as these models represent a dynamic test system in which the therapeutic 
effect of anti-TB drugs can be measured, taking into account the biological availability of 
these anti-TB drugs as observed in patients. One of the major merits of using animal models 
is that these models enable comparative therapeutic studies at similar conditions of severity 
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and duration of infection, which is difficult to standardize in actual clinical patients due to 
their different underlying disease conditions. Several different animal models of TB infection 
have been developed including models using zebra fish, mice, rats, guinea pigs and monkeys. 
These animal models are diverse (with respect to costs and equipment required) and their 
predictive value for clinical trial outcomes is sometimes uncertain. Recently, several large 
research consortia, including the Critical Path to TB Drug Regimens and IMI joint undertaking 
entitled - “Model-based preclinical development of anti-tuberculosis drug combinations”, 
have been formed in order to compare the predictive value of different animal models. The 
limitations of animal models for research into human TB infection should also be emphasized. 
limitations include the artificial induction of infection, differences in bacterial virulence and 
immunological host responses, and differences in pharmacokinetics and toxic side effects of 
anti-TB drugs in experimental animals. as a result, comparative therapeutic studies in animal 
TB models may only serve as a basis for studies in TB patients. nonetheless, despite these 
limitations, animal models for TB are needed as they provide the only rational basis for the 
design of therapeutic clinical trials in TB patients.
In all, there is a need to further understand the selection of drug-resistant Mtb mutants 
and the mechanisms of development of drug resistance. also, more insight into the value 
of the new diagnostic tools might be helpful in restricting the burden of TB. ultimately, as 
the current treatment for TB is complicated by its length and complexity, which has led to 
inadequate response and emergence of MDR-TB and even XDR-TB, there is very urgent need 
for new powerful TB regimens and strategies to minimize mortality and/or morbidity of TB.
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OuTlInE Of ThE ThESIS
The aim of this thesis is to answer the following questions:
– what are the important factors that determine the translational value of an animal model 
of TB?
 In chapter 2, we describe, characterize and validate our mouse respiratory TB model, 
using Mtb strain H37Rv. In chapter 3, we discuss the role of the route of infection in 
influencing the course of murine TB and the observed therapeutic response. In chapter 
6, we describe the course of infection and therapy response in “relapse episode of TB” 
versus “primary TB”, in order to provide an insight into dissimilarities between those two 
infection types.
– what are the limitations of current TB diagnostics and are additional assays useful?
 Chapter 4 illustrates the difficulties of accurately diagnosing TB using a case of possible 
congenital transmission of Mtb. In chapter 5, the value of the Interferon Gamma Release 
assay (IGRa) in diagnosing active murine TB caused by H37Rv is determined, and the role 
of cytokines as potential biomarkers in TB is explored.
– which novel in vitro assays for the measurement of the dynamics of anti-TB drug killing 
activity and for selection of Mtb drug-resistance are more informative than currently used 
in vitro assays?
 In chapter 7, we show that the Time-kill kinetic assay is required to investigate the in vitro 
time- and concentration dependent killing activity of anti-TB drugs and the selection of 
drug-resistant mutants in Mtb H37Rv. In chapter 8, micro-array analysis is used to geneti-
cally characterize selected rifampicin-resistant Mtb mutants.
– Is a lower intrinsic susceptibility of Beijing genotype Mtb strains to anti-TB drugs corre-
lated to epidemiologically observed treatment failures and the emergence of resistance 
in TB?
 In chapter 9, we compare the in vitro activity of anti-TB drugs towards clinically rel-
evant Beijing genotype and East-african/Indian genotype Mtb strains. we focus on the 
measurement of mutation frequencies, the mutant prevention concentration, and the 
concentration-window within which only drug-resistant mutants are selected. In chapter 
10, two prominent Beijing genotype and East-african/Indian genotype Mtb strains are 
used to further develop murine TB infection models and to determine the impact of the 
infecting strain on the course of infection and on therapeutic efficacy, during treatment 
compliance and treatment non-compliance.
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– Can we improve the therapeutic efficacy of the current treatment regimen by optimizing 
the use of rifampicin?
 In chapter 11, we describe the effect of increasing dosage of rifampicin on its tolerability, 
pharmacokinetics and efficacy in a mouse model of TB caused by the Beijing genotype 
Mtb strain, and investigate the consequences with respect to the duration of therapy 
required in order to ensure successful treatment of TB.
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Immunological parameters to define 
infection progression and therapy response 
 in a well-defined tuberculosis model in mice
J.E.M. de Steenwinkel, G.J. de knegt, M.T. ten kate, a. van Belkum, H.a. Verbrugh, 
R. Hernandez-Pando, D. van Soolingen, I.a.J.M. Bakker-woudenberg
Int J Immunopathol Pharmacol. 2009; 22(3):723-34
ABSTRACT
To evaluate novel approaches for tuberculosis (TB) diagnostics and treatment, well-validated 
animal TB models are needed. Especially the emergence and spread of drug resistant TB 
requires innovative therapy and accurate parameters for monitoring success or failure of 
therapy.
we developed a TB model in BalB/c mice, in which Mycobacterium tuberculosis (Mtb) infection 
was induced through the natural respiratory route, mimicking human TB infection. The lung 
showed a mild inflammatory infiltrate consisting of granulomas in the first phase of infection, 
followed by progressive increase of pneumonic lesions resulting in extensive lung consolida-
tion in the chronic phase. Dissemination to the extra-pulmonary sites was observed. The model 
was validated in terms of therapeutic outcome. The 26-weeks standard therapy, administered 
in human pharmacokinetic-equivalent doses, resulted in complete elimination of Mtb in all in-
fected organs, without relapse of infection in the post-treatment period. However, a 13-weeks 
therapy duration, simulating patient non-adherence resulted in relapse of infection.
In our quest to find biomarkers for monitoring success or failure of therapy, the concentra-
tions of various cytokines in serum and lung, determined by the Cytometric Bead array (CBa), 
were evaluated in relation to the in situ cytokine expression in the lung, assessed by im-
munohistochemistry. The IFn-γ concentration in serum increased with infection progression, 
and decreased during effective therapy, and as such appeared to be an appropriate immu-
nological parameter for success or failure of therapy. Relapse of infection, after inappropriate 
therapy manifested as an increase in the serum IFn-γ concentration.
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InTRODuCTIOn
Tuberculosis (TB) remains one of the leading causes of morbidity and mortality worldwide, 
especially the middle- and low-income countries. about one third of the world’s population 
is currently (latently) infected with Mycobacterium tuberculosis (Mtb), of which nine million 
develop TB and almost two million die.1 Together with the increasing amount of TB-HIV 
co-infection and ever-increasing emergence of resistance to anti-tuberculosis drugs, TB 
constitutes a global threat. This prompted the world Health Organisation (wHO) to declare 
improved diagnosis and enhanced treatment of TB as one of their top priorities. One of the 
wHO’s millennium development goals is “to have halted TB by 2015 as well as reverse the 
incidence of TB”.2 In order to achieve this ambitious goal, there are many challenges among 
which the development of new anti-tuberculous drugs as well as rapid and low-cost diag-
nostic tests.2
For evaluation of innovative therapeutic approaches, in TB patients only a few parameters are 
available, including sputum smear, general clinical observations, chest X-ray and laboratory 
infection parameters. The value of cytokines in serum of patients to assess the progression 
of infection and the efficacy of anti-tuberculosis treatment in the first month of therapy was 
investigated in previous clinical studies.3-7 However, at present it is not yet clear whether im-
munological parameters in serum may be indicative in this respect and by that can possibly 
be useful markers.
In the present study, we developed an infection model of TB in BalB/c mice that resembles 
human TB. we induced the infection through the natural respiratory route, as such mimick-
ing infection in patients, and we started treatment when the infection had achieved a late 
progressive phase. anti-tuberculosis drugs currently used, were administered in human 
pharmacokinetic-equivalent doses 8 and treatment duration was identical to the wHO guide-
lines (26 weeks). To simulate patient non-adherence, a treatment regimen of only 13 weeks 
was applied. Efficacy of both treatment regimens was assessed at various intervals during 
treatment, as well as 13 weeks after termination of treatment, to evaluate potential relapse of 
infection in the post-treatment period. To characterize infection progression and to monitor 
therapy response microbiological, immunological and histopathological parameters were 
used. To recognize treatment failure at an early stage, which is of high importance from the 
clinical point of view, we investigated whether immunological parameters in serum are ap-
propriate for monitoring therapy efficacy. Therefore the concentrations of various cytokines 
in serum and infected lung homogenates were determined by the Cytometric Bead array 
(CBa), and evaluated with respect to the in situ cytokine expression in the infected lung, 
assessed by immunohistochemistry.
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MATERIAlS AnD METhODS
Bacteria 
The Mycobacterium tuberculosis (Mtb) strain used in this study was the H37Rv strain, kindly 
supplied by C.w. wieland (academic Medical Centre, university of amsterdam, The nether-
lands). The H37Rv strain is a clinical isolate and nowadays the strain most commonly studied 
in vitro as well as in animal models.9 Mycobacteria were cultured on Middlebrook 7H10 
agar medium [Difco laboratories, Detroit, MI] supplemented with 10% oleic acid-albumin-
dextrose-catalase enrichment [OaDC; Baltimore Biological laboratories, Baltimore, MD] for 
21 days at 37°C and 5% CO2. Mtb suspensions were prepared in Middlebrook 7H9 broth 
[Difco laboratories, Detroit, MI] supplemented with 10% OaDC, 5% glycerol [BDH labora-
tory supplies, Poole, England] and 0.05% Tween 20 [Sigma Chemical Co, St. louis, MO]. Vials 
containing Mtb suspensions were stored at -80°C.
Animals
Specified pathogen-free female BalB/c mice were obtained from Charles River [les Oncins, 
France]. at the day of infection, the animals were 10-12 weeks old and weighted 20-25 grams. 
The experimental protocols adhered to the rules specified in the Dutch animal Experimenta-
tion act (1977) and the published Guidelines on the Protection of Experimental animals by 
the Council of the EC (1986). The Institutional animal Care and use Committee of the Erasmus 
MC Rotterdam approved the present protocols.
Infection
a suspension of Mtb, stored at -80°C was defrosted at room temperature and centrifuged 
for 10 min at 14,000xg. The Mtb pellet was resuspended in phosphate-buffered saline (PBS) 
and centrifuged again for one min at 1,900xg to eliminate any aggregated bacteria. The Mtb 
suspension was diluted in PBS to obtain a concentration of 2.4x106 CFu/ml. To establish the 
pulmonary infection, a 22-Gauge mouse gavage feeding needle, with a 1.25 mm diameter 
tip [Fine Science Tools; Foster City, Ca], a 1 ml syringe and a repeating dispenser [Hamilton 
company; Bonaduz, Switzerland] were used. Mice were infected by intratracheal instillation 
of 40 µl of Mtb suspension, containing 9.5x104 Mtb, under general anaesthesia using a mix-
ture of medetomidine [Domitor®, 0.5 mg/kg; Orion Corporation; Espoo, Finland], midazolam 
[Dormicum®, 5 mg/kg; Roche; Basel, Switzerland] and fentanyl [Fentanyl, 0.05mg/kg; Janssen 
Pharmaceuticals; Beerse, Belgium]. after inoculation mice were kept in a vertical position for 
5 min to ensure proper inhalation of the inoculum. Mice were antagonized using a mixture of 
atipamezol [antisedan®, 2.5 mg/kg; Orion Corporation; Espoo, Finland], flumazenil [anexate®, 
0.5 mg/kg; Hameln Pharma; Hameln, Germany] and nalaxon [narcan®, 1.2 mg/kg; Hospital 
Pharmacy; Rotterdam, The netherlands]. anaesthetic and antagonistic agents were adminis-
tered intraperitoneally, in a total volume of 175 and 250 µl, respectively.
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Anti-tuberculosis therapy
 The anti-tuberculosis drugs and dosage schedules used for treatment of the TB infected mice 
were according to the wHO guidelines.2,10 Treatment was continued during 26 weeks (ac-
cording to standard regimen) and consisted of a 9-week initial phase followed by a 17-week 
continuation phase. During the initial phase, animals received a combination of isoniazid 
[25 mg/kg; Hospital Pharmacy; Rotterdam, The netherlands], rifampicin [10 mg/kg; Rifadin, 
aventis Pharma B.V., Hoevelaken, The netherlands] and pyrazinamide [150 mg/kg; P7136, 
Sigma Chemical Co, St. louis, MO]. agents were administered once daily, 5 days a week, sub-
cutaneously in the neck, to avoid potential damage following long-term, daily oral gavage. 
as the bioavailability of both rifampicin and pyrazinamide, after oral administration is 100%, 
and for isoniazid this is 90%, proper correction in this respect was made for the subcutaneous 
administration of isoniazid. In the continuation phase, only isoniazid and rifampicin were 
administered in the same frequency and dose. To simulate patient non-adherence, a treat-
ment regimen of only 13 weeks (9 weeks initial phase, followed by only 4 weeks continuation 
phase) was applied.
The therapeutic efficacy of both treatment regimens was assessed using various microbio-
logical, pathophysiological and immunological parameters. To this aim mice were dissected 
at indicated time points during the treatment period and 13 weeks after termination of 
treatment, in order to detect potential relapse of TB infection in the post-treatment period.
Determination of viable Mtb counts in infected organs and blood. Mice (n=4 per time point) 
were sacrificed at indicated time points by CO2 exposure. In mice sacrificed during treatment, 
administration of anti-tuberculosis drugs was stopped 72 hrs before dissection, in order 
to minimize carry-over of the anti-tuberculosis drugs onto the sub-culture plates. a blood 
sample was taken via a (transcutaneous) cardiac puncture and a protease inhibitor [P8340, 
Sigma Chemical Co, St. louis, MO] added to the blood sample to a final concentration of 5%. 
The lung, spleen and liver were removed and homogenized [Polytron, kinematica, luzern, 
Switzerland] in 2 ml of PBS containing a final concentration of 5% protease inhibitor for 
10 sec at 30,000 rpm at room temperature. with this method, intra- and extracellular Mtb 
were recovered. To further prevent carry-over of anti-tuberculosis drugs (if still present in 
the tissues) onto the subculture plates, tissue homogenate suspensions and blood were 
centrifuged at 14,000xg for 10 min, and pellets were re-suspended in PBS. Samples were 
serially diluted in PBS and plated onto 7H10 agar supplemented with 10 % OaDC. The plates 
were incubated for 21 days at 370 C and 5% CO2 before colonies were counted.
Histopathological examination of infected lung 
The histopathological changes in infected tissues during the course of the infection were 
determined by sacrificing the animals (n=3) at indicated time points, using an overdose of 
pentobarbital [nembutal®, a.u.V, Cuijk, The netherlands]. In situ, the lung was re-expanded 
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using ethanol absolute [Riedel-de Haën, Seelze, Germany] administered through a 22-gauge 
mouse gavage-feeding needle with a 1.25 mm diameter. The re-expanded lung was trans-
ferred to small flasks containing ethanol absolute, and stored for a minimum of 24 hrs and a 
maximum of 72 hrs at room temperature. after fixation, the lung lobes were separated. The 
tissues were subsequently dehydrated in ethanol absolute three times for 1 hr, in 100% xy-
lene [Sigma Chemical Co, St. louis, MO] three times for 1 hr and finally immersed three times 
in paraffin [Richard-allen Scientific, kalamazoo, MI] at 650 C for 1 hr. The paraffin-embedded 
tissues were cut into 4 µm sections and one in every 7 cuts was taken for haematoxylin-eosin 
(HE) staining. a pathologist, blinded to the experimental condition, examined the HE-stained 
sections under a microscope. In these slides, the average size of granulomas and the percent-
age of lung surface affected by pneumonia were (semi-quantitatively) determined using a 
nanoZoomer Digital Pathology system (Hamamatsu Photonics k.k, Hamamatsu City, Japan) 
and score as described by Hernandez-Pando et al.11
Immunohistochemical examination of infected lung 
 The cytokine expression in infected lung tissue, during the course of infection was deter-
mined. The paraffin-embedded tissue samples used for histopathology were subsequently 
cut in 4 µm sections, which were immunohistochemically stained following various steps, 
being deparaffinization by 5 min incubation in 100% xylene, three times washing in 100% 
xylene, three times washing in xylol-ethanol (50:50), three times washing in ethanol 96%, 
and finally submersion in distilled water for 2 min. Quenching of endogenous peroxidase 
was achieved by incubation of the sections in a mixture of 3% H202 [Sigma Chemical Co, 
St. louis, MO] in methanol [Biosolve, westford, Ma] for 30 min and five times washing in 
HCn-Tween 20 0.01% (HCn = Hepes 2.383gr [Sigma Chemical Co, St. louis, MO], naCl 8.766gr 
[Merck, Frankfurt, Germany] and CaCl2 0.2958gr [Merck, Frankfurt, Germany] per litre). aspe-
cific blocking was done with either goat- or rabbit serum (depending on the antigen used) 
diluted in HCn-Tween 20 0.01%, according to manufacturer’s protocol [Vectastain® Elite aBC 
kit; Vector laboratories, Burlingame, Ca] without exposure to light for 30 min, after which the 
samples were washed five times with HCn-Tween 20 0.01%. The specific antibody binding 
was achieved by incubation of the samples with 200 µl biotin-labelled rabbit- or goat poly-
clonal antibodies against Il-2 (sc-7896), Il-4 (sc-1260), Il-10 (sc-1783), Il-12B p40 (sc-1283), 
IFn-γ (sc-9344) or TnF-α (sc-1351), all purchased from Santa Cruz Biotechnology [Ca, uSa] 
and diluted 1/100 in PBS. Bound antibodies were detected using the Vectastain® Elite aBC kit 
[Vector laboratories, Burlingame, Ca] according to manufacturer’s protocol. The secondary 
antibody-stained sections were finally counterstained using haematoxylin.
Cytokine concentrations in infected lung homogenates and serum 
 The cytokine concentrations were assessed at indicated time points, in samples of lung ho-
mogenate and serum, of the sacrificed animals (n=3). Samples were preserved with 5% prote-
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ase inhibitor, stored at -800C and cytokines were determined using the Cytometric Bead array 
(CBa)-assay [CBa-flex kit, cat. no. 558266, Becton, Dickinson and Company, Franklin lakes, 
nJ]. In this assay a sequence of spectrally distinct particles, which are coated with different 
capture antibodies was used. These particles capture specific cytokines from the samples 
and after this primary binding, a secondary (fluorescent) antibody was used for labelling. The 
samples were characterised by detection of fluorescence (to quantify cytokine binding) and 
flow cytometric analysis (to designate the specific cytokine). The cytokine concentrations 
were calculated with a sandwich format assay (plotting sample results against a standard 
curve). The CBa-assay generates data that are analogous to those from ElISa-based assays; 
however, with the CBa-assay multiple cytokine concentrations can be detected and quanti-
fied in one single sample. In addition, with this technique only a limited sample volume of 
50 µl is required. In order to run the CBa in a non-tuberculosis laboratory and to prevent 
interference of tissue residue during the test, the samples were filtered before the CBa assay. 
we used a 10 µm in-tube filter [Vectaspin 10 µm, whatman, Maidstone, uk] as a prefilter and a 
secondary 0.2 µm in-tube filter [Vectaspin 0.2 µm, whatman, Maidstone, uk] as a sterilisation 
filter, before analyzing. The 10 µm in-tube prefilter was filled with 200 μl of the defrosted 
sample and centrifuged at 7,500xg for 10 min at room temperature. The filtered fluid was free 
of tissue residue and transferred to the 0.2 µm in-tube sterilisation filters. after centrifuga-
tion at 7,500xg for 10 min at room temperature, the sample was free of Mtb. The CBa-assay 
was performed according to the manufacturer’s protocol. In brief: 50 μl of the samples and 
of the standard dilutions were incubated with 50 μl capture beads for 1 hr, in a 96-wells 
filter plate at room temperature. Subsequently, 50 μl phycoerythrin (PE) detection reagent, 
consisting of fluorescent PE-conjugated anti-mouse Il-2, Il-4, Il-10, Il-12, TnF-α or IFn-γ was 
added, and incubated (protected from light) for 1 hr at room temperature. after incubation 
the sample was measured using a flow cytometry instrument [FaCS-scan, Becton, Dickinson 
and Company, Franklin lakes, nJ] and results were analyzed using CBa software. Cytokine 
concentrations for each sample were determined by interpolation from the standard curve.
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figure 1. TB infection in mice and efficacy of standard therapy for 26 weeks (diagonally striped bars) or 
therapy for 13 weeks only (chequered bars). TB infected untreated mice (black bars). Therapy was started 
4 weeks after inoculation of Mtb and consisted of isoniazid, rifampicin and pyrazinamide during 9 weeks, 
followed by an additional 4 or 17 weeks of isoniazid and rifampicin. Results are expressed as means ± SD 
(error bars) of the colony forming units (CFu) per organ, n = 4 per time point. numbers above bars are the 
numbers of culture-positive mice out of 4 mice. * 2 out of 4 untreated mice died due to TB before time 
point. ** 4 out of 4 untreated mice died due to TB before time point.
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RESulTS
Mouse model of TB infection
Intratracheal inoculation of 9 5x104 Mtb resulted in pulmonary TB in all mice. Dissemination 
of Mtb to extra-pulmonary sites, including spleen and liver, at a later stage of the infection, 
was observed. at 24 hrs after inoculation, Mtb organisms (5 8x104; range 4 7-8 9x104) were 
exclusively recovered from the lung, as at that time no Mtb was detected in the extra-
pulmonary sites or blood (figure 1). The Mtb load increased exponentially in the lung over 
B
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figure 2. Representative lung histopathology (A-D) and cytokine expression by immunohistochemistry (G-
I) in TB infected untreated mice. lung histopathology of mice treated with standard therapy for 26 weeks 
(E-f). (A) (400x), after 2 weeks of infection, perivascular inflammation (arrows) and well-formed granulomas 
(asterisk) were distinctive histological features. (B) (400x), after 4 weeks of infection, pneumonic patches 
(asterisk) and widening of alveolar-capillary interstitium due to inflammatory infiltrate were seen (arrows). 
(C) (100x), after 17 weeks of infection extensive lung pneumonia was observed. (D) (100x), after 30 weeks of 
infection, numerous foamy macrophages in the pneumonic areas were observed. (E) (100x), after 13 weeks 
of therapy, only small granulomas (arrows) were present and pneumonia was not observed. (f) (100x), 
after 26 weeks of therapy only lymphocyte cuffs around venules were observed without pneumonia or 
granulomas. (G) (1000x), after 4 weeks of infection, granuloma showed numerous IFn-γ positive cells. 
(h) (1000x), after 4 weeks of infection, activated macrophages in granulomas and in alveolar spaces 
(arrows) exhibited strong TnF-α expression. (I) (1000x), after 30 weeks of infection, numerous Il-4 positive 
lymphocytes were seen in granulomas.
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time and extra-pulmonary sites became infected 2 weeks after inoculation of Mtb into the 
lung. all blood cultures were positive for Mtb at 4 weeks after infection with an average of 0 
7x103 CFu/ml (data not shown). after this acute phase of infection the numbers of Mtb in the 
different organs stabilized and only some mice revealed positive blood cultures at low Mtb 
densities. From the time point that the maximum bacterial load in the different organs was 
reached, untreated mice became increasingly sick over time, as reflected by their loss of body 
weight and poor health-associated behaviour. untreated mice died or became moribund 
(resulting in euthanasia) between 22 and 38 weeks after infection. 
Histopathological examination of the lung after 2 weeks of infection revealed mild inflam-
matory infiltrate, consisting of lymphocytes and macrophages, located around blood vessels, 
bronchioles and in the alveolar-capillary interstitium (figure 2a). well-constituted granulomas 
became apparent near blood vessels or the bronchial walls and in the alveolar network. Many 
macrophages located in the interstitium, alveolar lumina and granulomas, showed morphol-
ogy characterized by the occurrence of large cells with abundant and compact cytoplasm 
and enlarged nuclei with marginal chromatin on the inner part of the nuclear membrane 
and an apparent nucleolus. after 4 weeks of infection, small patches of pneumonic lesions 
were seen. These areas were characterized by alveolar lumina occupied by lymphocytes, 
macrophages, occasional neutrophils and clumps of apparently coagulated or precipi-
tated eosinophilic proteins (figure 2B). These pneumonic areas progressively increased in 
untreated mice, producing extensive lung consolidation after 17 weeks of infection (figure 
2C), exhibiting focal areas of necrosis, thick lymphocyte-rich cuffs around blood vessels and 
hyperplastic lymphoid tissue associated with bronchial walls. after 30 weeks of infection, 
massive pneumonia was seen, alveolar spaces showed many large, foamy macrophages with 
numerous cytoplasmic vacuoles and small nuclei (figure 2D). Occasionally, multi-nucleated 
giant cells were observed in the alveolar areas. Semi-quantitative determination of the 
percentage of lung surface occupied by granulomas revealed an increase in the average 
and total granuloma size during the progression of the acute phase (figure 3a). The surface 
occupied by granulomas peaked after 5 weeks of infection and decreased from that time 
point. after 9 and 17 weeks of infection, there were hardly any granulomas detectable in the 
lung. also the percentage of lung area consisting of pneumonic lesions increased during the 
course of infection up to 75% at 30 weeks after infection (figure 3B). at that time mortality of 
mice was observed.
Immunological evaluation of the infection progression was done in two different ways. 
The presence and concentration of specific cytokines in serum and lung homogenates as 
measured by the CBa were determined. In addition, the lung sections were immunohisto-
chemically stained to reveal in situ cytokine expression in the lung. with respect to the cyto-
kines circulating in serum and present in lung homogenates, the most prominent cytokine 
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observed during the murine TB was IFn-γ. During the course of infection, the IFn-γ levels in 
lung homogenates and serum rose quickly and reached a peak concentration 4 weeks after 
infection (figure 4a). This indicates a strong Th-1 response during the acute phase of the 
infection. In the first weeks of the chronic phase of infection the IFn-γ levels decreased and 
subsequently reached a plateau level. The second prominent cytokine in the course of TB 
in this model was TnF-α. Elevated concentration levels of TnF-α were observed in lung ho-
mogenates and serum in the acute phase and these levels remained high during the chronic 
phase of infection (figure 4B). Il-4 levels were also increased in the lung homogenates and 
serum at 4 weeks after infection but in much lower concentrations compared to IFn-γ and 
TnF-α (figure 4C). also, the cytokine concentration profiles of Il-2, Il-10 and Il-12 were rela-
tively low during the infection progression (data not shown).
Immunohistochemical staining showed numerous IFn-γ expressing cells with the morphol-
ogy of activated lymphocytes located in granulomas after 2 and 4 weeks of infection (figure 
2G), and in the inflammatory infiltrate located in the alveolar-capillary interstitium and around 
the venules and bronchi. The granulomas at week 2 and week 4 showed numerous activated 
(foamy) macrophages with strong TnF-α expression(figure 2H). alveolar macrophages near 
to these granulomas and in the pneumonic areas also showed immunoreactivity against 
TnF-α (figure 2H). after 30 weeks of infection, lymphocytes located in the pneumonic areas 
and in granulomas frequently expressed Il-4 (figure  
Efficacy of anti-tuberculosis drugs
Therapy was started at 4 weeks after inoculation of Mtb, at the time of the apparent switch 
from the acute to the chronic phase of the infection, as illustrated by stabilization of the 
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figure 3. lung histopathology in terms of granuloma size en percentage pneumonic lesions during the 
course of infection. (A) The average size of granulomas in the lung. (B) areas of the lung, consisting of 
pneumonic lesions as percentage of total lung surface. TB infected untreated mice (black bars). Mice treated 
with the standard therapy for 26 weeks (diagonally striped bars) or therapy for 13 weeks only (chequered 
bars). Therapy was started 4 weeks after inoculation of Mtb and consisted of isoniazid, rifampicin and 
pyrazinamide during 9 weeks, followed by an additional 4 or 17 weeks of isoniazid and rifampicin. Results 
are expressed as means ± S.D (error bars), n = 3 per time point. From each mouse, 5 lung lobes were 
examined. * 4 out of 4 untreated mice died due to TB before time point.
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Mtb load in the infected organs and the histopathological findings. as shown in figure 1 
the administration of the combination of isoniazid, rifampicin and pyrazinamide, resulted in 
a rapid decline in Mtb load in the infected organs. after 1 week of therapy the numbers of 
Mtb in lung, spleen and liver had significantly decreased by 81%, 93% and 60%, respectively, 
compared to start of therapy. within 5 weeks of therapy a further rapid significant decrease 
in Mtb load was obtained in lung, spleen and liver. Blood was always sterile. after 13 weeks of 
therapy, viable Mtb could not be cultured from the infected organs. when anti-tuberculosis 
drugs were continued for a total of 26 weeks, complete elimination of Mtb from the infected 
organs was achieved in all mice, as evidenced by the absence of relapse of infection 13 weeks 
after termination of therapy. In contrast, when after 13 weeks of therapy the treatment with 
anti-tuberculosis drugs was stopped, 13 weeks later relapse of infection was observed in all 
mice (figure 1). at that time, numbers of Mtb in the lung of all mice had increased again up 
to 1.4x103 (range 1.0-6.8x103), whereas in 1 out of 4 mice bacterial numbers in the spleen and 
liver had increased to numbers not significantly different from the untreated controls.
Histopathological examination of the lung during therapy revealed that animals treated with 
anti-tuberculosis drugs, showed striking morphological changes, compared to the untreated 
animals (as described above). after 13 weeks of therapy only few and small pneumonic 
patches were observed with middle sized granulomas (figure 2E), while after 26 weeks of 
therapy, only occasionally granulomas and thick lymphocytes cuffs were observed. Patches 
of pneumonia were absent at this stage (figure 2F). at week 43 (13 weeks after the 26 weeks 
treatment period) histopathological evaluation of the lung revealed similar tissue morphol-
ogy as seen at week 30. (data not shown).
The quantitative histopathological examination during infection revealed prevention of 
extension of granulomas and pneumonic lesions during therapy for 26 weeks (figure 3). 
when after 13 weeks therapy was stopped, the average granuloma sizes increased (figure 
3a) and also the total numbers of granulomas increased (data not shown), indicating a strong 
progression of infection. also the percentage of lung area consisting of pneumonic lesions at 
week 30 was on average somewhat increased (figure 3B).
Regarding the cytokine expression, the IFn-γ concentrations in lung homogenates and serum 
which in untreated mice remained at a stable level until 30 weeks after infection, significantly 
decreased in mice receiving 26-weeks therapy (figure 4a). at the end of the 26-weeks therapy 
IFn-γ concentration in lung homogenates and serum had returned to the normal low values. 
The effect of therapy on the TnF-α level was less prominent. Though there was a decrease 
in TnF-α concentration in lung homogenates following therapy, this cytokine remained 
elevated until the end of the 26-weeks therapy. The therapy-induced decrease in TnF-α con-
centration was not seen in serum. There was no significant change in of Il-4 levels in serum 
following therapy, except that in lung homogenates Il-4 concentrations were significantly 
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figure 4. Concentrations of cytokines, in lung homogenates and serum during the course of infection. (A) 
IFn-γ. (B) TnF-α. (C) Il-4. TB infected untreated mice (black bars). Mice treated with the standard therapy 
for 26 weeks (diagonally striped bars) or therapy for 13 weeks only (chequered bars). Therapy was started 
4 weeks after inoculation of Mtb and consisted of isoniazid, rifampicin and pyrazinamide during 9 weeks, 
followed by an additional 4 or 17 weeks of isoniazid and rifampicin. Results are expressed as means ± S.D 
(error bars) of cytokine concentration in pg/ml, n = 5 per time point at weeks 4, 7 and 9 and n = 3 per time 
point at weeks 2 and 30. n.D. = not determined.
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decreased at the end of the 26-weeks therapy. Regarding the cytokines Il-2, Il-10 and Il-12, 
the low concentrations of these cytokines assessed in lung homogenates and serum, did 
not allow evaluation of the effect of therapy on their presence (data not shown). Since the 
IFn-γ concentration in serum showed a good correlation with the treatment efficacy, serum 
IFn-γ concentrations were measured in animals receiving only 13-weeks of therapy, showing 
relapse of infection in the post-treatment period. a rapid increase in IFn-γ concentration in 
serum was found at week 30, the end of the relapse period. This showed that the increase in 
CFu and histopathology damage was nicely reflected in an increase in IFn-γ concentrations 
in both lung homogenates and serum.
DISCuSSIOn
In TB patients, only a few parameters are available to monitor infection progression and 
therapy response. These parameters include: sputum smear, chest X-ray and general clinical 
and laboratory infection parameters. at present it is not clear whether the cytokine profile in 
serum or bronchoalveolar-lavage (Bal) fluid might be indicative and can be used as param-
eter. The role of cytokines in the host defence during TB was demonstrated in various studies 
in TB patients, showing levels of IFn-γ, TnF-α, Il-4, Il-6 and Il-10 in serum, Bal fluid as well 
as in pleural fluid. It is not clear whether these changes in cytokine expression are related to 
the infection progression and therapy response (and by that) possibly are useful markers.3-7 
Monitoring cytokine levels in Bal fluid is hindered by the fact that the collection of Bal fluid 
from patients is an invasive procedure and is susceptible to inter-procedure variations. as 
a result, routine use of cytokine determinations from Bal fluid seems to be inappropriate. 
The use of serum cytokine levels as a reflection of the cytokine levels in infected lung tissue 
might be more appropriate. In the present study the value of cytokine levels in serum for 
monitoring infection progression and therapy efficacy was investigated in an experimental 
TB model in mice. at various intervals during infection and during therapy including the 
post-treatment period, cytokine levels in serum were determined and evaluated with respect 
to the in situ cytokine expression in the infected lung at that moment. also the fluctuation in 
serum cytokine levels in relation to the success of therapy or failure of therapy followed by 
relapse of infection was assessed.
Regarding the course of cytokine levels in serum and Bal-fluid of TB patients, Verbon et al. 
and Morosini et al.4,5 showed that during active TB, circulating IFn-γ levels were elevated 
compared to healthy control groups, whereas Il-4 levels were low. Therefore, use of cytokines 
as a diagnostic tool in TB patients was previously proposed by küpeli et al. In their study, 
the TnF-α concentration in Bal-fluid appeared to be a useful tool to discriminate between 
smear-negative TB patients and healthy persons.3 However, these studies were performed in 
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relatively small groups of patients and had the disadvantage that cytokine concentrations 
were difficult to match to TB-infection stage. The standard deviation of cytokine levels in 
TB-patients, all in different stages of their infection, hinders proper interpretation of the cor-
relation of infection phase and cytokine level. animal models enabling such comparative 
studies can overcome these disadvantages and may provide further insight.
Our experimental TB model in BalB/c mice being characterized with respect to infection 
progression, immune response and validated with respect to therapy outcome appears to 
simulate human TB. also relapse of infection in the post-treatment period was evaluated. we 
used an inoculum of 9.5x104 CFu H37Rv to obtain a progressive disease with mortality of mice 
only late in the course of infection, enabling proper evaluation of efficacy of currently-used 
standard therapy, as well as novel therapeutic approaches in TB in future studies. we infected 
the mice via the respiratory route, to simulate human infection, and applied intratracheal 
instillation of Mtb to avoid potential variable deposition of the microorganisms in the lung.12 
The infection progressively developed and after 4 weeks the Mtb load in the lung had reached 
a maximum. From that time mycobacteria persisted for at least 30 weeks, indicating a chronic 
phase of the infection. Dissemination of Mtb to extra-pulmonary sites, such as spleen and 
liver, was observed from 2 weeks after infection. Blood cultures of infected mice were positive 
only during the initial acute phase of infection. The animals became increasingly sick over 
time and started dying 22 weeks after infection, due to the intensity of the inflammatory 
response and subsequently tissue damage.
Immunological characterization of the initial phase of Mtb infection in the mice revealed 
predominantly an IFn-γ driven T-helper cell-1 (Th-1) immune response, here CD4-Th1 cells 
as well as nk cells are involved, which is also seen in humans.13,14 The acute initial phase 
shifted to a T-helper cell-2 (Th-2) driven immune response resulting in stabilization of the 
Th-1 response and thus preventing early mortality of mice. This balance of the Th-1 and Th-2 
response during TB infection is a characteristic feature of TB. The mortality rate due to TB 
infection in the BalB/c mice is relatively low compared to various other mouse strains.14 The 
difference is likely due to the apparent two-phase-reaction of BalB/c mice to Mtb, leading to 
a chronic progressive character of the infection. Immunological examination of the infected 
lung in the first 4 weeks of the infection showed the pro-inflammatory cytokines (e.g. IFn-γ 
and TnF-α) were predominant in the lung. The histopathological feature of the infected lung 
in this acute phase of the infection was the formation of granulomas. Immunohistochemical 
staining of the lung sections revealed that the granulomas had numerous IFn-γ producing 
lymphocytes, indicating the strong Th-1 character of this response. The area of the lung oc-
cupied by granulomas and the average granuloma seize reached a peak at the end of the 
acute phase. at the same time the concentration of free IFn-γ in the lung homogenates and 
serum also reached a peak. Besides IFn-γ the, (immuno-) histopathological characterization 
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of the acute phase of the infection revealed activated macrophages, expressing high levels 
of TnF-α in the lung and these macrophages have remained during the chronic phase of 
infection. High levels of TnF-α were also found in the lung homogenates and serum, which 
increased rapidly and remained high during the chronic phase of infection.
after the acute phase of infection we observed that the immune response changed from 
a Th-1 derived acute infection to a chronic reaction, characterized by expression of anti-
inflammatory cytokines, such as Il-4.16 Histopathologically the chronic phase of the infection 
was characterized by the development of pneumonic lesions, visualized by intra alveolar 
presence of neutrophils, leukocytes and plasma proteins, and were related to the Th-2 re-
sponse. The histopathological changes in the lung corresponded with the load of persistent 
Mtb, and the mortality of mice. Immunohistochemical staining of the lung sections revealed 
that late in the chronic phase of the infection, numerous lymphocytes expressing Il-4 were 
seen in the lung. However this increase in Il-4 levels during the infection progression was 
just moderately observed in the lung homogenates and serum and as such did not provide 
additional information on the infection progression.
next, it was investigated whether success or failure of therapy was reflected in terms of changes 
in cytokine levels in serum. The anti-tuberculosis therapy applied, consisted of the standard 
combinations of currently used anti-tuberculosis drugs and was administered at time schedules 
according to the wHO guidelines.2,10 Rosenthal et al. and lalande et al, have demonstrated that 
with the dosages used in the present study, the plasma area under the concentration-time curve 
auC obtained in mice were similar to human plasma auC.8,17 The anti-tuberculosis therapy was 
started at 4 weeks after infection, when patches of pneumonic lesions were already observed and 
established infection was confirmed by stabilization of the Mtb load in the infected organs and 
TB characteristic histopathological findings. Therapeutic efficacy was established in terms of a 
rapid decrease in Mtb load in lung, spleen and liver. It was demonstrated that full 26-weeks dura-
tion of therapy is of primary importance in obtaining complete cure. although after a therapy 
duration of only 13 weeks Mtb could not be cultured from the infected organs, relapse of infec-
tion occurred in the 13 weeks post-treatment period, probably initiated by very low numbers of 
persistent dormant mycobacteria in the infected organs. The therapeutic results obtained in the 
present study are in agreement with those of nuermberger et al. 18 who administered the anti-
tuberculosis drugs orally via gavage in BalB/c mice infected via the aerosol route. They started 
therapy at 19 days after infection, and at that time the Mtb load in the lung was similar compared 
to the Mtb load in the lung at 4 weeks after infection in our model.
we demonstrated that a decrease of cytokine concentration in serum resulting from effective 
therapeutic intervention was clearly observed for IFn-γ, but not for TnF-α or Il-4. The increase 
in Mtb load in infected organs and histopathological damage in the lung was nicely reflected 
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by an increase in IFn-γ concentrations in serum. Successful therapeutic intervention resulted 
in decreasing Mtb load and limited tissue damage, as well as in decrease in IFn-γ in serum 
and during therapy failure, IFn-γ concentrations in serum increased again. The dynamics of 
the IFn-γ concentration in serum before, during and after therapy, as observed in this ex-
perimental study, may be considered as a tool to monitor infection progression and success 
or failure of therapy in patients under anti-tuberculous therapy. Verbon et al. demonstrated 
that IFn-γ levels in patients suffering from active TB were elevated in serum compared to 
healthy controls and declined during and after treatment.5 Our data obtained in mice are in 
agreement with the clinical data from Verbon, and suggest that the absence of a shift in IFn-γ 
levels, after starting therapy could be indicative for non-effective treatment, for example due 
to drug resistance of Mtb.
In summary, the serum cytokine IFn-γ accurately reflected the IFn-γ response at the primary, 
pulmonary infection site. Fluctuations in serum IFn-γ showed a good correlation with infec-
tion progression, successful therapeutic outcome and therapy failure following non-appro-
priate therapy. In this way, the serum IFn-γ concentration might be a useful immunological 
parameter to follow the presence of an early therapy response and to prevent unnoticed 
treatment failure due to resistance. The therapy efficacy in an individual TB patient can be 
monitored, thus contributing to a successful treatment-outcome.
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Course of murine tuberculosis and response to 
first-line therapy depends on route of infection and 
inoculum size
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R. Hernandez-Pando, I.a.J.M. Bakker-woudenberg
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ABSTRACT
Objective 
In the search for novel anti-tuberculosis (TB) drugs, numerous potential drugs are being 
screened in vitro. In animal models promising, novel anti-TB drugs are assessed in terms of toxic 
side effects and comparative therapeutic efficacy. Mice are frequently used and experimental 
infections are established in different ways. In the present study it is investigated to what extent 
the route of Mycobacterium tuberculosis inoculation is a determinant in the pathogenesis of TB 
and the therapeutic outcome. Results will contribute to insight into the translational value of TB 
models used for preclinical studies.
Design  
TB in mice was established through intratracheal or intravenous Mtb inoculation. The efficacy 
of a 26-weeks therapy was evaluated; including assessment of relapse of infection 13 weeks 
post treatment.
Results  
It was shown that the course of TB and the therapeutic response, in terms of histopathologi-
cal characteristics and Mtb load, in lung and extra-pulmonary organs is substantially different 
and dependent on the route of infection applied and the inoculum size used.
Conclusion 
 when evaluating the comparative therapeutic potential of novel anti-TB drugs or drug treat-
ment schedules investigated in different studies, it should be noted that the route of infec-
tion applied and inoculum size used influence the course of murine TB and the therapeutic 
response to the standard first-line TB drug regimen. 
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BACkGROunD
Tuberculosis (TB) remains a major cause of morbidity and mortality worldwide. Mycobacte-
rium tuberculosis (Mtb) has now infected about one third of the world’s population of which 
eight to nine million develop TB. Over one and a half million patients die annually as a result 
of TB.1 In order to reduce this enormous burden of disease, development of new anti-TB drugs 
or improvement in use of current anti-TB drugs is needed. To facilitate the development of 
new anti-TB drugs, libraries of small molecules and natural products are being screened for 
their activity against Mtb and previously identified crucial targets of Mtb are being explored 
to design new inhibiting molecules.2 numerous novel anti-TB drugs are being tested for their 
in vitro capacity to kill Mtb under different culture conditions. Only a small selection of them 
will proof to be active in vitro and will be further explored in animal models representing a 
dynamic test system in which the therapeutic antimicrobial effect depends on many fac-
tors. In animal models potential toxic side effects of promising, novel anti-TB drugs can be 
estimated in terms of toxicity assessed by body weight, discomfort score of mice and by 
liver- and kidney-function tests. Mice are frequently used in TB research, and experimental 
infections are established in different ways. The merits of animal models are that they enable 
comparative therapeutic studies at similar conditions of severity and duration of infection, 
which is difficult in patients due to different underlying conditions. However, the limitations 
of animal models among which the artificial induction of infection, differences in bacterial 
virulence and immunological host response, and differences in pharmacokinetics and toxic 
side effects, should be emphasized. as a result, comparative therapeutic studies in animal TB 
models may only serve as a basis for therapy trials in TB patients.3
In mice, TB infection is mostly established by pulmonary or intravenous inoculation of Mtb. 
It is expected that the route of Mtb inoculation is an important determinant in the patho-
genesis of the lung infection, and the dissemination. In the present study the course and 
pathogenesis of TB infection in lung and extra-pulmonary sites in relation to the route of 
infection, and the response to TB therapy is investigated. Mice were infected through the 
intratracheal (IT) or intravenous route (IV).
The efficacy of standard first-line therapy for 26 weeks was evaluated during therapy and 
after a 13-weeks period post therapy to assess relapse of TB infection. The Mtb load in the 
lung and extra-pulmonary organs and their histopathological characteristics were used as 
parameters.
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MATERIAlS AnD METhODS
Bacterium  
Mtb strain used was H37Rv (aTCC 27294). Mycobacteria were cultured on Middlebrook 7H10 
agar and incubated for 21 days, as described previously.4
Animals  
Specified pathogen-free female BalB/c mice were obtained from Charles River (les Oncins, 
France). at the day of infection, animals were 10-12 weeks old and weighted 20-25 grams. Ex-
perimental protocols adhered to the rules specified in the Dutch animal Experimentation act and 
the published Guidelines on the Protection of Experimental animals by the Council of the EC. The 
Institutional animal Care and use Committee of the Erasmus MC approved present protocols.
Infection  
Intratracheal inoculation was performed as previously described. 4 In short, mice were in-
fected by intratracheal instillation of a volume of 40 µl of Mtb suspension containing 9.5x104 
CFu. Intravenous inoculation was performed by intravenous injection of 0.2 ml of an Mtb 
suspension containing 1.5x107 CFu via the tail vein.
Anti-TB therapy 
The anti-TB drugs dosage and schedules used in our mouse TB model were derived from 
current clinical guidelines.5-6 a combination of isoniazid, rifampicin and pyrazinamide, in 
human-pharmacokinetic-equivalent doses 7-8 was administered, as described previously.4 
In short, treatment was started at 4 weeks after inoculation, when patches of pneumonic 
lesions were observed and established infection was confirmed by stabilization of the Mtb 
load and TB-characteristic histopathological findings.4 Treatment was continued during 26 
weeks consisting of a 9-week initial phase followed by a 17-week continuation phase. During 
the initial phase, animals received a combination of isoniazid [25 mg/kg], rifampicin [10 mg/
kg] and pyrazinamide [150 mg/kg]. In the continuation phase, only isoniazid and rifampicin 
were administered. agents were administered once daily, 5 days a week.
Determination of viable Mtb counts in infected organs and blood. at all indicated time points 
mice (n=4 per time point) were sacrificed by CO2 exposure. The lung, spleen and liver were 
removed aseptically and processed as described previously.4 In short, blood samples were 
taken via cardiac puncture and the entire organs were removed and homogenized each in 
2 ml PBS. To prevent carry-over of anti-TB drugs, therapy was stopped 72 hours before sac-
rificing the mice. Tissue homogenate suspensions were centrifuged at 14,000xg for 10 min, 
and pellets were re-suspended in 2 ml PBS. From the undiluted tissue homogenate and the 
10-fold serial dilutions of the homogenate, samples of 200 μl were plated onto solid medium.
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Assessment of relapse of infection  
The amount of viable Mtb counts in lung, spleen, liver and blood of mice (n=4) was assessed 13 
weeks after termination of anti-TB therapy. Relapse was defined as Mtb positive cultures of in-
fected organs, while immediately after termination of therapy, organs were Mtb culture negative.
Histopathological examination of infected organs 
Histopathological changes in lung, liver and spleen during the course of the infection were 
determined by sacrificing the animals (n=3) at indicated time points and processed as 
described previously.4 Paraffin-embedded tissues were cut into 4 µm sections from which 
one in every 7 cuts was used for haematoxylin-eosin staining. a pathologist, blinded to the 
experimental conditions, examined 4 slides of each tissue.
RESulTS
Course of TB infection after IT or IV inoculation  
at 4 weeks after IT or IV inoculation infection had developed, and a similar Mtb load was 
achieved in the lung being a median of 2.4x107 CFu [range, 2.9x106-5.5x107] and 1.5x107 CFu 
[range, 7.5x106-2.9x107] in the IT-infected mice and IV-infected mice, respectively. However, 
at that time histopathological changes in infected lung tissue of the IT-infected mice versus 
the IV-infected mice were clearly different.
In IT-infected mice, lung sections showed a limited number of pneumonia patches with 
areas of lung consolidation (figure 1a, asterisk), constituted by lymphocytes and numer-
ous activated macrophages in the alveolar lumina with fibrilar material that correspond to 
coagulated plasmatic protein. also, mild inflammatory infiltrates around bronchial and blood 
vessel walls and middle size well-formed compact granulomas were seen (figure 1a, arrow). 
Mtb load in the liver of the IT-infected mice was 6.3x104 CFu and liver sections showed a large 
number of large, well-formed granulomas which were randomly dispersed (figure 1B). The 
spleen load of the IT-infected mice was 1.4x105 CFu. Histopathology of the spleen exhibited 
mild white pulp hyperplasia without granulomas (figure 1C).
In contrast to the lung of IT-infected mice, at the same time-point of 4 weeks after infection 
the lung of IV-infected mice already showed extensive pneumonia and large granulomas 
on histopathological evaluation (figure 1G). The liver of the IV-infected mice showed an Mtb 
load of 2.6x107 CFu and numerous, large granulomas were seen particularly near to central 
veins as well as accentuated kupffer cell hyperplasia (figure 1H). Mtb load in the spleen of the 
IV-infected mice was 4.0x106 CFu. Histopathological evaluation revealed accentuated macro-
phage hyperplasia in the marginal zone with numerous large granulomas (figure 1I, arrows).
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at 17 weeks after IT infection Mtb load in the lung was 2.5x106 CFu. Histopathological evalu-
ation showed more pronounced changes and extensive fibrosis with numerous plasma cells 
around blood vessels and extensive pneumonia (figure 1D). Mtb load in the liver was 1.6x104 
CFu, and histopathology revealed numerous middle-sized and large granulomas (figure 2E, 
arrows). Mtb load in the spleen was 2.0x105 CFu and histopathological evaluation showed 
extensive hyperplasia of splenic white pulp (figure 1F).
In comparison to IT-infected mice, at the same time-point of 17 weeks after infection, the lung 
of the IV-infected mice had an Mtb load of 1.6x107 CFu. The corresponding histopathology of 
the lung showed extensive pneumonia, abundant interstitial fibrosis (figure 1J, asterisk) and 
numerous multinucleated giant cells and foamy cells were seen (figure 1J). The liver had an 
Mtb load of 1.5x107 CFu, and the histopathology of the liver consisted of large granulomas 
(figure 1k, asterisk) and extensive inflammatory infiltrate in the portal areas (figure 1k, arrow). 
Mtb load in the spleen was 1.6x107 CFu. Histopathological evaluation revealed numerous 
well-formed granulomas in the red pulp (figure 1l, arrows).
at 30 weeks after IT infection Mtb load in the lung was 3.5x106 CFu and histopathology of the 
lung was equivalent to that of 17 weeks after IT infection. Mtb load in the liver was 1.6x104 
CFu. no significant change of histopathological damage had occurred, compared to 17 
weeks after IT infection. The spleen had an Mtb load of 1.3x105 CFu and on histopathological 
examination the amount of hyperplasia was slightly increased (pictures not shown).
IV-infected mice all died between 23 and 30 weeks of infection. So, Mtb load or histopathol-
ogy at 30 weeks after IV infection could not be evaluated. From 30 weeks of infection onwards 
the IT-infected mice became increasingly sick over time, and at 43 weeks all animals had died.
Therapeutic efficacy of standard first-line therapy 
Therapy response was assessed in terms of decrease in Mtb load in lung, liver and spleen at 
the indicated time-points and success of therapy was defined as elimination of the Mtb load 
from infected organs and prevention of relapse of TB. Decreases in Mtb load in the different 
organs were expressed in figure 2.
after 13 weeks of therapy in the IT-infected mice Mtb elimination was achieved in lung, liver 
and spleen. However, in the IV-infected mice within 13 weeks, only the lung was Mtb-culture 
negative but longer therapy duration was needed to eliminate Mtb from liver and spleen. 
after 26 weeks of therapy, also liver and spleen from the IV-infected mice were Mtb-culture 
negative. whereas in IT-infected mice relapse of infection at 13 weeks after termination of 
therapy did not occur, in IV-infected mice relapse of infection in all organs was observed in all 
mice at that time point (figure 2).
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Figure 1.2
figure 1. Representative histopathological features in lung, liver and spleen of intratracheal (IT) or 
intravenous (IV) TB infected mice. Histopathology is shown at 4 weeks after IT infection, in the lung (A) 
(200x), liver (B) (200x) and spleen (C) (200x); at 17 weeks after IT infection, in the lung (D) (200x), liver (E) 
(200x) and spleen (f) (200x); at 4 weeks after IV infection, in the lung (G) (200x), liver (h) (200x) and spleen 
(I) (200x); at 17 weeks after IV infection, in the lung (J) (200x), liver (k) (200x) and spleen (l) (200x); after 
26 weeks of therapy in the IT-infected mice, in the lung (M) (200x) and liver (n) (200x); after 26 weeks of 
therapy in the IV-infected mice, in the lung (O) (200x) and liver (P) (200x); and after 26 weeks of therapy in 
the IV-infected mice followed by a therapy-free period of 13 weeks, in the lung (Q) (200x) and (R) (400x).
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The histopathological examination of infected tissues of the mice treated with anti-TB drugs 
still revealed significant histological changes. after 26 weeks of therapy, the lung of the IT-
infected mice exhibited some hyperplasia of the lymphoid tissue associated to bronchial wall 
(figure 1M, arrow) and small granulomas (figure 1M, asterisk). In the same animals, the liver 
showed complete elimination of granulomas and scarce chronic inflammatory infiltrate in 
portal areas, whereas some animals showed microvesicular steatosis (figure 1n, arrow). The 
spleen revealed stable white pulp hyperplasia. IV-infected mice, however, showed after 26 
weeks of therapy, foamy macrophages and giant multinucleated cells with foamy cytoplasm 
located at small pneumonic patches in the lung (figure 1O, arrow). The liver still exhibited 
numerous small granulomas (figure 1P, arrows). The spleen showed mild hyperplasia in the 
white pulp, but no granulomas (picture not shown).
at 13 weeks after termination of therapy (at week 43) the IT-infected mice showed complete 
absence of pneumonia and granulomas in the lung, and only revealed residual hyperplasia 
of lymphoid tissue associated to bronchial mucosa. liver and spleen showed a complete 
absence of granulomas or hyperplasia (pictures not shown). at the same time-point the 
IV-infected mice showed a relapse of infection. In their lung sections pneumonic patches 
constituted by lymphocytes and macrophages with foamy cytoplasm were seen (figure 1Q). 
These foamy cells and some activated cells showed erythrophagocytosis with cytoplasmic 
haematic pigment (hemosiderin) (figure 1R). at this time point, liver sections revealed many 
middle size granulomas and mild inflammation in the portal areas, and spleen sections 
showed hyperplastic white pulp without granulomas (pictures not shown).
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figure 2. Efficacy of standard first-line therapy for 26 weeks in intratracheal- or intravenous infected TB 
mice (⎕).untreated TB infected control mice (■). Start of therapy, at 4 weeks after infection, is indicated in 
the graphs as time zero. Mice were sacrificed at various intervals during therapy, and after termination of 
26-weeks therapy (indicated in the graph). In order to determine relapse of infection, mice were sacrificed 
at 13 weeks after termination of therapy. Results are expressed in mycobacterial numbers in the infected 
organs of mycobacterial culture-positive mice. * all mice were mycobacterial culture-negative. † 4 out of 4 
untreated mice died due to TB infection before indicated time point.
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DISCuSSIOn
In the present study it is demonstrated that the pathogenesis of TB infection, monitored by 
Mtb cultures and histopathology of infected lung and extra-pulmonary organs, depends on 
the “Porte d’entrée” of Mtb and the inoculum size used. Various studies have been published 
on histopathological characterisation of different stage of TB in experimental models of TB. 
Cardona et al. compared various mouse strains, which differ in their susceptibility to TB, in an 
aerosol infection model.{Cardona, 2003 #266} whereas north et al. described the difference in 
pathogenesis of TB in aerosol-infected mice versus intravenously-infected mice.10-11 Similar to 
the experimental set-up in the present study, north et al. applied different Mtb inocula (relative-
ly low numbers of Mtb for aerosol infection compared to the numbers of Mtb for intravenous 
infection), in order to achieve similar Mtb load in the lung. In the present study, the realization 
of a similar Mtb load in the lung for IV-infected and IT-infected mice resulted in a higher extra-
pulmonary load in the IV-infected animals compared to the IT-infected animals. This probably 
contributed to the observed increased time-period before extra-pulmonary organs became 
culture negative in the IV-infected animals. In addition, differences in immune response fol-
lowing IV infection versus IT infection may add to differences in Mtb clearance from the various 
organs. although in IV-infected animals the Mtb load in liver and spleen was similar to the load 
in the lung, different Mtb killing rate in these organs following therapy was observed, which 
might be related to differences in pathology and Mtb clearance capacity of these organs.
More recently, in a comparative study De Groote et al. used three different infection models 
and two mouse species, and evaluated these different models in efficacy studies with different 
anti-TB drugs regimens.12 They found that a TB infection, established through the intravenous 
route showed a delayed treatment effect and a higher relapse rate of infection, compared 
to a respiratory infection model established through aerosol. In our study, we showed that a 
respiratory infection model of TB established through intratracheal inoculation also showed 
a different therapeutic response in terms of bacterial killing and relapse rate, compared to the 
intravenously infected mice. In this way, our results are in agreement with the results of De 
Groote et al. and add a third method to establish TB infection, which was shown to influence the 
course of TB and therapeutic response. whereas we focused on the standard first-line therapy 
regimen, De Groote et al. showed that additionally to the standard first-line therapy regimen, 
when using other therapy regimens the observed differences related to the infection model 
remained standing.12 The comparative histopathology of the lungs of the IT-infected mice 
versus the IV-infected mice revealed more inflammation and tissue damage (pneumonia) in 
IV-infected animals despite slightly lower Mtb burden than in IT-infected mice after 4 weeks of 
infection. Considering the early high Mtb load in the spleen of IV-infected mice, it is possible 
that higher lymphocyte activation occurs in this organ followed by extensive cellular migration 
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to the lung tissue, producing more rapid death of the IV-infected animals by a combination of 
active Mtb growth and immunopathology (e.g. inflammation, fibrosis) in the lungs.
The dependency of the bacterial killing kinetics of the standard first-line therapy on the route 
of infection is a relevant issue, as novel anti-TB drugs such as moxifloxacin, Pa-824, TMC207, 
SQ-109 and SQ-641 have been investigated for their therapeutic potential in different animal 
models of TB. 13-16 These studies evaluating the most promising new anti-TB drugs are con-
ducted either in models of respiratory infected mice (moxifloxacin and Pa-824) or in models 
of intravenously infected mice (TMC207, SQ-109 and SQ-641).
The present study shows that in both IT-infected mice and IV-infected mice the standard first-
line therapy of 26 weeks seemed effective. However, all IV-infected mice showed relapse of 
infection. Probably the Mtb clearance in the infected organs following the 26-weeks therapy 
was not sufficient due to severe tissue damage. The therapy failure in the IV-infected mice, in 
contrast to the IT-infected mice, was reflected in differences in the histopathological character-
istics. at the end of the 26-weeks therapy IV-infected mice still exhibited lung and liver damage, 
although Mtb could not be cultured from both organs. The pneumonic lesions in the lung and 
granulomas in the liver further increased during the post-therapy period. These patches of 
pneumonia and liver granulomas might provide a unique environment for dormant Mtb which 
can not be cultured from these tissues at the end of therapy. However, after termination of 
therapy, regrowth of Mtb from these infection sites occurred. In this respect, interesting obser-
vations were described by Dhillon et al.17 He showed that focal residual pneumonic lesions were 
rich in foamy macrophages, specific cell population of late tuberculous lesions characterized 
by its high cytoplasmic lipid content, which favour persistence of non-replicating bacilli after 
chemotherapy that can reactivate and resume Mtb growth.
Summarizing, in the present study the mouse model of TB through the natural respiratory route, 
mimicking human TB infection, showed an evident inflammatory acute phase of infection, followed 
by a progressive chronic phase of infection. The model was validated in terms of therapeutic suc-
cessful outcome, with the rational time point for start of therapy at four weeks after infection, at 
transition of the acute to the chronic phase of infection. Relapse of infection in the post-therapy pe-
riod did not occur. This in contrast to our data obtained in the mouse model of TB infection through 
the intravenous route. It is concluded that the course of infection in an animal TB model and the 
therapeutic response to the standard first-line therapy, in terms of pathogenesis and Mtb load in the 
lung and extra-pulmonary sites, is substantially dependent on the route of infection applied and the 
inoculum size used. Related to this, we suggest that when clinicians are evaluating the comparative 
therapeutic potential of novel anti-TB drugs investigated in different animal studies, they should be 
aware that the route of infection applied and inoculum size used influence the course of murine TB 
and the therapeutic response to the standard first-line TB drug regimen.
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Tuberculosis mimicking ileocecal intussusception 
in a 5-month-old girl
J.E.M. de Steenwinkel, G.a. Driessen, M.H. kamphorst-Roemer 
a.G.M. Zeegers, a. Ott, M. van westreenen
Pediatrics 2008; 121(5):1434-7
ABSTRACT
a 5-month-old girl was diagnosed with tuberculosis, mimicking ileocecal intussusception. 
The mother of the patient was later diagnosed with renal tuberculosis attributable to the 
same (unique) Mycobacterium tuberculosis strain. Possibly, that transmission occurred by 
aspiration or ingestion of infected amniotic fluid or urine, which could occur before or during 
birth. This case illustrates that tuberculosis can mimic other common diseases and, therefore, 
can be a difficult diagnosis to make. Because respiratory infection was very unlikely in this 
case, congenital tuberculosis or postnatal infection via infected urine or breast milk should 
be in the differential diagnosis. In this article, we focus on different (non-respiratory) trans-
mission routes of Mycobacterium tuberculosis and give a short review of the recent literature 
on congenital tuberculosis.
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InTRODuCTIOn
worldwide there are an estimated 2 billion Mycobacterium tuberculosis (Mtb) infected per-
sons, of whom 8.8 million developed tuberculosis (TB) in 2003.1 This is in sharp contrast with 
the just over 300 reported cases of congenital tuberculosis (CTB). In 1994, Cantwell revised 
the diagnostic criteria as set by Beitzke and set the “Cantwell criteria” (table 1).2
The first symptoms of CTB typically occur within 3 months of birth. In most cases, onset of 
the disease is in the second half of the first month.3-4 The presenting signs and symptoms are 
often non-specific, mimicking other more common diseases. Cantwell et al. described the 
most prevalent symptoms (table 1).
we describe a 5-month-old child suspected to have an ileocecal intussusception, who ap-
peared to have miliary TB. This is an apparent example of the diverse and difficult ways TB can 
present. Because CTB should be in the differential diagnosis in such cases, we focussed on the 
different (non-respiratory) transmission routes of Mtb and the literature on CTB.
A “Cantwell” diagnostic criteria for congenital tuberculosis*
(1) lesions present in the first week of life
(2) a primary hepatic complex or caseating hepatic granulomas
(3) tuberculous infection of the placenta or maternal genital tract
(4) exclusion of the possibility of postnatal transmission by thorough investigation of contacts, including the infant’s 
hospital attendants, and by adherence to existing recommendations for treating infants exposed to tuberculosis.
B Symptom or Sign no. (%) of patients
(a) Hepatosplenomegaly 22 (76)
(b) Respiratory distress 21 (72)
(c) Fever 14 (48)
(d) lymphadenopathy 11 (38)
(e) abdominal distension 7 (24)
(f ) lethargy or irritability 6 (21)
(g) Ear discharge 5 (17)
(h) Papular skin lesions 4 (14) 
Table 1. The Cantwell criteria. * Cantwell et al. 2 described diagnostic criteria to differentiate congenital 
tuberculosis (A). at least one of these criteria (1-4) must be present, together with a (culture) proven 
tuberculosis, in order to make the diagnosis congenital tuberculosis. The presenting symptoms of 
congenital tuberculosis are very divers and differ in percentage of occurrence (B).
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CASE REPORT
a 5-month-old girl presented at a primary care hospital with a 5-day history of non-bloody 
diarrhoea. The patient had started vomiting two days previous to admission and had sub-
sequently developed a distended abdomen. She had developed a fever one day prior to 
admission.
The patient was the first child of an Indonesian mother and Dutch father and was born in 
the netherlands. The mother became pregnant spontaneously after several failed attempts 
of in vitro fertilization. Pregnancy and delivery were uneventful. Mother was HIV, HBsag and 
syphilis negative.
On physical examination, she appeared moderately ill, with a temperature of 37,5°C, pulse 
rate of 150/min, and respiratory rate of 30/min. She had a distended abdomen with sparse 
bowel sounds. The liver was slightly enlarged without splenomegaly. a non-tender mass was 
palpable in the right lower abdominal quadrant. Initial laboratory examination showed: Hb 
6,9 mmol/l, leucocytes 22,1x109/l with 43% granulocytes and 19% band-forms, and a CRP 
of 286 mg/l. The abdominal radiograph was normal, but the ultrasound showed a crescent-
in-doughnut sign or “multiple-concentric-ring-sign”, which was compatible with the initial 
diagnosis of ileocecal intussusception. There were no signs of appendicitis or abdominal 
abscesses. In an attempt to correct the intussusception with hydrostatic pressure, a barium 
enema was performed, which revealed a complete obstruction at ileocecal level. after the 
procedure, the patient developed a more distended abdomen, with deterioration of the 
clinical condition, metabolic acidosis and hyponatremia. She was subsequently referred to 
the intensive care unit of our tertiary care hospital.
Because of suspected intestinal ischemia or bowel perforation, a laparotomy was performed. 
This showed an inflammatory process in the ileocecal region with multiple adhesions, but 
indications for an intussusception or enlarged mesenteric lymph nodes were absent. Mainly 
in that region, the visceral and parietal peritoneum were covered with multiple white-greyish 
nodules with a diameter of 2-5 mm. auramine staining of multiple biopsies was mycobacteria 
positive. Culture of the nodules, ascites and gastric aspirate yielded Mtb.
CT-thorax showed miliary lesions throughout the lungs. Retrospectively, these fine lesions 
were already present on the preoperative chest radiograph, but unnoticed at that time. The 
CT-cerebrum and lumbar puncture excluded the presence of tuberculous meningitis. On reti-
noscopy a few choroidal tubercles were visible. The Tuberculin Skin Test (TST) was negative 
initially, but became positive one month later.
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Treatment was initiated with intravenous rifampicin and ciprofloxacin. within one week, the 
patient was able to take oral medication, so treatment switched to oral rifampicin, isoniazid, 
ethambutol and pyrazinamide. Isoniazid was discontinued when the Mtb strain showed 
resistance to isoniazid. Pyrazinamide was stopped after 2 months and treatment with rifam-
picin and ethambutol was continued for another 7 months. She fully recovered.
The TST of the father measured 22 mm; nonetheless his chest radiograph was normal. Since 
he did not have signs of active TB, he was diagnosed with a latent TB. The initial treatment 
was isoniazid but changed to rifampicin for 4 months when the strain, isolated from the child 
appeared to be isoniazid-resistant.
The mother, aged 30 immigrated to the netherlands at the age of 22. She was not Bacille 
Calmette-Guérin (BCG) vaccinated. The TST, on arrival in the netherlands, showed an indu-
ration of 18 mm. The chest radiograph showed a small pleural adhesion and calcification 
suspect for primary TB complex. The mother was not treated but followed for 2 years, by 
half-yearly chest radiographs, which remained unchanged.
after diagnosing TB in the child, we advised the mother to consult an internist and gynaeco-
logist to evaluate the presence of extra-pulmonary TB. However, the mother refused further 
examination, but when she developed fever and backache, investigations showed right-
sided hydronephrosis. The pyelum was drained by nephrostomy and urine samples showed 
acid-fast rods and PCR confirmed Mtb.
at that time, it became apparent that the mother had consulted a gynaecologist because 
of fertility problems. an abdominal ultrasound, at that time, showed calcification in the 
right ovary and tube. The mother refused further analysis of the ovarian lesions and no final 
diagnosis was made
Because the child’s Mtb strain was isoniazid-resistant, the mother received 2 months rifam-
picin, ethambutol and pyrazinamide followed by 7 months rifampicin and ethambutol. after 
2 months, when infection parameters had normalised, nephrectomy of the right kidney was 
performed. Histopathology analysis revealed extended granulomatous inflammation and 
caseous necrosis of the kidney. The strain recovered from the mother’s urine sample had the 
same Restriction Fragment length Polymorphism (RFlP)-pattern as the strain isolated from 
the child (figure 1). These two strains together form cluster 7195 and are unique in the neth-
erlands. The exclusive RFlP-pattern is indicative for the transmission of the Mtb strain from 
the mother to the child.5 Since the RFlP-pattern is unique in the netherlands, one can argue 
that the TB infection of the mother took place in another country or before RFlP analysis was 
done on all Mtb strains in the netherlands.
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according to the Dutch guidelines for contact and source tracing, the investigation of extra 
pulmonary TB patients focuses on the identification of a possible infectious source case. 
During these investigations by the Municipal Health Service, it became apparent that none 
of the 16 examined contacts (including the grandparents) had pulmonary TB. Ten of these 
contacts were examined with a TST. as mentioned above, the father of the child was the 
only person with a positive TST and thus treated for latent TB. Since there was no case of 
active (contagious) TB found, respiratory infection of the child became unlikely. This finding, 
together with similar and unique RFlP-pattern of the strains isolated from the mother and 
child, directed the differential diagnosis strongly to neonatal or CTB.
DISCuSSIOn
To our knowledge, this is the first report of TB mimicking an intussusception. Only after lapa-
rotomy the suspected intussusception became manifest as TB. Probably the obstruction of 
the bowel, that caused the symptoms, was due to the inflammatory process and the multiple 
adhesions. Because of the acute presentation, there was no substantial diagnostic delay in 
this patient, in contrast with many other cases with a gradual increase of symptoms. This 
diagnostic delay is of great importance, since it is an important determinant of poor disease 
outcome.3-4
The atypical presentation might lead to underestimation of the incidence of TB, especially in 
settings with inadequate access to health care and diagnostic facilities and undiagnosed TB 
or CTB, might be the cause of some unexplained infant-death.6
The Royal netherlands Tuberculosis association (knCV) registers the incidence of TB in the 
netherlands. In their surveillance report on the incidence of TB from 1996-2005, they showed 
that the incidence of TB in children between 0 and 14 years of age, is on average 3.0 per 
100.000 (range 1.7-3.9).7 Since CTB is a rare presentation of TB, there is no specific registration 
of CTB and therefore correct incidence number is difficult to give. In the literature there is 
only one Dutch case of CTB described in the last 50 years.4
IS6110 RFLP
NLA000500898
NLA000501250
7195
7195 Moeder
DochterN 005 0 98 7195 Daughter
N 00501250 7195 Mother
figure 1. The IS6110 restriction fragment length polymorphism (RFlP) analysis of the Mycobacterium 
tuberculosis strains isolated from the daughter (nl a 000500898) and the mother (nl a 00501250) showed 
to be identical. These 2 strains are unique for the netherlands.
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Extra-pulmonary TB, like genitourinary TB, occurs more often in developing countries, prob-
ably due to poorer treatment of pulmonary TB. about 20 percent of TB patients develop 
extra-pulmonary symptoms, 20-40 percent of those involve the genitourinary system.8 Most 
genitourinary TB cases are the result of haematogenous spread of mycobacteria from the 
primary pulmonary focus to the kidney and female genital organs. Genital TB often results in 
infertility. Consequently, the likelihood of vertical transmission decreases when the female 
genital organs are involved.
Possible routes of infection in-utero are haematogenous spread through the umbilical vein 
or ingestion of infected amniotic fluid. Transmission during labour is possible through direct 
contact with an infected birth canal or ingestion of infected amniotic fluid or urine. non-
respiratory infection after birth can be by ingestion of infected urine (which is highly conta-
gious) from an infected carrier and is possible when appropriate precautions are not taken.
The best prevention of transmission is to treat the mothers during pregnancy. Treatment of 
the (extra-) pulmonary TB of the pregnant women should be started as soon as possible, to 
guarantee the best treatment outcome.9 The place of isoniazid in this treatment is still under 
debate, because the prevention of TB might result in isoniazid-induced hepatitis, which 
increases the death rate of the unborn child. Other (new) medication enabling the treatment 
of (latent) TB without isoniazid possible could solve this problem.9
another route of infection is via infected mother milk, though accurate risk analysis on 
this matter is missing. One can argue that women with a high Mtb burden, who even have 
the bacteria in their blood, are at risk to transmit the disease this way. also when there are 
extra-pulmonary caseous lesions in the breast, the possibility of transmission is increased. 
Therefore, when a child is suspect for TB, without a liable route of respiratory infection, breast 
examination of the mother is indicated.
In CTB, the route of transmission directs the presentation and pattern of infection.2-3 Intra-
uterine infection via the umbilical vein typically results in a primary complex in the liver.10 It 
is known that, infection by aspiration or ingestion may give a primary infection in the lung 
or gut, and direct inoculation onto fragile epithelia even e.g. in the middle ear.11 Postnatal 
transmission of TB by inhalation of the bacteria is the most frequent mode, giving a primary 
complex in the periphery of the lung. In adults only a minority of Mtb infected persons de-
velop active infection. In children this proportion is not exactly known but considered to 
be higher because of an immature immune response. Therefore TB will also more easily dis-
seminate in young children.11 nonetheless, in neonates, possibly protective immunity of the 
mother could help to prevent development of active TB. This protective immunity through 
placental transmission of active elements of the immune system such as transfer-factors 
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might explain some cases of delayed CTB onset.12 Immature immune response of infants 
also explains a reduced value of the TST. For that reason, in case of suspected CTB, specific 
staining and cultures of gastric aspirates, urine and cerebral spinal fluid are mandatory. In 
addition aspirates and/or biopsies from affected organs are required. Furthermore, cerebral 
and thoraco-abdominal CT-scan or MRI and fundoscopy are essential to detect dissemina-
tion. To confirm congenital transmission, a thorough evaluation of possible sources of TB is 
necessary, including evaluation for maternal genitourinary TB.
To further understand the difficulties of CTB, a literature review on the “recent” publications 
related to CTB provides the following observations. Singh et al. described in 2007, four dif-
ferent cases of TB in young infants, all presented with divers, aspecific symptoms.13 Of these 
four cases, only one was classified as a CTB, due to the early onset of disease and the absence 
of an index patient at the time of presentation. In the CTB case, the mother of the child (like 
in our case) presented herself with neurological complains due to multiple tuberculomas 
one week after the TB diagnosis of the child. Singh et al. argue that it might be better to use 
the term perinatal TB instead of CTB or neonatal TB, because that differentiation is only of 
epidemiological importance and can be difficult.
nicolaidou et al. reported a classical case of CTB in 2005. They described a 1-month-old baby 
that was infected by endometrial TB during pregnancy. The mother did not have any symp-
toms during pregnancy, had no history of TB and remained with a normal chest radiograph. 
The only sign of possible infection was a positive TST. This lack of symptoms is seen more 
often. In about 75 percent of the cases of CTB, the pregnant women remained asymptomatic 
during the extra-pulmonary TB and as a result were misdiagnosed.4,14 again this case showed 
that CTB can present itself like a more common infection and delay in the correct therapy can 
be the result.3 Therefore, when a child does not respond to broad-spectrum antibiotics and 
supportive treatment, CTB should be in the differential diagnosis and unless a high index of 
suspicion is maintained the diagnosis can be missed.13,15
The similarity of strains, active genitourinary TB in the mother and absence of another source 
of TB, which is one of the Cantwell criteria’s, supports our hypothesis that transmission 
occurred pre- or perinatally. unfortunately, no endometrial biopsies were performed and 
therefore we cannot exclude intra-uterine exposure. Furthermore postnatal transmission of 
Mtb via breast milk or infected urine of the mother cannot be excluded. nonetheless we 
hypothesise that in our case transmission of mycobacteria occurred by ingestion of infected 
urine during delivery, because of the massive renal infection of the mother and the pos-
sible high risk of exposure to the infected urine, during labour. Since our patient was almost 
five months (136 days) on presentation, far above the average of previously reported cases 
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of CTB, we would like to illuminate that clinicians should consider CTB in their differential 
diagnosis even after the age of 3 months.
In conclusion, our case demonstrates that TB can present in a non-specific way. To our 
knowledge this is the first report of TB in an infant that is mimicking an intussusception. The 
way of infection of this child, where aerogenic infection is very unlikely, can be aspiration 
or ingestion of infected amniotic fluid, urine or breast milk, which could have taken place 
before, during or after birth.
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ABSTRACT
There are limitations on diagnostic methods to differentiate between active and latent 
tuberculosis (TB), and the prediction of latent progression to TB disease is yet complex. Tra-
ditionally, tuberculosis-specific host immune response was visualized using the tuberculin 
skin test. nowadays, IFn-γ release assays (IGRa) provide a more specific and sensitive tool, 
by which exposure to Mtb could be determined. However, the merit of IGRa in diagnosing 
active TB is yet unclear.
we adapted IGRa for use in mice, and quantifying bead-based flow cytometry techniques 
were used to assess cytokine profiles during the course of untreated infection and to investi-
gate the value of IGRa and cytokines as biomarkers for therapy response.
High variability of IGRa results during progression of active TB infection related to various 
phases of infection was obtained. However, a significant decrease in IGRa results and in levels 
of IFn-γ, Il-17, IP-10 or MIG was observed and appeared to be associated with successful 
therapy.
This outcome does not support the value of IGRa to accurately diagnose active TB or to moni-
tor infection progression. However, IGRa proved to be a useful biomarker to monitor therapy 
success. In addition, different cytokines might serve as biomarkers.
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InTRODuCTIOn
Diagnosing tuberculosis (TB) remains complex and challenging. Differentiating between 
latent TB infections (lTBI) and active TB is of vital importance. Various tools for diagnosing 
TB are available. First, there is detection of Mycobacterium tuberculosis (Mtb) in sputum and 
other fluids (e.g. microscopic determination of bacilli, culture or amplification of Mtb-specific 
genome parts). Second, recognition of TB can be made in terms of disease presentation (e.g. 
patient anamnesis or chest radiography) or detection of a TB-specific host immune response 
(e.g. tuberculin skin test (TST) or interferon gamma (IFn-γ) release assays (IGRa). a limitation 
of the gold standard, that is, Mtb culture, is that it may take as long as 6 weeks, so more rapid 
detection of TB is needed. Therefore, numerous studies have been performed to identify 
biomarkers to detect TB infection, among which IGRa as potential biomarker.1-4 The dynamics 
of IGRa during the course of untreated TB in not yet clear. The goal of the present study was 
to provide further insight in this respect and to investigate the value of IGRa as a biomarker 
to monitor therapy response.
IGRa are in vitro tests detecting an immune response to Mtb-specific antigens. IGRa was 
introduced in the last decade as replacement of the TST and should provide more specific 
test results in lTBI without cross-reactivity after a Bacillus Calmette-Guérin vaccination.5 Cur-
rently, two different IGRa are available, QuantiFEROn-TB Gold (QFT; Cellestis ltd, Carnegie, 
Victoria, australia) and T.SPOT. TB ElISpot (ElISpot; Oxford Immunotec, abingdon, uk). Both 
tests are based on quantitative measurement of IFn-γ production by peripheral blood cells 
after stimulation with the Mtb-specific peptides early-secreted antigenic target-6 (ESaT-6) 
and culture filtrate protein-10 (CFP-10). Both IGRa showed excellent specificity that is unaf-
fected by earlier BCG vaccination.5 Several studies showed that T-SPOT.TB was more sensi-
tive than QFT or TST.2,5 an important annotation to these findings is the absence of a gold 
standard to diagnose lTBI. nevertheless, the CDC recommended that QFT can be used in all 
circumstances in which TST was used, including contact investigations, evaluation of recent 
immigrants, and sequential-testing surveillance programs for infection control.6 This advice is 
incorporated in many national guidelines. at present the merit of IGRa for diagnosing active 
TB, additionally to their use in diagnosing lTBI, is still under debate.
From clinical studies the additional value of using respiratory samples next to blood samples 
for IGRa is not (yet) clear. It is hypothesized that an IGRa performed in a sample from the 
primary site of infection (e.g. the lungs) might differentiate between active TB and lTBI. In pa-
tients bronchoalveolar lavage fluid or pleural fluid is used in such a way.7 In the present study 
we also addressed this matter, by comparing respiratory sample IGRa results with blood IGRa 
results. additionally, we assessed the cytokine/ chemokine profile in serum samples from 
mice at the acute and chronic phases of TB infection and during therapy and investigated 
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the diagnostic value of 17 immunological markers using a multiplex panel of bead-labelled 
cytokine and chemokine receptors.
In order to provide further insight into the dynamics of IGRa we adapted IGRa for use in our 
murine TB model.8 a mouse model enables investigation of the value of this new test during 
the acute phase and chronic phase of infection and during standardized, well-controlled 
therapy. In animal models comparative studies at similar conditions of severity and duration 
of infection and therapy exposure can be performed, which is difficult in patients due to 
different underlying clinical conditions.9
MATERIAlS AnD METhODS
Animals  
Specified pathogen-free female BalB/c mice, obtained from Charles River (les Oncins, 
France) were infected at 10–12 weeks of age, as described previously.8 The experimental 
protocols adhered to the rules specified in the Dutch animal Experimentation act and the 
published Guidelines on the Protection of Experimental animals by the Council of the EC. 
The Institutional animal Care and use Committee of the Erasmus MC Rotterdam approved 
the present protocols.
Infection  
Mice were infected through intratracheal instillation of a 40-μl suspension containing 9.4x104 
CFu Mtb (H37Rv), as previously described.8
Anti-tuberculosis drugs  
Therapy was administered from 4 weeks after the infection onwards. The therapeutic regi-
men consisted of a combination of isoniazid, rifampicin and pyrazinamide during the initial 
phase of 9 weeks, followed by a combination of isoniazid and rifampicin during 4 weeks, as 
described previously.8 anti-tuberculosis drugs were administered in human pharmacokinet-
ic-equivalent doses.10-11
Interferon-gamma release assay  
Peptides ESaT-6 / CFP-10 were synthesized by Pepscan (Pepscan Therapeutics, lelystad, The 
netherlands). Blood samples were obtained from sacrificed mice by cardiac puncture at 
indicated time points. In mice receiving therapy, administration of anti-tuberculosis drugs 
was stopped 72 h before dissection. within 15 minutes of collection of blood, the heparin-
ized samples were diluted five times using a mixture of RPMI 1640 medium (Biowhittaker–
Cambrex, East Rutherford, new Jersey, uSa) enriched with 2 mM lglutamine (Invitrogen, 
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Carlsbad, Ca, uSa), 100 units of 100 μg/ml penicillin-streptomycin solution (Invitrogen), 10% 
heat-inactivated fetal calf serum (Invitrogen) and β-mercaptoethanol 0.002‰ (Sigma M7522, 
Sigma Chemical, St. louis, MO, uSa). Samples were divided into three portions, and stimu-
lated with either concanavalin a (Invitrogen) in a final concentration of 10 μg/ml (positive 
control) or with enriched RPMI 1640 medium (negative control) or with a peptide mixture 
of ESaT-6 and CFP-10 (Pepscan) both in a final concentration of 0.25, 0.5, 1 or 2 μg/ml (Mtb-
specific antigen response). after incubation for 24, 48, 72 or 96 hrs, at 37°C and 5% CO2, 50 
μl of the supernatant was used to assess the IFn-γ concentration in duplicate, employing the 
Mouse IFn-γ ElISa-kit II according to the manufacturers protocol (Becton Dickinson, Franklin 
lakes, nJ, uSa) and a Bio-Rad Elisa Reader model 680 (Bio-Rad laboratories, Veenendaal, the 
netherlands). To prepare lung cell suspensions from sacrificed mice the lungs were aseptically 
removed and processed using a cell strainer with 70 μm nylon mesh (Becton Dickinson). Cell 
suspensions were subsequently processed according to the protocol described for blood.
Cytokine / chemokine concentrations in EDTA plasma  
Quantification of cytokines / chemokines was performed using a bead-based flow cytometry 
technique (xMap; luminex Corporation, austin, TX, uSa). The mouse soluble cytokine recep-
tor multiplex panel used (Millipore Corporation, Billerica, Ma, uSa), consisted of a beadla-
belled cytokine receptor against the following biomarkers: GM-CSF, IFn-γ, Il-1β, Il-2, Il-4, Il-6, 
Il-10, Il-12 (p40), Il-13, Il-17, IP-10, M-CSF, MCP-1, MIG, MIP-1α, MIP-1β and TnF-α. Tests were 
performed according to manufacturers protocol. Samples were tested in duplicates. Results 
in median fluorescence intensity (MFI) values were converted to pg/ml using MIllIPlEX 
analyst software (Millipore) and subsequently averaged. Statistical analysis was performed 
using a two-tailed, unpaired Mann-whitney test. Only statistically significant (p-value ≥0.05) 
changes in cytokine concentrations were presented.
RESulTS
Adaptation and interpretation of IGRA in mice with untreated TB infection  
To optimize IGRa for use in our mouse TB model, in blood samples obtained from phosphate 
buffered saline (PBS)-inoculated control mice and TB-infected mice at different ages, the op-
timum concentration of antigens ESaT-6 and CFP-10 peptides and the optimum time period 
of incubation were determined. In blood from TB-infected mice a maximum IFn-γ production 
after stimulation with 1 μg/ml of each peptide was found and optimum time of antigen ex-
posure was 72 h (data not shown). IFn-γ production level resulting from exposure of blood to 
Mtb-specific antigens minus IFn-γ concentrations present in the negative controls was used 
as final read-out of the test and referred to as IGRa results, similar to the evaluation of IGRa 
results obtained in human blood.
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at week four of the TB infection, six individual mice were investigated; different responses 
were obtained (figure 1). a distinct pattern per mouse was observed. Three out of six mice 
showed that a high response in the positive control (figure 1d) also showed a high response 
on Mtb-specific antigens stimulation (figure 1b) and a high response in the negative control 
(figure 1a). These mice still showed a high IGRa result (figure 1c). Three out of six mice showed 
overall lower responses.
IGRA in blood during the course of untreated TB infection in mice  
Dynamics in immune response, expressed in IGRa results during the course of infection, are 
shown in figure 2. In the acute phase of TB, the positive control response was present at 
week 1 and remained at a certain level (figure 2b). However, IGRa results were not observed 
at week 1, but were significantly induced at week 3 and week 4 (figure 2a). at the beginning 
of the chronic phase of the TB infection, IGRa results dropped dramatically between week 
4 and week 9 (figure 2a), whereas positive control response did not decrease (figure 2b). In 
order to determine sequestration, IGRa were performed in suspensions of lung cells from 
infected mice at 4, 9 and 17 weeks of infection. High IGRa results in lung cell suspensions 
were observed at 4 weeks of infection, reflecting high activity of lung T-cells upon stimula-
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figure 1. IFn-γ production in blood from six individual mice at 4 weeks after untreated TB infection. 
Blood samples were processed in IGRa. (A) negative controls. (B) Mtb-specific-antigens responses after 
stimulation with ESaT-6 and CFP-10. (C) IGRa results (Mtb-specific antigens responses minus the negative 
controls). (D) Positive controls. Data shown are mean IFn-γ concentrations of measurements in duplicate.
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tion with Mtb-specific-antigens (data not shown). During the course of infection IGRa results 
in lung cells observed at week 4 decreased 15-fold at week 9 and another 1.5-fold at week 
17 (data not shown). From 9 weeks after infection onwards IGRa results in blood gradually 
and significantly increase until 15-fold response at week 17 compared to 9 weeks of infection 
(figure 2a). Interestingly, also positive control response increased 4-fold in that period (figure 
2b).
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figure 2 IFn-γ production in blood from mice (n=7) during the course of untreated TB infection and 
TB-infected mice receiving therapy. Blood samples were processed in IGRa.Mice without therapy (dark 
gray bars) and mice receiving therapy (diagonally striped bars). (A) IGRa results (Mtb-specific-antigens 
responses minus the negative controls). (B) Positive controls. Data shown are mean IFn-γ concentrations 
of measurements in duplicate. The whiskers represent the standard deviation (SD). Statistical significance if 
present (p-value ≤0.05) is indicated.
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IGRA in blood of TB-infected mice receiving therapy 
IGRa results in blood from mice both after 5 weeks and after 13 weeks of therapy were 
significantly decreased compared to untreated TB-infected mice (figure 2a). Positive control 
response did not significantly change after 5 weeks of therapy, but was lower after 13 weeks 
of therapy (figure 2b). when, after 13 weeks, the therapy was stopped, IGRa results did not 
increase again at 6 weeks after termination of therapy. Even at 13 weeks after therapy termi-
nation, when relapse of TB infection in terms of increased numbers of Mtb in the lung and 
Histopathological changes was observed [8], IGRa results remained low (data not shown).
Cytokine or chemokine profile in plasma during the course of untreated TB 
infection in mice and TB-infected mice receiving therapy
Five of the 17 cytokines and chemokines assessed showed a dynamic profile with significant 
changes during infection progression or following therapy (figure 3). IFn-γ concentration in 
blood reached a maximum at 4 weeks after infection. During the chronic phase of infection 
IFn-γ concentration significantly decreased. as found for IFn-γ also Il-17 and IP-10 showed 
an initial increase, which resulted in peak concentrations at 4 weeks after infection, followed 
by a decrease from that time. Dynamics of TnF-α concentration showed a somewhat different 
pattern, with increased concentrations from week 4 onwards. MIG concentrations during the 
course of the untreated infection were constant.
In mice receiving therapy, concentrations of IFn-γ, Il-17, IP-10 and MIG were decreased after 
5 weeks of therapy, which was also observed after 13 weeks of therapy except for IFn-γ. 
Decreased levels of TnF-α were only observed after 13 weeks of therapy (figure 3).
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figure 3: Concentrations of cytokines or chemokines in plasma from mice (n=4) during the course of 
untreated TB infection and TB-infected mice receiving therapy: mice without therapy (dark gray bars) and 
mice receiving therapy (diagonally striped bars). Data shown are mean concentrations of cytokines or 
chemokines of measurements in duplicate. The whiskers represent the standard deviation (SD). Statistically 
significance if present (p-value ≤0.05) is indicated.
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DISCuSSIOn
In this study the dynamics of IGRa in TB infection and the effect of therapy were investigated 
in a mouse model. To this aim IGRa was optimized for use in mice. we observed a variety 
in IGRa responses between individual mice, which might be explained by differences in 
phase of TB infection in these mice and hence the number of reactive T-cells in blood. In a 
previous study, we showed that around 4 weeks after Mtb inoculation, the acute phase of 
infection progresses into the chronic phase.8 at that time point mouse to mouse variation in 
T-cell response can be expected. unfortunately, T-cell numbers in blood of TB-infected mice 
could not be determined, since the fluorescence-activated cell sorting technique using Mtb 
infected blood samples could not be performed at our institute due to safety regulations.
Dynamics in immune response expressed in IGRa results during TB showed a very slow start, 
which might be due to T-regulatory cell activity in the initial phase of infection, as described 
by Shafiani et al.11 However, a significant increase in IGRa results was observed up to 4 weeks 
after infection. The observed fall in IGRa results at 9 weeks after inoculation suggests that 
this might be due to migration of specific T-cells to the lung and/or due to strong regulation. 
IGRa results in lung cell suspensions during the active phase of infection showed indeed 
peak values at 4 weeks after infection. These data are in concordance with the study of arko-
Mensah et al.1, showing that increased levels of (free) IFn-γ in the respiratory tract correlated 
with active pulmonary TB in mice. However, our observation that IGRa results in lung T-cells 
decreased after 4 weeks of infection (data not shown) discarded the hypothesis that migra-
tion of T-cells to the lung was responsible for decreased IGRa results in blood. Possibly the 
decline in IGRa result might be due to down-regulation of T-cells.12 It may also be related to 
the IFn-γ depressing capacity of Mtb during the active infection, by inhibiting IFn-γ receptor 
signalling, as demonstrated in a study of Sahiratmadja et al.13 The observed increase in IGRa 
results and positive results from 9 weeks of infection onwards might reflect an increase in 
cellularity associated with severity of disease in mice during the advanced phase of TB.
The data obtained in this animal model of TB do not support the value of IGRa in blood to 
diagnose active TB. IGRa responses are highly variable according to various phases of active 
infection and might lead to false negative results during active TB. These findings are in line 
with a recent review by Hooper et al., who concluded that there is inadequate evidence to 
support the use of IGRa in the diagnosis or exclusion of active pleural TB in patients.14
However, the data of the present study suggest that IGRa might be a useful biomarker to 
monitor therapy response. Our results are in line with the findings obtained by lee et al, 
demonstrating that IGRa results decreased after successful treatment.15. In our experimental 
TB model, it was also demonstrated that, next to IFn-γ, also Il-17 and IP-10 as cytokines in 
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the pro-inflammatory reaction cascade, might be adequate markers indicative for successful 
therapy. The results of the dynamics of free IFn-γ concentrations as a biomarker during the 
different phases of infection are in concordance with results earlier described in other stud-
ies.8,16 However, it should be noted that the free IFn-γ concentration level in blood is also 
influenced by other factors not related to the TB infection. The TnF-α concentrations also 
revealed a strong increase during the acute phase of infection and sustained high concentra-
tions throughout the chronic phase of infection. MIG concentrations showed no dynamics 
during the course of infection but revealed to be an adequate marker in therapy effect and 
in that perspective might contribute to proper follow-up of patients starting anti-TB therapy. 
These results indicate that besides IFn-γ also the pro-inflammatory cytokines like Il-17, IP-10, 
TnF-α and MIG are adequate biomarkers in the acute phase of infection. Recruiting T-cells, 
macrophages and neutrophils have a strong Th-1 reaction in this phase. In the present TB 
model changes in cytokine concentrations can be related to the TB infection. It should be 
realised that changes in pro-inflammatory cytokines can be caused by many other factors. 
However, the use of these cytokines to measure therapy efficacy seems achievable when 
using two paired samples taken before the start of therapy and after 3 weeks.
To our knowledge, only Beamer et al. reported studies on the use of IGRa in a mouse TB model. 
They showed that IGRa results from blood samples after exposure to Mtb-specific-antigens 
reflected IGRa results in lung cells.17 They observed that a low IFn-γ response to Mtb-specific-
antigens was associated with elevated risk of severe disease, compared to high responders. 
Their study using various mouse strains demonstrated that the course of TB was different and 
dependent on the mouse strain used, which is also reflected in their IGRa results.17
Summarizing, the present study demonstrates a limited value of IGRa to monitor infection 
progression or even to detect active TB infection. These animal data do not support use of 
IGRa as an accurate diagnostic tool for active TB. By contrast, the value of IGRa in monitor-
ing therapy response in the acute phase of TB infection is demonstrated. This may indicate 
that IGRa can be an adequate biomarker for therapy failure due to Mtb resistance. also, a 
decrease in plasma concentrations of IFn-γ, Il-17, IP-10 or MIG was associated with successful 
therapy. as it is known that in TB patients the concentrations of cytokine biomarkers can be 
influenced by other non-TB-related factors, IGRa as a TB-specific biomarker is preferable to be 
used for monitoring therapy efficacy in TB patients.
69
Value of IGRa in tuberculosis diagnosis
REfEREnCES
 1. arko-Mensah J, Rahman M, Julian E. et al. Increased levels of immunological markers in the re-
spiratory tract but not in serum correlate with active pulmonary mycobacterial infection in mice. 
Clin Microbiol Infect 2009; 15: 777-86
 2. Diel R, loddenkemper R, nienhaus a. Evidence based comparison of commercial interferon-
gamma release assays for detecting active tuberculosis -- a meta-analysis. 2010 apr; 137(4):952-6
 3. Jiang J, Shi H, liang Q. et al. Diagnostic value of interferon-gamma in tuberculous pleurisy: a 
metaanalysis. Chest 2007; 131:1133-41
 4. lange C, Pai M, Drobniewski F. et al. Interferon-gamma release assays for the diagnosis of active 
tuberculosis: sensible or silly? Eur Respir J 2009; 33:1250-3
 5. Pai M, Zwerling a, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent 
tuberculosis infection: an update. ann Intern Med 2008; 149: 177-84
 6. national Tuberculosis Controllers a, Centers for Disease Control and P. Guidelines for the investi-
gation of contacts of persons with infectious tuberculosis. Recommendations from the national 
Tuberculosis Controllers association and CDC. MMwR Recomm Rep 2005; 54: 1-47
 7. Jafari C, Thijsen S, Sotgiu G. et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid 
diagnosis of tuberculosis: a Tuberculosis network European Trialsgroup study. am J Respir Crit 
Care Med 2009; 180:666-73
 8. De Steenwinkel J, De knegt G, Ten kate M. et al. Immunological parameters to define infection 
progression and therapy response in a well-defined tuberculosis model in mice. Int J Immuno-
pathol Pharmacol 2009; 22:723-34
 9. Bakker-woudenberg Ia. Experimental models of pulmonary infection. J Microbiol Methods 2003; 
54:295-313
 10. Rosenthal I, Zhang M, williams k. et al. Daily dosing of rifapentine cures tuberculosis in three 
months or less in the murine model. PloS Med 2007; 4:e344
 11. Shafiani S, Tucker-Heard G, kariyone a. et al. Pathogen-specific regulatory T cells delay the arrival 
of effector T cells in the lung during early tuberculosis. J Exp Med 2010; 207:1409-20
 12. Joosten S, van Meijgaarden k, Savage n. et al. Identification of a human CD8+ regulatory T cell 
subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc natl acad 
Sci uSa 2007; 104:8029-34
 13. Sahiratmadja E, alisjahbana B, de Boer T. et al. Dynamic changes in pro- and anti-inflammatory 
cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis 
disease activity and response to curative treatment. Infect Immun 2007; 75:820-9
 14. Hooper C, lee Y, Maskell n. Interferon-gamma release assays for the diagnosis of TB pleural effu-
sions: hype or real hope? Curr Opin Pulm Med 2009; 15:358-65
 15. lee S, lee C, Yim J. Serial interferon-gamma release assays during treatment of active tuberculosis 
in young adults. BMC Infect Dis 2010; 10:300
 16. Gonzalez-Juarrero M, kingry l, Ordway D. et al. Immune response to Mycobacterium tuberculosis 
and identification of molecular markers of disease. am J Respir Cell Mol Biol 2009; 40:398-409
 17. Beamer G, Flaherty D, Vesosky B. et al. Peripheral blood gamma interferon release assays predict 
lung responses and Mycobacterium tuberculosis disease outcome in mice. Clin Vaccine Immunol 
2008; 15:474-83

Chapter 6
Relapse of tuberculosis versus primary tuberculosis; 
course, pathogenesis and therapy in mice
J.E.M. de Steenwinkel, G.J. de knegt, M.T. ten kate, H.a. Verbrugh, 
R. Hernandez-Pando, P.J.M. leenen, I.a.J.M. Bakker-woudenberg
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ABSTRACT
Relapse of tuberculosis (TB) is defined as re-emergence of clinical symptoms after stopping 
anti-TB treatment, while this treatment appeared effective initially. Relapse of TB can occur in 
patients that are therapy-compliant, but the risk of relapse of is dramatically increased when 
patients are non-compliant. additionally, the probability of antibiotic resistance is higher in 
those patients who have a relapse of TB and thus longer treatment is recommended. Fur-
ther insight in the pathogenesis of relapsing TB could provide a basis for future treatment 
improvement. In the present study, using a murine TB model, we assessed the differences 
between primary TB and relapse of TB in terms of mycobacterial load in infected organs, 
(immuno-) histopathology, and plasma cytokine concentrations. Compared to primary TB, in 
relapse of TB we observed a lower mycobacterial load in lung, spleen and liver at the phase of 
established infection. also the levels of TnF-α, IFn-γ, Il-6, MIG/CXCl9, IP-10/CXCl10 and Il-17 
were significantly lower. It was observed that in relapse of TB memory Th-1 cells were locally 
and systemically expanded and congregated in the lung, permitting an efficient control of 
Mtb growth. Treatment response in relapse of TB is as good as the treatment response in 
primary TB; thereby no supportive evidence could be given for the recommended longer 
treatment duration in case of relapse of TB.
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InTRODuCTIOn
Tuberculosis (TB) remains an infectious disease that requires extremely lengthy treatment.1 
a number of studies are ongoing to reduce treatment duration using new TB drugs while 
preserving treatment efficacy.2 However, the current (minimal) six-month therapy leads to 
many problems, among which the high proportion of patients failing to adhere to the TB 
treatment.3 as a result of this non-compliance (non-adherence) of patients, especially in 
TB-HIV co-infected patients there seems to be an increased risk of therapy failure, resulting 
in relapse of infection and/or development of resistance.3-6 These potential problems were 
among the driving forces to enrol patients in Directly Observed Therapy (DOT) programmes.7
Recurrent TB infection should be divided into relapse of infection and re-infection, which are 
two fundamentally independent forms of TB infection.8 Re-infection occurs in endemic areas 
where there is high incidence of TB in a crowded population (such as prisons and townships), 
with limited coughing hygiene and high vulnerability to infection due to malnutrition and 
HIV infection.3-4 Thus, re-infection is an infection caused by a new (exogenous) strain of Myco-
bacterium tuberculosis (Mtb). In contrast, relapse of TB infection is recurrence of an untreated 
or inadequately treated TB infection, with the same (endogenous) Mtb strain.
Regarding the therapy of re-infection versus relapse of infection a different approach is 
needed. Re-infection of TB can be considered as a new primary infection allowing standard 
regimens to be started. This re-infection occurs often, partly because patients that had TB 
once have a strongly increased risk of developing TB when they are re-exposed.9 In contrast 
to re-infection with TB, relapse of TB infection carries an increased risk of infection due a 
resistant variant of their original mycobacterial strain persisting after inadequately-treated 
primary TB infection, and re-growing during the relapse period.10 as a consequence, the 
recommended treatment for relapsing TB infection is an 8-month re-treatment regimen, 
consisting of 2 months of isoniazid, rifampin, pyrazinamide, ethambutol and streptomycin 
followed by 1 month of isoniazid, rifampin, pyrazinamide and ethambutol and finally 5 
months of isoniazid, rifampin and ethambutol.7
The present study was performed to investigate the course and pathogenesis of relapse of 
TB versus primary TB. In our mouse TB model we induced relapse of TB by administration of 
suboptimal TB therapy to mice with primary TB infection, in this respect closely mimicking 
non-compliance of patients.11 Parameters to characterize the course of TB infection were 
quantitative mycobacterial cultures from infected organs, histopathology in infected organs 
and cytokine profile in blood. In addition, we investigated differences in therapy response of 
mice with primary TB versus mice with relapse of TB.
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MATERIAlS AnD METhODS
Bacterial culture
Mtb strain H37Rv (aTCC 27294) was used. Bacterial suspensions were cultured in Middlebrook 
7H9 broth (Difco laboratories, Detroit, MI, uSa), supplemented with 10% oleic acid-albumin-
dextrose-catalase enrichment (OaDC, Baltimore Biological laboratories, Baltimore, MD, uSa), 
0.5% glycerol (Scharlau Chemie S.a, Sentmenat, Spain) and 0.05% Tween 20 (Sigma Chemical 
Co, St. louis, MO, uSa), under shaking conditions at 96 rpm at 370C. Mtb suspensions were 
stored at -80°C. Cultures on solid media were grown on Middlebrook 7H10 agar (Difco), 
supplemented with 10% OaDC for 21 days at 37°C with 5% CO2.
Primary TB, relapse of TB, and treatment with anti-TB drugs  
Experimental TB in mice was established via infection using the respiratory route, as described 
previously.11 In short, TB drugs dosage and schedules used were derived from current clinical 
guidelines.12-13 Isoniazid, rifampin and pyrazinamide, in human pharmacokinetic-equivalent 
doses 14-16 were administered, as described previously.11 In short, treatment of primary TB was 
started at 4 weeks after Mtb inoculation, when patches of pneumonic lesions were observed 
and established infection was confirmed by stabilization of the Mtb load in infected organs 
and TB-characteristic histopathological findings 11. Treatment consisted of a 9-week initial 
phase followed by a 4- or 17-week continuation phase. During the initial phase, animals 
received a combination of isoniazid [25 mg/kg], rifampin [10 mg/kg] and pyrazinamide [150 
mg/kg]. In the continuation phase, animals continued with isoniazid and rifampin. agents 
were administered subcutaneously once daily, 5 days a week. In mice with primary TB, treated 
for 13 weeks only, relapse of TB infection occurred in all mice at the end of the 13-weeks 
post-treatment period. at that time point the treatment of relapse of TB was started and 
continued for 26 weeks.
Determination of viable Mtb counts in infected organs and blood  
at indicated time points mice (n=4 per time point) were sacrificed by CO2 exposure. The lung, 
spleen and liver were removed aseptically and processed as described previously.11 Blood 
samples were taken via cardiac puncture and the entire organs were removed and homog-
enized in 2 ml PBS. From the undiluted tissue homogenate and the 10-fold serial dilutions of 
the homogenate, samples of 200 μl were plated onto solid medium for CFu counting after 3 
weeks of incubation of the subculture plates.
Selection of drug-resistant Mtb  
In order to detect the presence of drug-resistant Mtb mutants, samples from infected tissue 
homogenates were cultured on rifampin-containing and isoniazid-containing solid media. 
The concentrations of rifampin and isoniazid in the subculture plates were 4-fold the “critical 
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concentration”, and were 4 mg/l rifampin, 0.8 mg/l isoniazid. Resistant Mtb colonies, able 
to grow on this media, were characterized using the GenoType® MTBDRplus assay (Hain 
lifescience GmbH, nehren, Germany), to detect the most common mutations.17
Assessment of relapse of TB infection  
The number of CFu in lung, spleen and liver of mice (n=4) was assessed 13 weeks after 
termination of TB treatment. Relapse of was defined as Mtb-positive organ cultures, while 
immediately after termination of treatment organs were Mtb culture-negative.
Histopathological examination of infected organs  
Histopathological changes in lung, liver and spleen during the course of the (un-)treated infec-
tion were determined by sacrificing the animals (n=3) at indicated time points, as described 
previously.11 Paraffin-embedded tissues were cut into 4 µm sections from which one in every 
7 cuts was used for haematoxylin-eosin staining. a pathologist, blinded to the experimental 
conditions, examined 4 slides of each tissue. The same paraffin-embedded material prepared 
for the histopathological studies was used to determine the local cytokine production by im-
munohistochemistry. lung sections from infected mice were de-paraffinized and maintained 
in HCn buffer (Hepes, naCl and CaCl2). Sections were washed with HCn + 0.05% Tween 20, 
and the endogenous peroxidase activity was blocked with 6% H2O2 dissolved in PBS + 0.1% 
sodium azide and incubated for 1 hour. after blocking with normal swine sera, tissue sections 
were incubated with primary antibodies overnight at 4ºC at optimal dilutions, which had 
been determined previously. we used primary antibodies against TnF-α (rabbit polyclonal 
IgG, 281 clone H-156, sc-8301, Santa Cruz Biotechnology), IFn-γ (goat polyclonal IgG, clone 
D-17, sc- 9344, Santa Cruz Biotechnology), and Il-4 (goat polyclonal IgG, Santa Cruz Biotech-
nology). Secondary biotinylated antibodies (anti-rabbit-biotin IgG or anti-goat-biotin IgG) 
were used to detect the binding of the primary antibodies. Finally, HPR-conjugated avidin 
and 3,3-diaminobenzidine (DaB)/hydrogen peroxide were used to develop the reaction. Tis-
sue sections were counterstained with haematoxylin.
Cytokine- / chemokine concentrations in blood  
at week 4, 9 and 17 of primary TB and relapse of TB blood was obtained from mice, and 
from EDTa-blood plasma samples were prepared. Quantification of cytokines / chemokines 
was performed using a bead-based flow cytometry technique (xMap; luminex Corporation, 
austin, TX, uSa). Mouse soluble cytokine receptor multiplex panel used (Millipore Corpora-
tion, Billerica, Ma, uSa), consisted of bead-labelled cytokine receptor against following bio-
markers; granulocyte colony-stimulated factor (G-CSF), interferon gamma (IFn-γ), interleukin 
(Il)-1β, Il-2, Il-4, Il-6, Il-10, Il-12 (p40), Il-13, Il-17, IFn-γ-induced protein-10 (IP-10/CXCl10), 
macrophage colony-stimulated factor (M-CSF), monocyte chemoattractant protein-1 (MCP-
1/CCl2), macrophage induced by IFn-γ (MIG/CXCl9), murine macrophage inflammatory 
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protein-1α (MIP-1α), MIP-1β and tumor necrosis factor alpha (TnF-α). Tests were performed 
according to manufacturer’s protocol. Samples were tested in duplicates. Results in median 
fluorescence intensity (MFI) values were converted to pg/ml using MIllIPlEX analyst soft-
ware (Millipore) and subsequently averaged.
Statistical analysis  
CFu counts were log10 transformed before analysis. The CFu counts and serum cytokine 
levels of the primary TB groups of mice and relapse of TB groups of mice were averaged 
and subsequently compared using two-tailed, unpaired Mann-whitney test with Bonferroni 
correction (GraphPad Prism 5).
RESulTS
Primary TB – non-compliance treatment – relapse of TB  
as shown in figure 1 during the primary TB infection Mtb loads in lung, spleen and liver 
increased respectively up to 2.1x107 [1.4 - 3.7x107], 0.3x105 [0.2 - 1.0x105] and 0.6x105 [0.2 - 
1.3x105] cfu/organ at week 4. TB treatment was started at week 4 and resulted in a decrease in 
Mtb load. after 13 weeks (week 17) treatment was stopped, and from that time point relapse 
of TB infection occurred in all mice. at week 22 the relapse of TB had resulted in an Mtb load 
of 0.7x103 [0.1 – 1.6x103] in the lung, 0 [0 – 95] in the spleen and 0 [0 – 0] in the liver. at week 30 
(13 weeks post-treatment) the relapse of TB was established at a plateau level and the mean 
Mtb numbers had increased up to 1.2x104 [0.7 – 4.1x104], 5 [0 – 4.5x104] and 0 [0 – 3.6x102] in 
the lung, spleen and liver, respectively, and remained at this level up to week 56.
Mtb load in primary TB and relapse of TB  
The mycobacterial load in lung, spleen and liver during relapse of TB was significantly lower 
than in the primary TB (p-value = <0.0001, two-tailed, unpaired Mann-whitney) (figure 1). 
about half of the mice with relapse of TB developed extra-pulmonary TB. In none of the 
relapsed animals rifampin-resistant or isoniazid-resistant Mtb mutants were cultured from 
the infected organs.
Histopathology in primary TB and relapse of TB  
Histopathological evaluation of the relapse of TB showed chronic inflammatory infiltrates 
around medium size blood vessels and in airways wall and, at a later stage, pneumonic 
patches in coexistence with middle size granulomas. In contrast, primary infection was 
histologically characterized by progressive pneumonia. More specific, in mice with primary 
TB extensive areas of pneumonia and middle size granulomas were seen after 4 weeks of 
infection (figure 2a). after 30 weeks of primary TB there was a more extensive alveolar pa-
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figure 1: Mycobacterial load in infected organs in untreated mice with primary TB (gray bars) and in untreated 
mice with relapse of TB (black bars). Relapse of TB developed in mice with a primary TB infection that were 
treated for only 13 weeks (diagonally striped bars). Results are expressed as median ± range (error bars) of 
the colony forming units (CFu) per organ, n = 4 per time point. numbers above bars are the numbers of 
culture-positive mice out of 4 mice. * 2 out of 7 untreated mice died due to TB before time point. note that 
mycobacterial loads were significantly lower (p<0.001) during relapse of TB compared to primary TB.
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figure 2: Representative histopathological features in lung tissue of untreated primary TB (A-D) or relapse 
of TB (E-f), in liver tissue of untreated primary TB (G) or relapse of TB (h) and in spleen tissue of untreated 
relapse of TB (I). (A) large areas of pneumonia (asterisk) in the lung were observed 4 weeks after the 
infection. (B) larger area of pneumonia with extensive fibrosis (arrows) occurred at week 30 of the primary 
infection. (C) 5 weeks of primary TB treatment resulted pneumonia disappearance, only peribronchial and 
perivascular lymphocytic nodules (arrows) are seen. (D) Only mild inflammatory infiltrate in the wall of 
bronchi and blood vessels (arrows) was observed at 26 weeks of treatment of the primary TB. (E) Start of the 
relapse of TB showed big nodules constituted by lymphocytes and macrophages in the wall of airways and 
blood vessels (arrows) with patches of pneumonia (asterisk). (f) Increased lymphocytic nodules around 
bronchi and blood vessels were seen in the lung of the relapse of TB, at week 43. (G) Mild size granuloma 
(arrow) in the liver at week 4 of the primary TB. (h) Small granuloma (arrow) in the liver at the start of 
the relapse of TB (week 30); note the numerous hepatocytes with large and hyperchromatic nucleus or 
binucleation, which correspond to regenerative changes. (I) Extensive white pulp hyperplasia (asterisk) in 
the spleen at 26 weeks of treatment of relapse of TB (week 56). all images have an original magnification 
of 200 times.
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thology in coexistence with interstitial fibrosis (figure 2B). Immunohistochemistry analysis 
of the pneumonic areas revealed IFn-γ positive lymphocytes (figure 3a), in coexistence with 
numerous Il-4 positive lymphocytes (figure 3B) and TnF-α positive macrophages (figure 3C). 
In contrast, 5 weeks of treatment of primary TB resulted in an evident decrease of pneumonia 
in coexistence with granulomas with activated macrophages which showed strong TnF-α 
immunostaining (figure 3F) and distinctive middle size cuffs of lymphocytes around blood 
vessels and airways (figure 2C). The majority of these cells were positive for IFn-γ (figure 3D). 
also some Il-4 positive cells around blood vessels and airways were observed (figure 3E). 
after 26 weeks of treatment of primary TB the lung histology was almost normal, only small 
cuffs of lymphocytes, many of them IFn-γ positive, with occasional plasma cells and scar Il-4 
positive lymphocytes around venules or bronchi were seen (figure 2D).
at the start of relapse of TB (week 30) large inflammatory cuffs constituted by lymphocytes 
and distinctive activated macrophages, without apparent alveolar pathology were seen 
around blood vessels and airways (figure 2E). at week 5 of the relapse of infection, these cuffs 
of inflammatory cells were bigger and coexisted with middle size granulomas, numerous 
activated macrophages and small pneumonic patches. The untreated relapse of infection 
induced even bigger perivascular or peribronchiolar nodules consisting of lymphocytes 
and activated macrophages, and small patches of pneumonia with numerous activated 
macrophages at week 43 (figure 2F) and week 56. Many of the lymphocytes around blood 
vessels and bronchial walls were IFn-γ positive (figure 3G), and highly TnF-α immunoreac-
tive macrophages were present in granulomas and in the interstitial inflammatory infiltrate 
(figure 3I). Fewer and weakly Il-4 positive cells in the perivascular inflammatory infiltrate of 
the lung were observed (figure 3H).
The histological analysis of the spleen of mice with primary TB showed extensive and diffuse 
hyperplasia of the white pulp at week 4 and week 30, while during relapse of TB extensive 
white pulp hyperplasia was present and numerous plasma cells were observed around arte-
rioles and in the red pulp (not shown).
Regarding the liver, animals after 4 weeks of primary TB showed occasional middle size ran-
domly located granulomas and diffuse kupffer cell hyperplasia (figure 2G). after 30 weeks of 
infection, there were more and larger granulomas, kupffer cell hyperplasia and some portal 
areas with mild inflammatory infiltrate essentially populated by lymphocytes. However, at 
the start of relapse of TB, the mice showed smaller granulomas surrounded by hepatocytes 
with large and hyperchromatic nuclei or two nuclei compatible with regenerative cells.
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figure 3: Representative immunohistochemical features in lung tissue of untreated primary TB at week 30 
(A-D), treated primary TB at week 9 (E-f), untreated relapse of TB at week 35 (G-I) and treated relapse of TB 
at week 56 (J-l). lung tissue was immunostained with anti-IFn-γ (A, D, G, J), anti-Il-4 (B, E, h, k) or anti-
TnF-α (C, f, I, l), respectively. lungs of mice with 30 weeks of primary TB infection showed (A) moderate 
amount of IFn-γ immunostained cells in the pneumonic areas, (B) numerous amounts of Il-4 positive 
cells in the same lungs and (C) a ‘scar’ of TnF-α immunostained macrophages (arrow). lungs of mice with 
primary TB that had been treated for 5 weeks showed (D) numerous IFn-γ immunostained cells in the 
inflammatory infiltrate around blood vessels, (E) some Il-4 immunostained cells around blood vessels and 
airways and (f) macrophages immersed in the pneumonic areas showed TnF-α immunostaining (arrow). 
lungs of mice with relapse of TB, at week 35, showed (G) perivascular cuffing with numerous and strongly 
IFn-γ immunostained cells, (h) fewer and weak Il-4 immunostained cells in the perivascular inflammatory 
infiltrate and (I) middle size granuloma shows immunostained TnF-α macrophages. In the lungs of mice 
with relapse of TB and 26 weeks of retreatment we observed (J) perivascular inflammatory infiltrate with 
numerous IFn-γ immunostained cells, (k) a ‘scar’ of Il-4 positive cells in the perivascular inflammation 
and (l) alveolar activated macrophages that showed TnF-α immunostaining. all images have an original 
magnification of 200 times.
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figure 4: Concentrations of cytokines or chemokines in plasma from mice during the course of untreated 
primary TB, untreated relapse of TB and in uninfected mice. Data are represented for individual mice with 
indicated mean (n=3 per time point).
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Cytokines / chemokines in primary TB and relapse of TB  
Plasma cytokine profiling during the course of primary TB versus the course of relapse of TB 
revealed significantly (p ≤0.003, two-tailed, unpaired Mann-whitney) different levels for 6 of 
the 17 cytokines (figure 4). The cytokines TnF-α (p-value = 0.0002), IFn-γ (p = 0.0005), Il-6 (p 
= 0.003), MIG/CXCl9 (p = 0.0002), IP-10/CXCl10 (p = 0.002) and Il-17 (p = 0.0009) were sig-
nificantly lower during the relapse of TB compared to the primary TB (figure 4). whereas only 
a trend of lower concentration at the relapse of TB compared to the primary TB was observed 
for Il-12p40 (p = 0.005) and MCP-1/CCl2 (p = 0.01). The data showed that cytokine levels in 
all cases are significantly higher in primary TB compared to relapse of TB. In relapse of TB, the 
circulating cytokine and chemokine levels generally do not exceed the levels observed in 
non-infected mice (data not shown).
Treatment response in primary TB and relapse of TB  
The data in figure 5 represent the response to a 26 weeks treatment in mice with primary TB 
and mice with relapse of TB in terms of mycobacterial load of lung, spleen and liver. From the 
start of treatment (time zero) a decline of the Mtb load in the lungs was observed. after 13 
weeks of treatment (week 13) a similar efficacy in terms of sterilization of the infected organs 
was observed in primary TB as well as relapse of TB. Due to the fact that the mycobacterial 
loads in the spleen and liver of the relapsed animals were very low or even undetectable in 
some of the animals (figure 1), the efficacy of treatment could not be assessed or adequately 
be compared to mice with primary TB. after 26 weeks of treatment (week 26) in primary TB 
as well as relapse of TB all organ cultures were negative. Relapse of infection at 13 weeks 
after termination of the 26 weeks of treatment (week 39) did never occur, indicating that a 
26-weeks treatment period was completely successful in both primary TB and relapse of TB 
(figure 5).
Histopathology in relapse of TB during treatment  
Mice with relapse of TB started re-treatment at week 30. In the lungs of the re-treated mice 
at week 35 and 43, well constituted granulomas with activated macrophages, small patches 
of pneumonia with numerous activated macrophages and multinucleated giant cells were 
observed (data not shown). after 26 weeks of re-treatment slight perivascular and peribron-
chiolar inflammatory cuffing was observed, with small granulomas and small patches of 
pneumonia. almost all the lymphocytes around blood vessels were IFn-γ positive (figure 3J), 
while activated macrophages exhibited strong TnF-α immunoreactivity (figure 3l). addition-
ally, only few Il-4 positive cells were observed in the perivascular inflammation areas (figure 
3k).
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figure 5: Efficacy of standard TB treatment administered for 26 weeks in mice with primary TB (▢with 
gray line) and in mice with relapse of TB (■ with black line). Start of therapy is indicated in the graphs as 
time zero. Mice were sacrificed at various intervals during treatment and at 13 weeks after termination of 
treatment (week 39). Results are expressed as median ± range (error bars) of the colony forming units (CFu) 
per organ, n = 4 per time point.
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In the liver of mice with relapse of TB, after 13 weeks of treatment, occasional middle size 
granulomas were seen, while 26 weeks of treatment induced numerous hepatocytes with 
regenerative changes, as well as focal steatosis and occasional small granulomas (figure 2H).
In the spleen of mice with relapse of TB extensive white pulp hyperplasia and numerous 
plasma cells around arterioles and in the red pulp were observed. These histological features 
remained evident after re-treatment for 26 weeks (week 56, figure 2I).
DISCuSSIOn
In the present study we investigated the characteristic features of primary TB versus relapse of 
TB in a murine model closely mimicking the natural human TB infection. The most prominent 
phenomenon we observed was the substantially lower mycobacterial load in infected organs 
without significant fluctuation during relapse of infection compared to the primary infection. 
In addition, mice with relapse of TB showed no signs of illness, and none of the mice died.
The analysis of the inflammatory mediator profile in plasma during the course of primary 
TB versus relapse of TB revealed for 8 of 17 tested cytokines and chemokines a significant 
difference at the moment of established infection for both. a likely explanation for this ob-
servation is that in relapse of TB the mycobacterial loads in infected organs are approximately 
1000-fold lower than in primary TB. Relapse of TB, like primary TB, was not confined to the 
lung, but frequently disseminated. However, the host response locally resulting from expo-
sure of parenchymal and host defence cells to mycobacterial products including cytokine 
and chemokine production by activated cells, apparently do not permeate into the circula-
tion in case of relapse of TB. analysis of the immunohistochemistry characteristics in primary 
TB showed predominance of IFn-γ positive lymphocytes in the perivascular nodules as well 
as in the hyperplastic lymphoid tissue associated to bronchial mucosa, in coexistence with 
strong TnF-α immunostained activated macrophages distributed in the alveolar-capillary 
interstitium and granulomas. Thus, in contrast with the low concentrations in plasma of these 
protective cytokines during relapse of TB, in the lung numerous IFn-γ and TnF-α immunos-
tained cells were located in the perivascular and peribronchial inflammatory infiltrates as 
well as in granulomas where even macrophages were intensely IFn-γ positive. This suggests 
that during primary TB and anti-TB treatment numerous Th-1 cells were activated while in 
relapse of TB many memory Th-1 cells are locally and systemic expanded and congregated 
in the lung, permitting an efficient control of mycobacterial growth. after the completion of 
successful anti-TB treatment in relapse of TB, only small perivascular cuffs and mild hyper-
plasia of bronchus-associated lymphoid tissue (BalT) remained with clear predominance of 
IFn-γ positive cells.
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In primary TB the mediator profiles of infection in plasma showed some remarkable trends 
over time. The inflammatory ‘driver’ cytokines TnF-α, IFn-γ and Il-6 all displayed a biphasic 
pattern, with elevated levels early in the phase of chronic infection (week 4), and significant 
reduction to lower levels during the established infection stage at week 9. Subsequently, the 
cytokine levels rose again at later time points during infection. a similar pattern was found 
for systemic Il-17 and IP-10/CXCl10 levels. Production of IP-10/CXCl10 is strongly induced by 
IFn-γ, while Il-17 can be produced by the same T cells in TB.18 Production of the chemokine 
MIG/CXCl9 is also strongly stimulated by IFn-γ, but this showed no decrease at week 9. The 
circulation of Il-12p40 and MCP-1/CCl2 showed a different development over time. Both 
were not found to be elevated at the start of the chronic phase of infection, week 4, but only 
observed at later stages of infection. Interestingly, both Il-12 and MCP-1/CCl2 are induced by 
Il-4 in mononuclear phagocytes, and MCP-1/CCl2 is also produced by Th2 cells rather than 
Th1 cells. Together, this further emphasizes that, in primary TB in mice the initial peak of Th1 
polarization at week 4 is followed and balanced by activation of Th2 cells at week 9, which is 
in concordance with our previous histopathological observations.11
In relapse of TB the decreased levels of several cytokines and thus reduced chemotaxis of 
inflammatory cells might indicate that the less severe manifestation of untreated infection in 
relapse of TB is a result of an improved host reaction.
a few notes of caution on the interpretation of the histopathological findings are justified. 
First, relatively large differences were noted between cytokine profiles in different animals. 
This is remarkable, especially since the mycobacterial counts in infected organs showed 
relatively small inter-individual variation. This diversity probably relates to the fact, already 
stated above, that systemic levels of mediators are only derivatives of inflammatory processes 
that occur locally in the various infected organs, in particular the lung. Specific conditions in 
individual animals may strongly influence the level to which these processes are reflected in 
the levels of cytokines and chemokines in blood. This is further strengthened by the finding 
that levels of different mediators in individual animals show no clear correlation, i.e. there are 
no evident high or low responders identifiable within the cohort.
Considering treatment efficacy in relapse of TB, this study showed that the standard treat-
ment of 26 weeks using human pharmacokinetic-equivalent dosage resulted in therapeutic 
efficacy that was similar, in terms of decrease of mycobacterial load, to that observed in 
primary TB.11 In addition, the 26 weeks treatment of relapse of TB did not result in a second 
relapse of TB. These data do not provide evidence that relapse of TB should be treated longer 
than the standard 6 months course, an approach recommended by the wHO.7 The therapeu-
tic success of the standard therapy regimen in relapse of TB is finding is noteworthy, since 
a difference in treatment response in relapse of TB versus primary TB would be expected 
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as a consequence of the low regrowth of the mycobacteria in relapse of TB that might be 
associated with low susceptibility to anti-TB drugs.19 a recent review article by van der werf 
et al.10 provided further evidence that treatment non-compliance carries the risk of becoming 
resistant. However, throughout the treatment period and the post-treatment period of pri-
mary TB and relapse of TB, rifampin or isoniazid-resistant Mtb mutants were never selected.
In conclusion, the present study shows that the course of relapse of TB and primary TB are 
different in terms of mycobacterial load in infected organs, circulating cytokine levels and 
histopathology. This is possibly due to an improved host reaction in relapse of TB. although 
in relapse of TB the increase in mycobacterial load in the infected organs is slow and limited 
reflecting a low metabolic-active mycobacterial population, the 6 months standard anti-TB 
regimen is sufficient to achieve a curative therapy in relapse of TB. Emergence of drug resis-
tance during and after treatment of relapse of TB did not occur.
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Chapter 7
Time-Kill Kinetics of anti-tuberculosis drugs, and 
emergence of resistance, in relation to metabolic 
activity of Mycobacterium tuberculosis
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ABSTRACT
Objectives  
The pharmacodynamics of tuberculosis (TB) treatment should be further explored, to pre-
vent emergence of resistance, treatment failure and relapse of infection. The diagnostic drug 
susceptibility tests guiding TB therapy investigate metabolically active Mycobacterium tuber-
culosis (Mtb) isolates under static conditions and as such are not informative with respect to 
the time–kill kinetics of anti-TB drugs and the emergence of resistance in metabolically lowly 
active or even dormant Mtb cells.
Methods  
In vitro, the killing capacity of rifampicin, isoniazid, ethambutol and amikacin regarding the 
degree of killing, killing rate and selection of resistant mutants was investigated in metaboli-
cally highly active versus metabolically lowly active Mtb cells.
Results  
Isoniazid showed rapid and high killing capacity towards highly active mycobacteria, but due 
to the emergence of resistance could not eliminate the Mtb. Efflux pump-mediated isoniazid 
resistance was predominant. Rifampicin revealed a relatively slow and time-dependent kill-
ing capacity, but achieved elimination of all mycobacteria. Ethambutol was not bactericidal. 
amikacin showed a high and extremely rapid killing activity that was not time dependent 
and could eliminate all mycobacteria. Exposure of lowly active Mtb populations to isoniazid, 
rifampicin or amikacin led to the emergence of resistant mutants. Compared with the highly ac-
tive mycobacteria, elimination of the susceptible lowly active mycobacteria required a 64-fold 
increased isoniazid concentration and a 4-fold increased rifampicin concentration, whereas 
amikacin was equally effective irrespective of the metabolic state of the mycobacteria.
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Conclusions  
The anti-TB drugs differ significantly regarding their time-kill kinetics. In addition, the meta-
bolic state of Mtb significantly affects its susceptibility to antimicrobials, with the exception 
of amikacin. Optimization of dosage of anti-TB drugs is required to achieve maximum drug 
concentrations at the site of infection in order to maximize reduction in Mtb load and to 
minimize the emergence and selection of resistance.
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InTRODuCTIOn
Tuberculosis (TB) remains one of the most important preventable infectious diseases world-
wide. with over two billion persons latently infected with Mycobacterium tuberculosis (Mtb) 
worldwide, nine million patients with active TB diagnosed each year and almost two million 
deaths due to this disease annually, TB is a major cause of mortality and morbidity.1 although 
the incidence of TB is stabilizing, from a worldwide perspective the prevalence is still rising. 
Improvement in TB treatment is urgently needed, since the global spread of drug-resistant TB 
is being observed.1,2 Optimal dosing and treatment duration, which is of the utmost impor-
tance to obtain maximum efficacy and to prevent resistance, has not been fully established. 
although the usefulness of new drugs is evaluated,3 more efficient use of the available drugs 
could be a more realistic short-term goal. This may also serve the development of combined 
regimens of conventional and new drugs. For optimization of current treatment regimens, 
regarding dose and duration, insight into the dynamics of the activity of the anti-TB drugs is 
of critical importance. The in vitro drug susceptibility tests currently used are not informative 
in this way, as they provide only endpoint data obtained after a continuous 2-4 week drug 
exposure of the Mtb isolate. In this respect in vitro tests do not simulate the in vivo situation, 
being a static equilibrium, where the pharmacokinetic curve reflects fluctuating drug con-
centrations.4 Moreover, besides the degree of killing the rate of killing is also highly clinically 
significant, but this is not measured in current susceptibility assays.
Clinical experience is that inadequate exposure to anti-TB drugs may result in the emergence 
of resistant mycobacteria.5,6 However, the mechanism by which resistance is induced is 
not always known. The term “phenotypic drug resistance” is used to indicate drug-tolerant 
mycobacteria that exhibit reduced susceptibility to anti-TB drugs without known genetic 
mutations. Phenotypic drug resistance might, for instance, be due to increased efflux pump 
activity, porin loss, permeability decrease or drug-modifying enzymes, resulting in reduced 
intracellular drug concentrations.7-9 “Genotypic drug resistance” indicates resistance associ-
ated with known mutations in the genome of Mtb and relates to known levels of resistance.
In this study we aimed to visualize the concentration-dependent and time-dependent kill-
ing capacity of relevant, currently used anti-TB drugs towards Mtb and the emergence of 
resistance in relation to the metabolic state (growth phase) of the Mtb population. In the 
present study, the drug concentrations are also static; however, by using a wide range of 
concentrations and assessment of Mtb killing at different time-points during drug exposure 
(instead of an endpoint assay), insight is provided into the dynamic killing capacity of fluctu-
ating drug concentrations. This knowledge will contribute to a better understanding of the 
time-kill kinetics of anti-TB drugs and the emergence of resistance, and as such may help to 
optimize the use of these drugs.
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MATERIAlS AnD METhODS
Mtb cultures  
The Mtb strain used was H37Rv, a clinical isolate and reference strain nowadays commonly used 
in vitro as well as in animal TB models. The MICs determined as described by the ClSI (formerly 
the nCClS) document M24-a10 were 0.125 mg/l for rifampicin, 0.125 mg/l for isoniazid, 8 
mg/l for ethambutol and 2 mg/l for amikacin. Mtb suspensions were cultured in Middlebrook 
7H9 broth (Difco laboratories, Detroit, uSa), supplemented with 10% oleic acid-albumin 
dextrose catalase enrichment (OaDC; Baltimore Biological laboratories, Baltimore, MD, uSa), 
5% glycerol (Scharlau Chemie, Sentmenat, Spain) and 0.05% Tween 20 (Sigma Chemical Co., 
St louis, uSa), under shaking conditions at 96 rpm at 378C. Vials with Mtb suspensions were 
stored at -800C. Cultures on solid medium were grown on Middlebrook 7H10 agar (Difco), 
supplemented with 10% OaDC for 21 days at 370C with 5% CO2. Metabolic activity of highly 
active/low-density and lowly active/high-density Mtb cultures The metabolic activity of Mtb in 
cultures was assessed by measuring the adenosine-5’-triphosphate (aTP) level using the firefly 
luciferase bioluminescence assay.11 with a luminometer, light emission, which is proportional 
to the aTP concentration in Mtb, was quantified. The microbial aTP kit HS (BioThema aB, Dalarö, 
Sweden) was used according to the recommendations of the manufacturer.12
Anti-TB drugs
Rifampicin, isoniazid, ethambutol and amikacin were purchased from Sigma Chemical Co. 
(I-3377, R-3501, E-4630 and a-3650). Dilutions of anti-TB drugs were prepared according to 
the recommendations of the manufacturers.
Concentration- and time-dependent bactericidal activity of anti-TB drugs  
Mtb vials were defrosted and used to generate Mtb cultures in the early logarithmic phase of 
growth and at a density of 5×105 cfu/ml (range 4–6×105), as confirmed by quantitative plate 
counts. These cultures were exposed to each of the individual anti-TB drugs at 2-fold increasing 
concentrations, ranging from 0.0005 mg/l to 256 mg/l, in 125 ml Erlenmeyer flasks (Corning 
Costar, Cambridge, Ma, uSa) for 6 days at 370C, under shaking conditions at 96 rpm. On days 1, 
2, 3 and 6, samples of 500 ml were taken for cfu counting, provided the Mtb suspensions did 
not show visible aggregation, as from aggregated Mtb cultures accurate cfu counts could not 
be established. log cfu values were plotted against time (in days) to obtain time–kill curves. 
In order to prevent drug carry-over, samples were washed once by centrifugation at 14000 g 
for 10 min and resuspended in medium without anti-TB drugs. The washed suspensions were 
serially diluted in PBS and plated onto antibiotic-free 7H10 agar supplemented with OaDC. 
after 21 days of incubation at 370C and 5% CO2 cfu values were determined.
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Selection of drug-resistant Mtb 
In order to detect drug-resistant Mtb, in the highly active/low-density culture, the samples 
taken after 6 days of exposure to each of the individual anti-TB drugs at concentrations rang-
ing from 0.0005 mg/l to 1024 mg/l were cultured on anti-TB drug-containing 7H10 agar 
plates. The concentrations of the drugs in the subculture plates were 4-fold the ‘critical’ con-
centrations of the agents,10 i.e. 4 mg/l rifampicin, 0.8 mg/l isoniazid, 20 mg/l ethambutol and 
20 mg/l amikacin. Only the drug-resistant Mtb were able to grow on these drug-containing 
subculture plates, whereas both susceptible and drug-resistant Mtb showed growth on the 
subculture plates without anti-TB drugs.
Detection of drug-resistant Mtb in the lowly active/high-density culture after 6 days of drug ex-
posure was performed using the same selection method as described earlier. The high-density/
late-log-phase culture containing 0.9×108 cfu/ml (range 0.3–1.3×108 cfu/ml) was obtained 
after 4 days of incubation of the early-log-phase culture in the absence of anti-TB drugs at 370C.
Characterization of drug-resistant mutants 
Occurrence of phenotypic drug resistance caused by induction of efflux pumps was inves-
tigated by plating the samples from the anti-TB drug-exposed cultures not only onto agar 
plates containing anti-TB drugs but also onto agar plates containing a combination of 
anti-TB drugs and 20 mg/l reserpine (R0875-16; Sigma Chemical Co.), a known efflux pump 
inhibitor.7,8 In our assay we confirmed that the presence of 20 mg/l reserpine alone in the 
agar plates did not affect the growth of H37Rv (data not shown). From plates containing 
anti-TB drug and 20 mg/l reserpine, 10 colonies were picked randomly and investigated for 
known drug resistance-associated mutations (genotypic resistance).
From the isoniazid-resistant mycobacteria obtained from the highly active/low-density culture 
exposed to 64 mg/l isoniazid, the stability of resistance was also explored by repeated culture 
in isoniazid-free medium. To this aim the BaCTEC MGIT-960TM system (Becton Dickinson & Co., 
Franklin lakes, nJ, uSa) was used. Two colonies picked from the isoniazid/reserpine-containing 
agar plates were each resuspended in 600 ml of Middlebrook 7H9 medium and cultured in an 
MGITTM control tube (isoniazid-free medium), in a 0.2 mg/l isoniazid-containing MGITTM tube 
and in a 1.0 mg/l isoniazid-containing MGITTM tube. The time to positivity of each of these 
three tubes was registered. The mycobacteria from the positive control tube (without isoniazid) 
subsequently underwent further stability control, by inoculating a new set of MGITTM tubes con-
taining isoniazid-free medium, medium containing 0.2 mg/l isoniazid and medium containing 
1.0 mg/l isoniazid. This procedure was repeated for a total of five times. The percentage of 
isoniazid-resistant organisms in the total Mtb population was assessed and it was investigated 
whether isoniazid genotypic resistance could be detected.
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From the drug-resistant Mtb isolates obtained, 10 colonies were randomly picked from the 
reserpine-containing plates and investigated for the presence of genotypic resistance. The 
GenoType® MTBDRplus assay (Hain lifescience GmbH, nehren, Germany) was used to detect 
the most common mutations in rpoB conferring rifampicin resistance and those in katG and 
inhA leading to isoniazid resistance.13 The GenoType® MTBDRplus assay (Hain lifescience 
GmbH) was used to detect mutations in the rrs gene related to amikacin resistance.14 Both 
assays were performed according to the manufacturer’s recommendations.
In addition to the GenoType® MTBDRplus assay to detect mutations in the katG gene, deletion 
of the katG gene (so-called ΔkatG) was also determined, described by Bergval et al.15 In short, 
10 colonies grown on 7H10 agar containing 0.4 mg/l isoniazid were selected and Dna was 
prepared. Primer sets specific for katG codon 315 and for katG codon 463 were used in a PCR 
assay using a Geneamp® PCR system 9700 (applied Biosystems, nieuwerkerk aan den IJssel, 
The netherlands). Isolates were scored ΔkatG if one or both of the PCR products were absent.
RESulTS
Metabolic activity of Mtb by growth phase  
we differentiated between ‘metabolically highly active’ and ‘metabolically lowly active’ Mtb as as-
sessed by determination of the amount of aTP per viable Mtb. The highly active/low density Mtb 
population increased from the start of the experiment with 5.0×105 cfu/ml to 0.9×108 cfu/ml on 
day 3. The active metabolism during the 3 day period was reflected by a 6-fold increasing aTP con-
tent per cfu, being 1.5×10-18 mol aTP/cfu (range 1.4-1.6×10-18) at the beginning of the experiment 
and 0.9×10-17 mol aTP/cfu (range 0.7-1.2×10-17) on day 3. From day 4 onwards the aTP content 
per cfu was lower and remained at a constant level of 4.7×10-18 mol aTP/cfu (range 2.8–7.4×10-18), 
reflecting metabolically lowly active mycobacteria showing a constant but reduced metabolism.
Time-Kill Kinetics of anti-TB drugs towards highly active/low-density Mtb  
In the absence of anti-TB drugs, the density of the Mtb H37Rv culture increased from 5.0×105 
cfu/ml at the start of the experiment to 5.7×106 cfu/ml on day 1, 3.6×107 cfu/ml on day 2 
and 1.1×108 cfu/ml on day 3. On day 6 the Mtb suspension was aggregated due to increased 
density of mycobacteria and as a result appropriate quantification of the non-drug exposed 
Mtb on day 6 could not be performed. The time–kill kinetics of rifampicin, isoniazid, eth-
ambutol and amikacin on the highly active Mtb cultures are shown in figures 1 and 2. The 
data shown in the figures ranged from the concentrations that proved ineffective (identical 
growth compared with the control) up to 256 mg/l.
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figure 1. Concentration- and time-dependent bactericidal effect of anti-TB drugs on metabolically active 
Mtb strain H37Rv. Cultures of Mtb at low density in the early logarithmic phase of growth (5×105 cfu/ml) 
were exposed to rifampicin or isoniazid at 2-fold increasing concentrations for 6 days at 370C. after 1, 
2, 3 and 6 days of exposure, quantitative cultures were performed on subculture plates without anti-TB 
drugs. Due to aggregation of the mycobacteria in the culture, at 6 days of exposure to some of the low 
concentrations, accurate cfu counts could not be performed.
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figure 2. Concentration- and time-dependent bactericidal effect of anti-TB drugs on metabolically active 
Mtb strain H37Rv. Cultures of Mtb at low density in the early logarithmic phase of growth (5×105 cfu/ml) 
were exposed to ethambutol or amikacin at 2-fold increasing concentrations for 6 days at 370C. after 1, 
2, 3 and 6 days of exposure, quantitative cultures were performed on subculture plates without anti-TB 
drugs. Due to aggregation of the mycobacteria in the culture, at 6 days of exposure to some of the low 
concentrations, accurate cfu counts could not be performed.
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Rifampicin showed clear concentration-dependent killing activity, which was also strongly time 
dependent. at a high concentration of 128 mg/l, ≥99% killing was achieved within 1 day of 
exposure. a moderate concentration of 8 mg/l was needed to achieve ≥99% killing after 3 days 
of exposure (table 1) and this concentration eliminated Mtb after 6 days of exposure (figure 1).
Isoniazid also showed concentration-dependent killing activity, which was more rapid 
compared with rifampicin (figure 1). at a low concentration of 0.125 mg/l, ≥99% of the 
Mtb was killed within only 1 day of exposure (table 1). within 2 days of exposure a 2-fold 
lower concentration killed ≥99%; however, from that time onwards the number of cfu in 
the Mtb cultures increased again. This regrowth of Mtb was observed over a wide range of 
isoniazid concentrations, and was caused by the development of an isoniazid-resistant Mtb 
subpopulation. after 6 days of drug exposure, a concentration of 32 mg/l was needed to 
achieve ≥99% Mtb killing (table 1). Only at a concentration of ≥128 mg/l was the expansion 
of isoniazid-resistant mycobacteria completely prevented (table 2).
Ethambutol showed moderate killing activity that was almost independent of its concentra-
tion, and not time dependent (figure 2). Even at the highest concentration of 256 mg/l, Mtb 
could not be fully eliminated. The concentrations of ethambutol needed to achieve ≥99% 
killing were >256 mg/l on day 1, >256 mg/l on day 2, 64 mg/l on day 3 and 2 mg/l on 
day 6 (table 1).amikacin showed strong concentration-dependent killing capacity and a high 
killing rate (figure 2). killing of ≥99% after 1 day was achieved at a concentration of only 2 
mg/l. To achieve ≥99% killing after 6 days of exposure, a modest decrease in concentration 
of only 4-fold was required (table 1), indicating that the killing activity of amikacin was largely 
independent of time of exposure to this agent. The amikacin concentration needed for 100% 
elimination of Mtb after 6 days of exposure was only 16 mg/l (figure 2 and table 2).
Selection of drug-resistant mutants in highly active/low-density Mtb  
In the highly active Mtb population, drug-resistant mutants were only observed after expo-
sure to isoniazid and not after exposure to the other anti-TB drugs. Isoniazid concentrations 
lowest concentration (mg/l) resulting in ≥99% 
killing at various time points during exposure to anti-TB drug
day 1 day 2 day 3 day 6
rifampicin 128 64 8 0.031
isoniazid 0.125 0.062 0.125 32
ethambutol >256 >256 64 2
amikacin 2 1 2 0.5
Table 1. Concentration-dependent bactericidal effect (≥99% killing) over time of anti-TB drugs towards 
highly active/low-density Mtb strain H37Rv. Cultures of Mtb strain H37Rv (5×105 cfu/ml) were exposed to 
rifampicin, isoniazid, ethambutol or amikacin at 2-fold increasing concentrations for 6 days at 370C. after 1, 
2, 3 and 6 days of exposure, quantitative cultures were performed on plates without anti-TB drugs.
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of ≥4mg/l resulted in equal numbers of mycobacteria on the subculture plates without 
anti-TB drugs and the drug-containing subculture plates, whereas ≥128 mg/l resulted in 
elimination of all mycobacteria, including the resistant Mtb. The isoniazid concentrations 
within which resistant mutants were selected ranged from 0.031 up to 64 mg/l, whereas in a 
concentration window between 4 and 64 mg/l isoniazid equal numbers of mycobacteria on 
the subculture plates without anti-TB drugs and the drug-containing subculture plates were 
cultured. Surprisingly, genotypic characterization revealed no mutations in inhA or katG, as 
assessed by the GenoType® MTBDRplus assay. However, using the katG gene PCR, according 
to Bergval et al,15 a deletion of the katG gene was demonstrated in two of the 10 isolates 
tested.
additional differentiation between phenotypic and genotypic isoniazid-resistant isolates 
demonstrated that only 1.9% of the isoniazid-resistant mycobacteria that were selected 
after 22 days of exposure to 64 mg/l were able to grow in the presence of the efflux pump 
inhibitor. This suggests that the majority of the isoniazid-resistant population represents ef-
flux pump-mediated phenotypic drug resistance. Twenty colonies that were picked from the 
isoniazid-reserpine-containing plates for genetic characterization revealed no mutations in 
the inhA or katG genes using the GenoType® MTBDRplus assay. However, deletion of (a part 
of ) the katG gene was demonstrated in two out of eight isolates tested.
The stability of the isoniazid-resistant mutants was demonstrated by subculture of two mutant 
isolates in MGITTM medium without isoniazid, with 0.2 mg/l isoniazid or with 1.0 mg/l isoniazid. 
Mutants showed similar growth rates in all media. This indicates that the isoniazid resistance 
was conserved even without isoniazid pressure, suggesting that genotypically resistant mu-
lowest concentration (mg/l) resulting in 100% killing
after 6 days of exposure to anti-TB drugs
Mtb highly active / low-density Mtb low active / high density
susceptible
mycobacteria
resistant
mycobacteria
genotypic
mutation a
susceptible
mycobacteria
resistant
mycobacteria
genotypic
mutation a
rifampicin 8 - - 32 512 rpoB
isoniazid 4 128 ΔkatG b 256 512 ΔkatG b
ethambutol >1024 - - >1024 - -
amikacin 16 - - 8 512 rrs
Table 2. Elimination (100% killing) of susceptible or resistant Mtb strain H37Rv by anti-TB drugs, in relation 
to metabolic activity of the mycobacteria. Cultures of Mtb strain H37Rv at low density (5×105 cfu/ml) or 
at high density (1×108 cfu/ml) were exposed to rifampicin, isoniazid, ethambutol or amikacin at 2-fold 
increasing concentrations for 6 days at 370C. after 6 days of exposure, quantitative cultures were performed 
on plates without anti-TB drugs and plates containing 4 mg/l rifampicin, 0.8 mg/l isoniazid, 20 mg/l 
ethambutol or 20 mg/l amikacin.
a Detection of mutations in rpoB for rifampicin, katG and inhA for isoniazid and rrs for amikacin.
b ΔkatG indicates that the katG gene was (partly) deleted.
99
antibiotic time-kill kinetics and selection of resistance
tants were present. The genetic characterization of the isoniazid-resistant mutants that after 
sub-culturing consecutively for five times remained stable revealed no mutations in the inhA or 
katG gene, as assessed by the GenoType® MTBDRplus assay. However, in these stable genotypi-
cally resistant mutants, a deletion of a part of the katG gene was observed in one out of two.
Selection of drug resistant mutants in low active / high density Mtb 
In the low active Mtb population, drug resistant mycobacteria were selected during exposure 
to rifampicin, isoniazid and amikacin, but not during exposure to ethambutol.
after rifampicin exposure, selection of resistant mutants was only observed in a rifampicin 
concentration window between 32 and 256 mg/l. Resistant mycobacteria did not emerge 
at the concentration of ≥512 mg/l. analysis of 10 rifampicin-resistant colonies showed an 
altered rpoB gene sequence. Eight colonies had a mutation at codon 526 of the rpoB gene; 
six of these had the His526Tyr mutation and two had an unknown mutation at this position. 
One colony exhibited the Ser531leu mutation and the remaining colony had an unknown 
mutation at codon 531 or 533 (table 2).
after isoniazid exposure also resistant Mtb were observed. Isoniazid concentrations of ≥256 
mg/l resulted in equal numbers of mycobacteria on the subculture plates without anti-TB 
drugs and the drug-containing subculture plates, whereas ≥512 mg/l resulted in elimina-
tion of all mycobacteria, including the resistant Mtb. The analysis of these isoniazid-resistant 
mycobacteria revealed no mutations in the inhA or katG, as assessed by the GenoType® 
MTBDRplus assay (table 2). using the katG gene analysis, in three of the 10 isolates, a (partial) 
deletion of the katG gene was observed.
Exposure to ethambutol did not result in selection of resistant Mtb. at the concentration of 4 
mg/l multiplication of Mtb up to high levels resulting in aggregation of the Mtb suspension 
was prevented, and ≥99.9% killing of Mtb was obtained, whereas full elimination of Mtb was 
not achieved (table 2). Continuation of ethambutol exposure up to 10 days did not result in 
further decrease of Mtb numbers (data not shown).
Exposure to amikacin did result in resistant Mtb. Selection of only resistant mutants was found 
within an amikacin concentration window between 8 and 256 mg/l. amikacin concentrations 
of ≥8 mg/l resulted in equal numbers of mycobacteria on the subculture plates without anti-
TB drugs and the drug-containing subculture plates, whereas ≥512 mg/l resulted in elimina-
tion of all mycobacteria, including the resistant Mtb. Ten amikacin-resistant mutants were 
investigated and revealed a mutation in the rrs gene at codon 1401 (ala1401Gly) (table 2).
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DISCuSSIOn
The ideal anti-TB drug should exhibit a high killing rate, resulting in a rapid decrease in Mtb load 
and, hence, a reduced risk of spreading the disease and development of resistance. also the 
bactericidal activity of the anti-TB drug against mycobacteria at low growth rate is important, 
as deep-seated Mtb in tissues during dormant state probably exhibit low metabolic activity, 
and may be more difficult to eliminate.16 Moreover, attainable tissue concentrations of anti-TB 
drugs at the infectious foci are important; they may be too low with the current dosing regimes. 
It is expected that suboptimal concentrations of anti-TB drugs facilitate the emergence of resis-
tance by allowing enrichment and amplification of resistant Mtb subpopulations.5,6
all first line drugs currently used to treat TB have a long history of clinical use. However, their 
pharmacodynamics are yet to be fully elucidated and there are indications that improve-
ment of dosage could be of great value. The results of the present study provide additional 
insight in the in vitro killing dynamics of the anti-TB drugs, with respect to the degree of kill-
ing (concentration dependence), the rate of killing (time dependence) and the selection of 
phenotypic and/or genotypic resistant mutants. Furthermore, the metabolic activity (growth 
phase) of the Mtb population was taken into account. To our knowledge this is the first study 
in which the cornerstone anti-TB drugs isoniazid and rifampicin, as well as ethambutol and 
amikacin have been investigated in this way.
Isoniazid and rifampicin differed strongly with respect to their killing rate of metabolically active 
mycobacteria. noticeably, isoniazid showed extremely rapid and completely concentration-
dependent killing. In contrast, rifampicin revealed relatively slow and strongly time-dependent 
killing. This evident difference in dynamics of the bactericidal activity between isoniazid and 
rifampicin is in concordance with therapeutic results obtained in studies in TB patients investigat-
ing the early bactericidal activity (EBa) of anti-TB drugs, assessed by the decline of viable Mtb in 
consecutive sputum samples during the initial days of therapy.17 also the EBa studies show the 
rapid killing of mycobacteria by isoniazid. whereas in the present study a rapid and high killing 
capacity of isoniazid towards highly active mycobacteria was demonstrated, isoniazid could not 
eliminate all mycobacteria, due to emergence of resistant mutants. This indicates that EBa studies 
in humans have a very limited predicting value relating to the sterilizing activity of anti-TB drugs.
Compared to isoniazid, the EBa of rifampicin was demonstrated to be substantially less.17 Based 
on this observation the essential therapeutic role of rifampicin is thought to be during the 
continuation phase of the TB treatment, where rifampicin is responsible for sterilization.7 also 
in the present study, a slow and time-dependent killing activity of rifampicin was observed 
as well as elimination of the highly active Mtb population, provided adequate concentrations 
of rifampicin were available. we concluded that our in vitro data support the concepts of a 
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biphasic action of isoniazid and rifampicin against Mtb. Isoniazid plaid the most eminent role 
in the first phase of treatment, whereas rifampicin became of importance in the second phase 
of TB treatment. as a result, one could contemplate increasing dosing of isoniazid to acceler-
ate the time to sputum-smear conversion. Increasing dosing of rifampicin to generate a faster 
sterilizing effect may result in the possibility of reduced total treatment duration.
The cessation of Mtb killing after three and four days of isoniazid exposure and resistance 
development were also observed in the studies of Gumbo et al. who investigated the bacte-
ricidal activity of isoniazid in an in vitro pharmacodynamic model in which Mtb strain H37Rv 
was exposed to isoniazid concentration-time profiles encountered in TB patients.7 Gumbo 
et al. demonstrated, as we now confirmed, that the Mtb population remaining at the time 
bactericidal activity ceased represented an isoniazid-resistant sub-population. we character-
ized the isoniazid-resistant mutants that were selected from the highly active Mtb population 
in the present study. within a broad isoniazid concentration range only isoniazid-resistant 
mycobacteria were cultured. we concluded that the majority of the isoniazid-resistant mu-
tants found are not due to genetic mutations in known drug resistance-associated genes. 
as such, they are not identified as genotypic resistant mycobacteria. we demonstrated 
that this resistance was efflux-mediated, by the use of the efflux pump inhibitor reserpine. 
Efflux pump inhibitors were also applied in the studies of Viveiros et al.8 and Colangeli et 
al.18 who examined their role in isoniazid resistance in Mtb. Their studies suggested that 
efflux pump inhibitors can reverse the mycobacterial tolerance to isoniazid and that even 
high-level resistance to isoniazid can be induced in isoniazid-susceptible Mtb strains by the 
induction of a reserpine-sensitive efflux mechanism.8,18 Gumbo et al. also have found in their 
pharmacodynamics model that isoniazid resistance is partly due to single point mutations 
in the katG gene and is partly the result of an efflux pump mechanism.7 all these findings, 
including our data, indicate there may be a role for efflux pump inhibitors in treatment of TB, 
as they also have proven potency to treat MDR-TB.19
The emergence of resistant mutants during exposure to the anti-TB drugs in relation to the 
metabolic activity of the mycobacteria was also explored in the present study. whereas in the 
highly active Mtb population resistant mutants were only observed after exposure to isoniazid, 
in the low active Mtb population selection of resistant mutants was found after exposure to 
isoniazid, rifampicin or amikacin. Selection of resistant Mtb is primarily expected from the 
high density Mtb population in view of the mutation frequency. as for isoniazid the mutation 
frequency is known to be relatively high compared to the other drugs, selection of isoniazid-
resistant mutants from the low density population is not surprising. again the isoniazid-
resistant genotypic mutants were difficult to characterize, but we conclude that the minority 
of genotypically resistant mutants was characterized by deletion of the katG gene, whereas 
the majority of isoniazid-resistant genotypic mutants remained unclassified. The rifampicin-
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resistant mutants on the other hand, all exhibited mutations in their rpoB gene. whereas, 
compared to highly active bacteria, for elimination of low active Mtb a 64-fold higher isoniazid 
concentration was needed, for rifampicin only a 4-fold increase in concentration was required. 
It is therefore concluded that rifampicin is superior to isoniazid with respect to killing of Mtb 
with a low metabolic activity. This supports the existing concepts on the role of rifampicin in TB 
therapy.20,21 we also found that the killing of isoniazid-resistant or rifampicin-resistant mutants 
required extremely high drug concentrations. as to achieve such high drug concentrations at 
the site of infection is expected to be impossible, it is important to avoid selection of resistant 
mutants. Our data underline the need to optimize the dosage schedule of anti-TB drug in order 
to achieve the maximum-attainable drug concentration that results in maximum reduction in 
Mtb load, and in this way to minimize the selection of resistant mutants.
Ethambutol exhibited a primarily bacteriostatic activity. not even at 1024 mg/l for six days 
ethambutol killed all mycobacteria. This confirms the limited efficacy of ethambutol on active 
multiplying Mtb and the poor efficacy on the low active Mtb subpopulation, as also seen in 
other studies.17, 22,23 It is clear that the primary role of ethambutol in the treatment of TB is to 
minimize the risk of emergence of resistance towards the other anti-TB drugs administered.
amikacin displayed a concentration-dependent, rapid bactericidal activity. Interestingly, 
complete elimination of highly active Mtb compared to low active Mtb required similar ami-
kacin concentrations, indicating that amikacin is effective irrespective of the growth phase 
and metabolic state of the Mtb cells. In this respect, amikacin was superior to the other 
agents. However, as with isoniazid resistance and rifampicin resistance, for killing of amikacin-
resistant mutants extremely high drug concentrations are required.
In conclusion, the classes of anti-TB drugs differ substantially with respect to the dynamics of 
their mycobactericidal effect. In addition, these drugs are significantly different in their capacity 
to kill metabolically low active Mtb. This might be an important observation as the deep-seated, 
low-active or dormant mycobacteria in the infected tissues are probably responsible for relapse 
of TB. also the risk of selection of resistance is strongly dependent on the class of drug used and 
on the growth phase (metabolic activity) of the Mtb. with respect to isoniazid, phenotypic resis-
tance is the dominant resistance type, and reserpine-inhibitable efflux pumps might play a role 
as a mechanism contributing to this phenotypic resistance. However clinical relevance should 
be further evaluated. In genotypic isoniazid-resistant Mtb as yet unknown genetic mutations 
contribute to isoniazid resistance. The present study indicates that increasing rifampicin and/or 
amikacin dosing resulting in enhanced anti-TB drug concentration at the site of infection, may 
significantly improve the therapeutic outcome of TB.
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ABSTRACT
Objectives  
Tuberculosis (TB) is still a major life-threatening infectious disease, within which especially 
the rise of multidrug resistant TB (MDR-TB) is currently worrying. This study focuses on mech-
anisms of development of rifampicin resistance, since rifampicin seems to play an important 
role in the development of MDR-TB.
Methods  
To provide further insight in rifampicin resistance, we performed a genome-wide transcriptional 
profile analysis for Mycobacterium tuberculosis using microarray technology and qRT-PCR analysis. 
a rifampicin-susceptible H37Rv wild type (H37Rv-wT) and a rifampicin-resistant progeny H37Rv 
strain with a H526Y mutation in the rpoB gene (H37Rv-H526Y) were exposed to several concen-
trations of rifampicin, to define the effect of rifampicin on the transcription profile.
Results  
Our study showed that there are rifampicin resistance-dependant differences in response 
between both Mtb strains. Gene clusters associated with efflux, transport and virulence were 
altered in the rifampicin-resistant H37Rv mutant compared to the rifampicin-susceptible 
H37Rv-wT strain after exposure to rifampicin.
Conclusions  
The small gene cluster Rv0559c-Rv0560c in the H37Rv-H526Y strain showed a remarkable 
up-regulation in the microarray analysis and qRT-PCR results and appeared to be depen-
dent on rifampicin concentration and time of exposure. Therefore this study suggests that 
Rv0559c and Rv0560c play a pivotal role in rifampicin resistance of Mtb. Further investigation 
of Rv0559c and Rv0560c is needed to reveal function and mechanism of both genes that 
were triggered upon rifampicin exposure.
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InTRODuCTIOn
Tuberculosis (TB) is one of the major life-threatening infectious diseases. In 2011, with 8.8 
million new cases reported, TB was responsible for the death of 1.5 million people, equal to 
4100 deaths a day.1 Due to a considerable increasing rate of isoniazid and rifampicin resis-
tance among strains of Mycobacterium tuberculosis (Mtb) and the poor treatment outcome 
of multidrug resistant (MDR)-TB treatment,1 more insight in the development of MDR-TB is 
needed. The world Health Organization estimated that world wide 3.3% of all new TB cases in 
2009 were MDR-TB2 and over 85% of rifampicin-resistant clinical isolates are also resistant to 
isoniazid.3 Our study focused on rifampicin-induced transcriptome responses in rifampicin-
susceptible and rifampicin-resistant Mtb strains, since rifampicin seems to play a driving role 
in the development of MDR-TB.
Resistance can either be intrinsic or acquired via genotypic changes. Mtb is intrinsically 
resistant to a wide range of antimicrobial compounds due to the unusually low permeability 
of the bacterial outer membrane.4 additionally, Mtb can become resistant to rifampicin via 
various routes. Genotypic resistance towards rifampicin is caused for almost 95% by target 
alteration due to non-synonymous single nucleotide polymorphisms (nsSnP).5 The nsSnP, 
which primarily occurs in an 81 base pair region in the rpoB gene, known as the rifampicin 
resistance-determining region (RRDR), results in several changes in the β-subunit of Rna 
polymerase. Due to these changes, rifampicin is less competent to bind to the β-subunit of 
Rna polymerase,5-6 resulting in Mtb mutants that are less susceptible or resistant to rifampi-
cin. Recently, Siu et al. showed two new mutations in the rpoB gene outside the RRDR that 
also resulted in rifampicin resistance.7 another form of genotypic resistance is for example 
porin loss by mutations in genes encoding porin proteins leading to decreased cell wall 
permeability.8 Resistance can also be caused by efflux pump activity. Efflux pump-induced 
drug extrusion will result in suboptimal intracellular drug concentrations.9-11 The activity of 
efflux pump genes and transporter genes can be actively induced by rifampicin at the level 
of gene expression.12
To define the effect of rifampicin on the transcription profile, we performed a genome-wide 
transcriptional profile analysis for Mtb exposed to rifampicin using microarray technology. 
we compared the transcription profiles of an isogenic pair of rifampicin-susceptible and 
rifampicin-resistant Mtb strains, to provide further insight in the influence of rifampicin 
resistance on overall gene expression upon rifampicin exposure.
109
Rifampicin-induced transcriptome response
MATERIAlS AnD METhODS
Bacterial culture and drug treatment  
The two Mtb strains used were: a H37Rv wild type (H37Rv-wT) strain and a progeny H37Rv 
strain with a H526Y mutation in the rpoB gene (H37Rv-H526Y). The minimum inhibitory con-
centration (MIC) for rifampicin (Rifadin®, aventis Pharma B.V, Hoevelaken, the netherlands) 
was determined and was 0.25 mg/l for the H37Rv-wT strain and 512 mg/l for the H37Rv-
H526Y strain, using ClSI guidelines.
Mtb suspensions were taken from a frozen stock, thawed and cultured in Middlebrook 7H9 
broth (Difco laboratories, Detroit, MI, uSa), supplemented with 10% oleic acid-albumin-
dextrose-catalase enrichment (OaDC, Baltimore Biological laboratories, Baltimore, MD, uSa), 
0.5% glycerol (Scharlau Chemie S.a, Sentmenat, Spain) and 0.05% Tween 20 (Sigma-aldrich, 
St. louis, MO, uSa), under shaking conditions at 96 rpm at 37°C. after 6 days of growth 
cultures of H37Rv-wT were exposed to 0.063 mg/l and 0.25 mg/l rifampicin, and cultures 
of H37Rv-H526Y to 128 mg/l and 512 mg/l rifampicin. These rifampicin concentrations 
represent ¼x MIC and 1x MIC of rifampicin for both strains. In the controls solvent was added. 
The Mtb suspensions were cultured to late log-phase, prior to addition of rifampicin. Samples 
were collected 30 minutes and 12 hours after exposure to rifampicin, or solvent.
RNA extraction  
Rna was isolated using a FastPrep-24 with a FastRna® Pro Blue kit (MP Biomedicals, Irvine, Ca, 
uSa). To remove residual Dna, Rna samples were treated with Rnase-free Dnase (ambion, 
austin, TX, uSa) and were purified using the Rneasy MiniElute Clean-up kit (Qiagen Benelux, 
Venlo, the netherlands), all according to the manufacturers protocol. The amount of Rna was 
measured using the nanoDrop nD-1000 (Thermo Scientific, wilmington, DE, uSa) and the 
integrity was investigated with the 2100 Bioanalyzer (agilent Technologies Inc., Santa Clara, 
Ca, uSa) using a Rna nano 6000 kit (agilent Technologies) yielding RIn-values ≥ 8.9.
Labelling protocol  
Per test sample, 5 µg total Rna together with 1 µg random octamers (Biolegio, nijmegen, 
the netherlands) in 4.5 µl was heated to 65°C for 10 min to denature the Rna and was al-
lowed to cool in an ice-water bath for 10 min. This 4.5 µl was supplemented to 10 µl with a 
first strand mastermix. The mastermix contained final concentrations of 50 mM Tris-Cl (pH 
8.3), 3 mM MgCl2, 75 mM kCl, 200 mM Raffinose (Sigma-aldrich), 0.015% Triton X-100, 30 ng 
actinomycin-D (Sigma-aldrich), 0.01M DTT, 0.5 mM dGaC, 0.35 mM duTP, 0.15 mM duTP-
Cy3 (test) or duTP-Cy5 (common reference) (GE Healthcare, Hoevelaken, the netherlands) 
and 200u SuperScript-II (life Technologies, Bleiswijk, the netherlands). The mixture was 
incubated for 2 min at 25°C, 120 min at 42°C and 15 min at 70°C. Finally, 1.5 µl of 2.5M naOH 
Chapter 8
110
was added to hydrolyze the remaining Rna upon heating for 10 min at 70°C. 8.5 µl 2M MOPS 
was added for neutralization and the labeled cDna was purified with the E.Z.n.a. MicroElute 
Rna Clean-up kit (Omega Biotek, norcross, Ga, uSa). Dye incorporation and cDna yield was 
measured on the nanoDrop nD-1000 yielding 2-2.5 µg per sample and a FOI >8 pmol/µg. The 
common reference was made by an equimolar pool of the test samples (5 µg per sample) and 
subsequently labeled as the test samples with Cy5 incorporation.
Microarray hybridization and scanning  
Each hybridization mixture was made up from 500 ng test (Cy3) and 500 ng common refer-
ence (Cy5) material. Hybridization mixtures were prepared as described in the agilent Two-
Color Microarray-Based Gene Expression analysis guide version 5.5 (G4140-90050, agilent 
technologies) without the inclusion of the Rna fragmentation mixture. Mtb whole genome 
arrays were supplied by the Bacterial Microarray Group at St. George’s Hospital, university of 
london. Hybridization samples were loaded onto 8x15k Mtb microarrays (Design ID: 027543, 
agilent Technologies) and hybridized for 17 hours at 65°C. afterwards the slides were washed 
and scanned (20 bit, 5 µm resolution) in an ozone-free room with the agilent G2505C scanner 
as described in the agilent G4140-90050 guide. Data were extracted with Feature Extraction 
(v10.7.3.1, agilent Technologies) with the GE2_107_Sep09 protocol for two-color agilent 
microarrays.
Microarray data processing  
The raw data from all arrays were subjected to multiple quality control checks, i.e. visual 
inspection of the microarray scans, testing against criteria for foreground and background 
signals, testing for consistent performance of the labeling dyes, checking for spatial effects 
through pseudo-color plots, and inspection of pre- and post-normalized data with box plots, 
ratio-intensity (RI) plots and PCa plots. These checks revealed significant position effects on a 
slide. Subsequently, within-array normalization was performed using lOESS. Between-array 
normalization was run on the Cy3-channel by summarizing the intensity values of the probes 
in a probe set using the robust multi-array average (RMa) algorithm. The study (basically 
a three-factorial design) was subjected to 2 types of contrast analyses using mixed linear 
models with coefficients for slide-position and sample isolation day (both random) and each 
experimental group (fixed), to determine differential gene expression between ¼x MIC, 1x 
MIC of rifampicin and non-exposure, per genotype and time-point and also to determine 
differential gene expression between the H37Rv-H526Y and H37Rv-wT per MIC treatment 
and time-point.13-14 For hypothesis testing, a Fs test was used and correction of the result-
ing P-values for false discoveries was done according to Storey and Tibshirani.15-16 all data 
handling was performed using R-2.11.1 (http://www.R-project.org) and Bioconductor (www.
bioconductor.org) software. Microarray data are available via an open access database.
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qRT-PCR analysis  
Reverse transcriptase was performed with 50 ng of total Rna of each sample using a Re-
verse Transcriptase Core kit (Eurogentec, Seraing, Belgium). Primers were designed using 
Primer-BlaST (nCBI) and primer sequences are shown in table 3. Quantitative Real-Time 
PCR (qRT-PCR) was performed with a 7500 Fast Real-Time PCR System (applied Biosystems, 
Bleiswijk, the netherlands) using a MESa FaST qRT-PCR MasterMix Plus for SYBR® assay low 
ROX (Eurogentec). The relative fold induction level of each transcript was obtained by ∆∆Ct 
analysis and was performed on duplicate biological samples that were assayed in duplicate. 
For quantitative results siga was used for normalization.
h37Rv-wT
¼ x MIC RIF (0.06 mg/l) 1 x MIC RIF (0.25 mg/l)
Total nr. 
on array
30 min 12 h 30 min 12 h
Functional class up Down up Down up Down up Down
1: Virulence, detoxification and adaption 216 0 0 0 1 0 0 5 5
2: lipid metabolism 270 0 0 0 0 0 0 10 10
3: Information pathways 241 0 0 0 0 0 0 5 5
4: Cell-wall and cell processes 762 0 0 0 0 0 0 24 24
5: Stable Rnas 0 0 0 0 0 0 0 0 0
6: Insertion sequences and phages 101 0 0 0 0 0 0 1 6
7: PE and PPE proteins 165 0 0 0 0 0 0 5 8
8: Intermediary metabolism and respiration 920 0 0 0 0 0 0 28 30
9: Proteins of unknown function 13 0 0 0 0 0 0 1 1
10: Regulatory proteins 194 0 0 0 0 0 0 3 10
11: Conserved hypothetical proteins 1005 0 0 0 0 0 0 22 50
Total 3887 0 0 0 1 0 0 104 149
h37Rv-h526Y
¼ x MIC RIF (128 mg/l) 1 x MIC RIF (512 mg/l)
Total nr. 
on array
30 min 12 h 30 min 12 h
Functional class up Down up Down up Down up Down
1: Virulence, detoxification and adaption 216 0 0 0 0 1 1 8 4
2: lipid metabolism 270 0 0 0 3 0 2 5 4
3: Information pathways 241 0 0 0 0 0 0 4 1
4: Cell-wall and cell processes 762 7 0 8 0 9 1 13 7
5: Stable Rnas 0 0 0 0 0 0 0 0 0
6: Insertion sequences and phages 101 0 0 0 0 0 0 0 0
7: PE and PPE proteins 165 0 0 0 1 0 0 2 3
8: Intermediary metabolism and respiration 920 1 1 1 1 2 0 14 10
9: Proteins of unknown function 13 0 0 0 0 0 0 0 0
10: Regulatory proteins 194 1 0 2 0 2 0 16 0
11: Conserved hypothetical proteins 1005 1 0 2 1 4 1 13 10
Total 3887 10 1 13 6 18 5 75 39
Table 1. numbers of differentially expressed genes assessed by microarray analysis, classified to their 
function in H37Rv-wT and H37Rv-H526Y after 30 minutes and 12 hours exposure to ¼x MIC and 1x MIC of 
rifampicin.
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RESulTS
Mtb growth  
H37Rv-wT and H37Rv-H526Y at a density of 7.4 x 105 [4.3 – 9.9 x 105] CFu/ml were cultured. 
after 6 days both cultures had increased up to 3.1 x 107 [2.1 – 4.0 x 107] CFu/ml. Both strains 
showed identical growth patterns. at day 6, rifampicin was added and quadruple cultures 
were exposed to either solvent or rifampicin concentrations at ¼x MIC or 1x MIC for each 
strain. after 30 minutes and 12 hours exposure the control growth of both strains reached 3.9 
x 107 [3.0 – 5.0 x107] CFu/ml and 2.5 x 107 [1.9 – 2.8 x 107] CFu/ml respectively. Exposure to 
¼x MIC of rifampicin led in both strains to similar CFu counts being 3.0 x 107 [2.1 – 4.1 x 107] 
after 30 minutes and 2.1 x 107 [1.5 – 3.1 x 107] after 12 hours exposure. Exposure to 1x MIC of 
rifampicin led in both strains also to similar CFu counts being 3.1 x 107 [2.8 – 3.4 x 107] after 
30 minutes and 2.3 x 107 [1.2 – 3.1 x 107] after 12 hours exposure.
Microarray analysis  
after microarray analysis, all genes that responded to rifampicin (FDR p-values ≤ 0.05), at each 
time point were categorized and the associated distribution between functional categories 
is displayed in table 1. Of the total number of up-regulated genes upon rifampicin exposure, 
4 genes were up-regulated in both strains and of the total number of down-regulated genes 
Gene Annotation forward primer Reverse primer
Rv0096 PPE1 CaGCaGCTGGCaGGGaaCCG aGCTCTGCTGGGGTGGGCaT
Rv0097 TCCGTCTCCGCGGGaGTTCa aTGCCaGaaCGCGCCGGTTT
Rv0098 fcoT aCaCCGaCTTGaCGCCCTGC TGGCGCTGTaCTGTGCGTCG
Rv0099 faD10 GaTGGCaTCGGCCCTaCCGC CCGGTGTTCaCCCaGCCGTC
Rv0100 CGCCGTCTGCGaCGTGTTGTa GGCCaaTCGGGaCGGCaGTT
Rv0101 nrp aTTCCTGGCCGCTCTGCaCG GCaCCGTaTGCCGCaCCaGT
Rv0251c hsp GCTGCGCCTGaGTTTCGGCT TCaTTCCGCCGCTCGTTCCG
Rv0450c MmpL4 GTCGCTGCTCaTCGCCaaGGG CGCCaTCCaTCGCCGCaCTa
Rv0451c MmpS4 CaCGGTaGCaCCGCTCCaTCG GaTCCGCGGCTTCTTCGGCTC
Rv0452 aaCGGCTGTCGCaGGTCGTG aGCTGCTCGCaTaCCGTGCC
Rv0559c CGCCCaCaTGCTCaGGGCaG GGCGTTGaCGGCGaTGCGTa
Rv0560c GTGTCCCCGTTCGGCCaGTG GGaGGGaGTCCGaCCGCCaT
Rv0676c MmpL5 CCaaCGGCaCaCCGaGGGTC CaGGaCCGGGaGTCGGCGTa
Rv0677c MmpS5 GCCaTCGaCGGTGaTTCGGCa GaCCTCGaCGCCaaGCCaCaG
Rv0678 TCCGGGCaaTGGCCGaaCTG GTCCTCTCCGGTTCGCTGGC
Rv0711 atsA GCCCGaCaaGCCGTGGTTCa TGTCGGGTGGCaCGaTCCCT
Rv1216c GCaCGCGCTCaGCaCCaTCa aGCaCCaCGaTTGGCCCCaC
Rv1217c CGaaCGTCaCGCCGTCGGaa CGCTGTaCCTGCTCGGCTCG
Rv1218c TCGCaCaGCGCTTCGGTCTC GCGCGCaCCTaCTCCaaGGG
Rv1219c CGGCGCGTaCTCCTTCGTCC aaCGaCCCGaCCaCCTGGCT
Rv2703 sigA GTCGGaGGCCCTGCGTCaaG aGGCCaGCCTCGaTCCGCTT
Table 3. Primer sequences as used in the quantitative reverse transcriptase-PCR analysis.
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upon rifampicin exposure, 2 genes were down-regulated in both strains. In H37Rv-wT no 
genes were induced after 30 minutes exposure to ¼x MIC and 1x MIC of rifampicin. after 12 
hours exposure to ¼x MIC of rifampicin, Rv1397c (vapC10) encoding a possible toxin was 
found down-regulated, a 12 hour exposure to 1x MIC of rifampicin resulted in 104 up-regu-
lated genes and 149 down-regulated genes. after 12 hours exposure to 1x MIC of rifampicin 
vapC10 was also down-regulated which was stronger compared to exposure to ¼x MIC.
The H37Rv-H526Y showed more response upon rifampicin exposure compared to the 
H37Rv-wT. Exposure to ¼x MIC of rifampicin resulted in 10 up-regulated genes and 1 down-
regulated gene after 30 minutes, and 13 up-regulated genes and 6 down-regulated genes 
after 12 hours. Exposure to 1x MIC of rifampicin resulted in 18 up-regulated and 5 down-
regulated genes after 30 minutes and 75 up-regulated and 39 down-regulated genes after 12 
hours. under all conditions in the H37Rv-H526Y strain nine genes were found up-regulated. 
Of all these genes, 20 genes were selected that showed in at least 2 conditions differential 
expression ≥ 4 fold (14 genes) or ≤ ¼ fold (6 genes) in H37Rv-H526Y and not in H37Rv-wT 
upon exposure to rifampicin (table 2). From the 14 ≥ 4 fold up-regulated genes, 8 appeared 
to be involved in cell wall and cell processes (Rv0450c, Rv0451c, Rv0559c, Rv0676c, Rv0677c, 
Rv1216c, Rv1217c and Rv1218c), 2 encode proteins involved in intermediary metabolism and 
respiration (Rv0560c and Rv0711), 2 encode regulatory proteins (Rv0452 and Rv1219c), 1 is 
associated with virulence, detoxification and adaption (Rv0251c), and 1 encodes a conserved 
hypothetical protein (Rv0678). Of the 6 down-regulated genes, 3 encode proteins that are 
involved in lipid metabolism (Rv0098, Rv0099 and Rv0101), 1 belongs to the PPE family 
proteins (Rv0096), 1 encodes a protein involved in intermediary metabolism and respiration 
(Rv0097), and 1 encodes a conserved hypothetical protein (Rv0100).
qRT-PCR confirmation  
aliquots of the Rna from rifampicin-treated and control samples were also used for qRT-
PCR analysis. The samples obtained after 12 hours 1x the MIC of rifampicin exposure, were 
compared with the 12 hours control samples; siga was used for normalization. Results of 
the ∆∆Ct analysis are in agreement with the microarray data. The direction of change was 
in concurrence by both qRT-PCR and microarray analysis for all samples. However, the fold 
change determined by qRT-PCR is different from that determined by the microarray analysis 
as shown in table 2 and figure 1. another ∆∆Ct analysis of independent Rna samples showed 
that the direction of change was in agreement by both qRT-PCR and microarray analysis for 
70% of the samples. However, in general gene-expression levels are lower compared to the 
microarray analysis and to the expression levels obtained from the first qRT-PCR experiment.
Of the 20 genes that were up-regulated in at least two conditions in the microarray analysis, 
only Rv0559c and Rv0560c were found strongly and constantly up-regulated in both qRT-PCR 
experiments in H37Rv-H526Y compared to H37Rv-wT.
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DISCuSSIOn
we have investigated differences in rifampicin-induced gene responses between rifampicin-
susceptible and rifampicin-resistant Mtb strains using microarray analysis and qRT-PCR. at 
¼x MIC of rifampicin exposure more genes are differentially expressed in H37Rv-H526Y than 
H37Rv-wT, whereas at 1x MIC of rifampicin and long exposure this is reversed. These results 
show that the rifampicin-susceptible and rifampicin-resistant Mtb strain have an altered 
response upon rifampicin exposure.
using qRT-PCR we assessed if biological duplicates showed similar up-regulation. This re-
vealed that one cluster of genes (Rv0559c-Rv0560c) was strongly up-regulated in all experi-
ments after exposure to rifampicin in the H37Rv-H526Y. These results were confirmed in a 
second qRT-PCR experiment in which expression of Rv0559c and Rv0560c was also highly 
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figure 1. Differentially expressed genes assessed by quantitative Real-Time PCR (qRT-PCR). The relative 
gene expression of H37Rv-wT (A) and H37Rv-H526Y (B) assessed with qRT-PCR and normalised to siga 
after 12 hours of exposurse to 1x MIC of rifampicin
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up-regulated in the H37Rv-H526Y strain compared to the H37Rv-wT strain (data not shown). 
The Rv0559c gene encodes a protein with an unknown function. However, a previous study 
of Denkin et al. showed that Rv0559c is also induced upon salicylate exposure.17 Rv0560c 
is also induced by salicylate and probably encodes a benzoquinone methyltransferase.17-18 
Schuessler et al. showed that Rv0559c and Rv0560c have slow induction kinetics after 
exposure to salicylate and that gene expression is increasing over time.19 Our results are in 
agreement with these findings, since our microarray data also revealed that up-regulation 
of Rv0559c and Rv0560c is time-dependent and rifampicin concentration-dependent. The 
data showed an increase in expression of Rv0560c between 30 minutes and 12 hours of 
rifampicin exposure. an increased expression was also observed for both genes comparing 
exposure to rifampicin at ¼x MIC and 1x MIC. Sun et al. suggested that Rv0559c, Rv0560c 
and Rv0561c are located within the same operon,18 and Schuessler et al. showed that only 
Rv0559c and Rv0560c are regulated by the same promoter. In our microarray analysis we did 
not find a significant up-regulation of Rv0561c after rifampicin exposure in the H37Rv-H526Y 
strain, which is in concordance with earlier observations by Schuessler et al. In all, our study 
provides further evidence that Rv0559c and Rv0560c are potentially involved in (rifampicin) 
resistance and thereby further investigation on the function of the proteins they encode for 
is appropriate.
we have also found 4 other distinct clusters of genes and 2 different genes differently ex-
pressed between both strains after 12 hours of exposure to 1x MIC of rifampicin. The first 
cluster of Rv0096 to Rv0101 is strongly down-regulated in the H37Rv-H526Y strain upon 12 
hours of rifampicin exposure. The other clusters, Rv0450c to Rv452, Rv0676c to Rv678 and 
Rv1216c to Rv1219c are strongly up-regulated in the H37Rv-H526Y. none of these clusters 
are induced in the H37Rv-wT in response to rifampicin exposure. Genes of the Rv0096-
Rv0101 operon encode a PPE protein family member (Rv0096), a putative oxidoreductase of 
the tfdA dioxygenase family (Rv0097), a type III thioesterase (Rv0098), a fatty acid aMP ligase 
(Rv0099), an acyl carrier protein (Rv0100) and a nonribosomal peptide synthase (Rv0101). 
These genes seem to be co-regulated by a two-component regulatory system (senX3-regX3)20 
and are involved in biosynthesis of Phthiocerol Dimycocerosate (PDIM).21 PDIM is part of 
the lipid-rich content of the mycobacterial cell envelop and is associated with an increased 
Mtb virulence.22-23 Interestingly, no down-regulation was found after microarray analysis for 
Rv2942 (MmpL7), which is also involved in the transport of PDIMs.24 So, upon rifampicin expo-
sure, down-regulation of this virulence-associated operon in the H37Rv-H526Y is observed. 
Thus a possible direct linkage between loss of fitness and mutations in the RRDR region is 
given.
another gene, up-regulated after 12 hours of exposure to 1x MIC of rifampicin in the H37Rv-
H526Y is Rv0251c, which is associated with stress response.25 The up-regulation of stress-
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related genes after exposure to rifampicin seems a logic event. However with these results, 
an exact gene is known and thus a more precise study can be conducted to unravel the exact 
function of Rv0251c in Mtb and thereby provide a possible drug-target.
Furthermore, two up-regulated gene clusters being Rv0450c to Rv452 and Rv0676c to Rv678 
were found. Both clusters consist of genes of the Mmpl (Mycobacterial membrane protein 
large) family, of the MmpS (Mycobacterial membrane protein Small) family and a gene with 
unknown function. The Mmpl proteins belong to the group of resistance, nodulation and 
cell division proteins (RnD) and are associated with drug efflux.26 The RnD family is a group of 
multidrug resistance pumps that recognize and mediate the transport of a great diversity of 
compounds and has been well-documented in Gram-negative bacteria. However, Domenech 
et al. concluded in their study that these Mmpl genes seem to play a limited role in anti-TB 
drug resistance in Mtb.26 MmpL4 (Rv0450c) and MmpL5 (Rv0676c) are transcriptional coupled 
with MmpS4 and MmpS5, these smaller genes are predicted to encode proteins with one 
transmembrane domain. Still, little is known about the MmpS family. In Mycobacterium smeg-
matis MmpS4 (Rv0451c) is associated with glycopeptidolipid biosynthesis and export cell 
surface glycolipids.27 In our experiments, the up-regulation of Rv0450c to Rv0452 is almost 
constant in all conditions tested. Our data showed that the response of Rv0676c to Rv0678 
is higher after 30 minutes of exposure to both rifampicin concentrations compared to 12 
hours of rifampicin exposure. This suggests that Rv0676c to Rv0678 are early response genes. 
MmpL5 and MmpS5 (Rv0677c) are associated with efflux pump-related azole resistance in 
Mtb and are regulated by Rv0678.28 Milano et al. showed that Rv0678 has almost 50% homol-
ogy with the well-characterized MarR of Escherichia coli,28 this family of regulatory proteins 
plays an important role in of the development of antibiotic resistance.29 Based on the already 
known function of Mmpl and MmpS genes and the up-regulation found in the microarray 
analysis it is likely that in Mtb MmpL4, MmpS4, MmpL5 and MmpS5 are involved in rifampicin 
efflux out of the cell. This indicates that although previous studies showed no crucial role for 
some of the proteins they encode for in drug resistance, the up-regulation of these genes 
upon rifampicin exposure is a genuine phenomenon and thereby might possess a target for 
future drug efflux inhibition.
Rv0711 (atsA) encodes for a possible arylsulfatase but knowledge about atsA is very limited 
in Mtb. The knowledge about the up-regulated gene cluster Rv1216c-Rv1219c in the H37Rv-
H526Y is also very limited. Rv1216c and Rv1217c encode for probable integral membrane 
proteins. Rv1218c encodes an aBC transporter and previous studies suggest an important 
role for this gene product in mediating efflux to a wide variety of compounds.30-31 However 
Balganesh et al. showed that the MIC of rifampicin is not influenced in Rv1218c knock-out 
mutants.30 This suggests that Rv1218c is not primarily involved in regulation of the intracel-
lular concentration of rifampicin. In our rifampicin-resistant H37Rv-H526Y mutant however, 
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Rv1218c is strongly up-regulated, which implies an association between up-regulation of 
Rv1218c and rifampicin resistance. Rv1219c probably encodes for a transcriptional regula-
tory protein but further function and regulation is unknown.
To conclude, our results show that several interesting gene clusters associated with efflux, 
transport and virulence show an altered response in the rifampicin-resistant H37Rv mutant 
compared to the rifampicin-susceptible H37Rv wild type strain upon exposure to rifampicin. 
not all genes could be completely confirmed with qRT-PCR. although the directions of 
change were identical, fold changes appeared in general to be lower in qRT-PCR. This lack of 
concurrence between methods for genes exhibiting low levels of change has been reported 
by several others.32-35 In the present paper we show by microarrays and qRT-PCR experiments 
that Rv0559c and Rv0560c are strongly rifampicin-inducible. This indicates that the induction 
of both genes is dependent on concentration of rifampicin and exposure time. Therefore this 
study suggests that Rv0559c and Rv0560c play a pivotal role in rifampicin resistance of Mtb. 
Further investigation on the exact function and regulation of Rv0559c and Rv0560c is needed 
to understand the mycobacterial mechanisms that are triggered upon rifampicin exposure.
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Drug susceptibility of Mycobacterium tuberculosis 
Beijing genotype, association with MDR-TB
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ABSTRACT
To determine differences in the ability of Mycobacterium tuberculosis strains to withstand 
anti-tuberculosis drug treatment, we compared the activity of anti-tuberculosis drugs 
against susceptible Beijing and East-african/Indian genotype Mtb strains. Beijing genotype 
strains showed high rates of mutation within a wide range of drug concentrations, possibly 
explaining this genotype’s association with multidrug-resistant tuberculosis.
Chapter 9
124
InTRODuCTIOn
The emergence of Mycobacterium tuberculosis (Mtb) resistance to anti-tuberculosis (anti-
TB) drugs is a major public health challenge that is threatening world Health Organization 
targets set for the elimination of TB).1 approximately 500,000 cases of multidrug-resistant 
TB (MDR-TB) are diagnosed annually, but the true magnitude of the MDR-TB problem is not 
known because adequate laboratory tools are lacking. Multiple factors contribute to low 
cure rates, treatment failures, and relapses: poor-quality guidance regarding treatment, HIV 
co-infection, transmission of resistant forms of TB, underdeveloped laboratory services, and 
unavailability of alternative drug treatments. However, the evolution of Mtb is an additional 
factor that presumably fuels the worldwide problem of emerging resistance. The Beijing 
genotype is significantly associated with drug resistance 2-6, especially in geographic areas 
where prevalence of resistance to anti-TB drugs is high, and it is associated with recent TB 
transmission.2-6 There are also indications that the population structure of Mtb in areas with 
a high prevalence of anti-TB drug resistance is changing rapidly toward an increase in Beijing 
genotype strains.2,6-8
The world Health Organization target rates for detecting and curing TB in Vietnam have 
been met; however, the rate of TB infection is not decreasing as expected.4-5. Earlier in this 
country, the Beijing genotype was strongly correlated with MDR-TB and treatment failures.9 
Extensive molecular epidemiologic studies showed that the Beijing and East-african/Indian 
(EaI) genotypes are predominating in Vietnam; each lineage causes ≈40% of the TB cases. 
according to the single-nucleotide polymorphism typing described by Hershberg et al. 10, the 
Beijing genotype is a representative of the modern lineage, and the EaI genotype is believed 
to represent an evolutionary lineage more closely related to the common ancestor of the 
Mtb complex.
we compared the in vitro activity of anti-TB drugs against susceptible Beijing and EaI Mtb 
isolates from Vietnam and determined the in vitro mutation frequency of these strains during 
drug exposure. we also determined time-kill kinetics of anti-TB drugs and assessed the emer-
gence of resistant mutants and the concentration range within which resistant mutants and 
no susceptible mycobacteria were selected. The concentration at which resistant mutants 
did not emerge (the mutant prevention concentration) was also ascertained. By using this 
approach, we established an in vitro model for determining differences in the ability of Mtb 
strains to resist anti-TB drug treatment.
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ThE STuDY
Results of a liquid culturing system (BD BaCTEC MGIT 960 System; BD Diagnostics, Sparks, 
MD, uS) (for details, see the Technical appendix) showed that all 5 Beijing and 5 EaI genotype 
strains were susceptible to isoniazid, rifampicin, moxifloxacin (MXF), and amikacin (aMk). 
MICs were determined by using the agar proportion method 11, which showed that ranges 
were small for the Beijing and EaI genotype strains; isoniazid: 0.062–0.125 mg/l, rifampicin: 
0.125–1 mg/l, MXF: 0.125–0.5 mg/l and aMk: 0.5–2 mg/l. Duplicate values showed only 
minor differences.
we determined the mutation frequencies of the Beijing and EaI genotype strains by using 
previously defined critical drug concentrations of 1 mg/l for isoniazid, rifampicin, and MXF 
and 5 mg/l for aMk (11,12) (for details, see the Technical appendix). The mutation frequen-
cies of the Beijing and EaI genotype strains were similar for isoniazid, MXF, and aMk, but 
they were significantly different for rifampicin (1.6 × 10−5 to 5.4 × 10−3 for Beijing strains 
vs. 6.3 × 10−8 to 3.8 × 10−4 for EaI strains; p = 0.003, unpaired Mann-whitney test) (table 1; 
figure 1). Because rifamycin drugs are widely used to treat TB, the difference in the mutation 
frequencies of Beijing and EaI genotype strains for rifampicin is a major finding.
For Beijing genotype strains, the increase in mutation frequency during exposure to rifampicin 
could be due to described missense mutations in the mut genes.13 Such mutations in the mut 
genes can change the Dna repair mechanism; as a consequence, the frequency of resistant mu-
tant formation might increase. However, a direct correlation between the occurrence of particular 
mutations in mut genes and altered mutation frequency has not been proven. Furthermore, 
werngren and Hoffner 14 found an equal mutation frequency for Beijing (3.6 × 10−8) and non-
Beijing (4.4 × 10−8) genotypes. a possible explanation for the discrepancy in findings might be the 
concentration of rifampicin used in the subculture plates. In our study, the critical concentration 
Mutation frequency
Beijing genotype strains East-African/Indian genotype strains
1585 1607 2115 2121 2145 1627 1606 1592 1596 2113
Inh
5.7x10-6 8.6x10-6 7.3x10-6 6.8x10-5 9.1x10-4 3.7x10-6 8.7x10-6 1.8x10-5 3.9x10-5 1.3x10-5
6.2x10-6 1.4x10-5 1.1x10-5 2.9x10-4 5.0x10-4 6.5x10-6 1.6x10-4 2.6x10-5 2.8x10-5 4.1x10-5
RIf
3.0x10-3 1.5x10-3 1.0x10-3 2.9x10-5 1.6x10-5 4.1x10-6 3.8x10-4 3.0x10-4 1.4x10-5 6.7x10-8
4.3x10-3 5.4x10-3 9.2x10-5 1.9x10-4 5.5x10-5 2.8x10-6 2.7x10-5 2.4x10-5 3.9x10-6 6.3x10-8
MXf
4.3x10-8 6.9x10-8 1.0x10-8 1.1x10-7 7.9x10-8 9.3x10-9 3.2x10-8 9.9x10-8 1.7x10-7 1.5x10-8
6.1x10-8 2.4x10-7 4.3x10-8 1.6x10-7 1.0x10-7 1.5x10-7 1.0x10-7 4.5x10-8 2.0x10-7 1.0x10-7
AMk
2.3x10-8 8.6x10-8 1.4x10-8 9.3x10-8 7.6x10-7 5.6x10-8 7.5x10-9 9.4x10-8 3.7x10-8 4.4x10-8
3.2x10-8 3.0x10-7 2.8x10-8 1.1x10-7 1.1x10-6 4.5x10-9 1.5x10-9 1.5x10-9 3.2x10-7 3.3x10-7
Table 1: Mutation frequency Mycobacterium tuberculosis genotype strains originating from Vietnam, by 
anti-tuberculosis drug, determined in duplicate.
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of 1 mg/l rifampicin was used 11, whereas werngren and Hoffner used a concentration of 2 mg/l 
rifampicin. In addition, werngren and Hoffner compared the Beijing and non-Beijing genotypes 
of several genotype families, whereas we compared Beijing and EaI genotype strains that were 
selected from the same tuberculosis-endemic area and during the same period.
we determined the time-kill kinetics of rifampicin toward 2 strains with significantly dif-
ferent mutation frequencies: Beijing-1585 (3.7 × 10−3 [3.0 × 10−3 and 4.3 × 10−3, duplicates]) 
and EaI-1627 (3.5 × 10−6 [2.8 × 10−6 and 4.1 × 10−6, duplicates]). Cultures with low and high 
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figure 1. Frequency of rifampicin (RIF)-resistant mutants in Mycobacterium tuberculosis Beijing and East-
african/Indian (EaI) genotype strains (5 strains each) originating from Vietnam. Mutation frequencies were 
determined in duplicate. Statistical analysis was performed by using an unpaired Mann-whitney test.
lowest concentration (mg/l) resulting in killing of Mtb
after various time points during RIf exposure
Beijing-1585 EAI-1627
≥99% killing 100% killing ≥99% killing 100% killing
low density 
†
high 
density ‡
low density 
§
high 
density ¶
low density 
†
high 
density ‡
low density 
§
high 
density ¶
Day 1 8 nD 256 nD 8 nD 32 nD
Day 3 1 0.008 64 1024 0.125 0.03 8 32
Day 6 0.001 0.008 2 64 0.001 0.06 1 2
Table 2. Concentration- and time-dependent bactericidal effect of rifampicin toward Mycobacterium 
tuberculosis genotypes in low- and high-density cultures. Cultures were exposed to RIF at 2-fold increasing 
concentrations for 6 days at 37°C; at indicated time-points, subcultures were performed on solid media for 
counting. low, low-density culture; high, high-density culture; nD, not determined.
† Density of 5.1 × 105 CFu/ml 
‡  Density of 4.4 × 106 CFu/ml 
§  Density of 6.8 × 105 CFu/ml 
¶ Density of 3.0 × 106 CFu/ml
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figure 2. Concentration- and time-dependent bactericidal effect of rifampicin (RIF) towards low density 
cultures of Mtb BE-1585 (5.1x105 cfu/ml) and Mtb EaI-1627 (6.8x105 cfu/ml). Cultures were exposed to 
rifampicin at 2-fold increasing concentrations for 6 days at 37°C. after 1, 3 or 6 days of exposure subcultures 
on solid media were performed for cfu-counting. * = Due to complete outgrowth of the mycobacteria at 6 
days of exposure aggregation had occurred and accurate cfu counting could not be performed.
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densities of Beijing-1585 and EaI-1627 were investigated as described.15 Rifampicin showed 
strong time- and concentration-dependent activity toward low-density cultures of the 2 
strains (figure 2). low concentrations of rifampicin were needed to achieve >99% Mtb killing; 
differences between Beijing-1585 and EaI-1627 were minor (table 2). However, to achieve 
100% killing, especially for Beijing-1585, rifampicin concentrations had to be increased 
substantially (table 2). Compared with the low-density culture for Beijing-1585, a substantial 
increase in rifampicin concentrations was needed to achieve 100% killing of the high-density 
culture (table 2). This finding may be relevant in the clinical context because high-density 
mycobacteria populations are expected to exist in infected tissues of TB patients.
Rifampicin-resistant mutants did not emerge in low-density cultures of Beijing-1585 and 
EaI-1627. However, rifampicin-resistant mutants were selected at relatively high numbers 
from high-density Beijing-1585 cultures compared with high-density EaI-1627 cultures. In 
Beijing-1585 cultures, exposure to rifampicin concentrations of 2–32 mg/l selected resistant 
mutants only; this was not observed in EaI-1627 cultures. analysis of rifampicin-resistant 
Beijing mutants showed the following altered rpoB gene sequences: CaC∙GaC (H526D), 
CaC∙TaC (H526Y), and TCG∙TTG (S531l), as assessed by using the GenoType®MTBDRplus 
(Hain lifescience, nehren, Germany) assay (for details, see the Technical appendix).
For 3 of the 4 anti-TB drugs, the difference in the range of mutant prevention concentrations 
for the Beijing and EaI genotype strains was small; isoniazid: 128–256 mg/l, RIF: 256–1,024 
mg/l and MXF: 2–8 mg/l. The mutant prevention concentration for aMk was >1,024 mg/l 
for all strains tested.
Conclusions
we showed that the currently used anti-TB drug susceptibility assays do not discriminate 
between the in vitro susceptibility, as determined by the methods used in this study, of the 
Mtb Beijing and EaI genotype strains. we also showed that the determination of mutation 
frequencies might be more informative than results of anti-TB drug susceptibility assays. 
For rifampicin, mutation frequencies in Beijing genotype strains were high compared with 
those in EaI genotype strains, and the selection of rifampicin-resistant mutants among 
Beijing strains, but not EaI strains, occurred within a wide range of rifampicin concentrations. 
In addition, the killing capacity of rifampicin toward the Beijing genotype is dependent on 
the density of mycobacteria: high concentrations of rifampicin are required to achieve 100% 
killing of high-density Beijing genotype populations but not of high-density EaI genotype 
populations. These in vitro characteristics might contribute to the less favourable treatment 
outcome of Beijing genotype TB infections and their significant association with drug re-
sistance. Our findings demonstrate the need for anti-TB drug treatments that will prevent 
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resistance among Mtb Beijing genotype TB cases, and they suggest that the development of 
genotype-specific TB therapy might be justified.
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TEChnICAl APPEnDIX
Bacteria  
The 10 Mtb strains used in this study were all clinical isolates from Vietnam of which five rep-
resented the Beijing genotype and five the East-african/Indian (EaI) genotype. Strains were 
stored at the national Tuberculosis Reference laboratory (RIVM, Bilthoven, the netherlands) 
as Beijing Vn 2002-1585 (Beijing-1585), Vn 2002-1607, Vn 1998-2115, Vn 1998-2121 and Vn 
1998-2145, and EaI Vn 2002-1627 (EaI-1627), Vn 2002-1606, Vn 2002-1592, Vn 2002-1596 
and Vn 1998-2113. a subculture of strain Beijing-1585 (known as strain Vn+) was previously 
subjected to genome sequencing described by Schürch et al. (Infection, Genetics and Evolu-
tion 2011; 11:587–597). The Mtb strains in this study were selected on basis of their diverse 
genotyping results, as determined by using spoligotyping and IS6110 restriction fragment 
length polymorphism (RFlP) typing according to the internationally standardized methods 
(kamerbeek et al. J Clin Microbiol. 1997; 35(4):907-14 and van Embden et al. J Clin Microbiol. 
1993; 31(2):406-9). The genotypes of the strains were defined as either Beijing or EaI accord-
ing to their characteristic spoligotypes, following the well-accepted genotype definitions 
described by kremer et al. (J. Clin Microbiol. 2004; 42(9):4040-9) and Brudey et al. (BMC Micro-
biol. 2006; 6:6-23). Comparison of the five different RFlP patterns of the five Beijing strains of 
this study to those of Beijing strains that were subjected to single nucleotide polymorphism 
(SnP) typing previously performed by Schürch et al. (submitted for publication) showed 
that strains Vn 2002-1585 and Vn 1998-2121 represent the typical Beijing SnP type and that 
strains Vn 2002-1607, Vn 1998-2115, and Vn 1998-2145 represent an intermediate Beijing 
SnP type. The EaI strains showed RFlP patterns with either two (Vn 2002-1596) or one copy 
of IS6110. However, the four 1-copy strains could be discriminated on basis of the molecular 
weight of the IS6110 containing RFlP fragment and/or their spoligo pattern.
Cultures 
Mtb suspensions were cultured in Middlebrook 7H9 broth (Difco laboratories, Detroit, MI, 
uSa), supplemented with 10% oleic acid-albumin-dextrose-catalase enrichment (OaDC, 
Baltimore Biological laboratories, Baltimore, MD, uSa), 0.5% glycerol (Scharlau Chemie S.a, 
Sentmenat, Spain) and 0.05% Tween 20 (Sigma Chemical Co, St. louis, MO, uSa), under shak-
ing conditions at 96 rpm at 370C. Vials with Mtb suspensions were stored at -80°C. Cultures 
on solid media were grown on Middlebrook 7H10 agar (Difco), supplemented with 10% 
OaDC and 0.5% glycerol for 28-35 days at 37°C with 5% CO2. The exact incubation time was 
dependent on the growth rate of the Mtb genotype strain investigated.
Anti-TB drugs  
The anti-TB drugs assayed were isoniazid (Hospital Pharmacy; Rotterdam, The netherlands), 
rifampicin (Rifadin®, aventis Pharma B.V, Hoevelaken, The netherlands), moxifloxacin (MXF, 
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avelox®, Bayer Schering Pharma a.G, Berlin, Germany) and amikacin (aMk, Hospira Benelux 
BVBa, Brussels, Belgium). Dilutions of the drugs were prepared according to the recommen-
dations of the manufacturers.
Susceptibility testing (MGIT)  
The Mtb genotype strains were subjected to the MGIT drug susceptibility testing at the 
national Tuberculosis Reference laboratory using the BaCTEC MGIT-960 system™ (Becton, 
Dickinson and Company, Franklin lakes, nJ, uS) liquid culturing system for isoniazid, rifam-
picin, aMk and MXF susceptibility (woods et al. national Committee for Clinical laboratory 
Standards M24-a, volume 23; 2003; 18:1-69).
Minimal inhibitory concentration (MIC)  
To determine the MIC of the Mtb genotype strains we used the agar proportion method as 
described by the Clinical and laboratory Standards Institute (ClSI) (woods et al. national 
Committee for Clinical laboratory Standards M24-a, volume 23; 2003; 18:1-69). Colonies 
grown on solid media were suspended in broth using glass beads and vortexing during 4 
min. The suspension was left for 30 minutes, after which the supernatant was taken and set 
to an optical density of McFarland standard 1. using broth, a 1:10 dilution of this Mtb suspen-
sion was plated onto solid media containing serial, twofold dilution concentrations of anti-TB 
drug. after incubation the degree of growth was assessed. The MIC was defined as the lowest 
concentration of anti-TB drug that resulted in >99% growth inhibition. MIC determinations 
were performed in duplicate.
Mutation Frequency (MF)  
Determination of the MF of the Mtb genotype strains was performed using the critical con-
centrations of the anti-TB drug, being 1 mg/l for isoniazid, 1 mg/l for rifampicin, 5 mg/l 
for amikacin and 1 mg/l for moxifloxacin, as defined by the ClSI (woods et al. national 
Committee for Clinical laboratory Standards M24-a, volume 23; 2003; 18:1-69) and Gumbo 
et al. (antimicrob agents Chemother. 2010; 54(4):1484-91). Starting from a high density 
(concentrated) Mtb culture (~1x1010 cfu), serial dilutions of the Mtb suspension were plated 
onto solid media without drugs and onto solid media containing the “critical concentration” 
of the respective anti-TB drugs. after incubation, the total numbers of colony forming units 
(cfu) and numbers of resistant mycobacteria were counted and the MF was calculated. MF 
were determined in duplicate. In order to assess the stability of the resistant mutants isolated 
from the anti-TB drug-containing solid media, 10 colonies were randomly picked and plated 
onto solid media without anti-TB drug. after incubation, these colonies were plated to check 
for re-growth on solid media containing the “critical concentration” of the same anti-TB drug.
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Time-Kill Kinetics 
For Beijing-1585 and EaI-1627 a time-kill kinetic assay for rifampicin was performed. The 
concentration- and time-dependent bactericidal activity of the anti-TB drug was determined 
as described previously (de Steenwinkel et al. J antimicrob Chemother. 2010; 65(12):2582-9). 
In short, Mtb cultures at low density or at high density were exposed to rifampicin at 2-fold 
increasing concentrations, ranging from 0,5 µg/l to 256 mg/l for six days at 370C. On days 1, 
3 and 6, samples were taken for cfu counting provided that the Mtb suspension did not show 
visible aggregation.
Selection of drug resistant Mtb
During the time-kill kinetic assay for Beijing-1585 and EaI-1627 the selection of resistant 
mutants was performed. In order to detect drug-resistant Mtb in the low density or the high 
density cultures, the samples taken after six days of exposure to rifampicin were cultured on 
rifampicin-containing solid media. The concentration of rifampicin in the solid media was 
4-fold the “critical concentration” (4 mg/l rifampicin). Resistant Mtb colonies, able to grow 
on this medium, were characterized using the GenoType® MTBDRplus assay (Hain lifescience 
GmbH, nehren, Germany), to detect the most common mutations in rpoB gene conferring 
rifampicin-resistance (J Clin Microbiol. 2007; 45(8):2635-40).
Mutant Prevention Concentration (MPC)  
The MPC of the Mtb genotype strains was determined using the protocol as described by 
Drlica et al. (J antimicrob Chemother. 2003; 52(1):11-7) and Goessens et al. (J antimicrob Che-
mother. 2007; 59(3):507-16). In short, from a high density (concentrated) Mtb culture approxi-
mately 1010 cfu was plated onto solid medium containing 2-fold increasing concentrations of 
anti-TB drug, ranging from 64 mg/l to 1024 mg/l for isoniazid, rifampicin or amikacin and 
from 1 mg/l to 32 mg/l for moxifloxacin. The MPC was defined as the lowest concentration 
of anti-TB drug in the solid medium, which prevented growth of Mtb.
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Chapter 10
Consequences of non-compliance on therapy 
efficacy and emergence of resistance in murine 
tuberculosis caused by the Beijing genotype
J.E.M. de Steenwinkel, M.T. ten kate, G.J. de knegt, H.a. Verbrugh, R.E. aarnoutse, 
M.J. Boeree, M.a. den Bakker, D. van Soolingen, I.a.J.M. Bakker-woudenberg
antimicrob agents Chemother. 2012; 56(9):4937-44
ABSTRACT
Despite great effort of health organizations worldwide in fighting tuberculosis (TB), morbidity 
and mortality is not declining as expected. One of the reasons is related to the evolutionary 
development of Mycobacterium tuberculosis (Mtb), in particular the Beijing genotype strains.
In a previous study, we showed the association between Beijing genotype and an increased 
mutation frequency for rifampicin. In this study we use a Beijing genotype strain and an East-
african/Indian genotype strain, to investigate in our mouse TB model whether the higher 
mutation frequency observed in a Beijing genotype strain is associated with treatment failure 
particularly during non-compliance therapy.
Both genotype strains showed a high virulence in comparison to Mtb strain H37Rv, resulting 
in a highly progressive infection with rapid lethal outcome in untreated mice. Full-compliance 
treatment was effective without relapse of TB irrespective the infecting strain, showing similar 
decrease of Mtb load in infected organs, and similar histopathological changes. non-compli-
ance treatment, simulated by a reduced duration and dosing frequency resulted in relapse of 
infection. Relapse rates were correlated with the level of non-compliance and were identical 
for Beijing infection and East-african/Indian infection. However, in only Beijing-infected mice 
isoniazid-resistant mutants were selected at the highest level of non-compliance. This is in 
line with the substantial selection of isoniazid-resistant mutants in vitro in a wide isoniazid 
concentration window observed for the Beijing strain and not for the EaI strain.
These results suggest that genotype diversity of Mtb may be involved in emergence of resis-
tance and indicates that genotype-tailor-made treatment should be investigated.
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InTRODuCTIOn
Resistance to anti-tuberculosis (TB) drugs is rapidly emerging worldwide 1 with nearly half a 
million cases of multidrug resistant TB (MDR-TB) recorded annually. The majority of MDR-TB is 
found in Former Soviet union States and asia.1 The true magnitude of resistance problem may 
be much greater, as in most high TB prevalence settings laboratory service is underdeveloped 
and resistance cannot be adequately detected. Moreover, in almost all countries worldwide, 
extensively drug resistant TB (XDR-TB) has also been reported 2 and there are already publica-
tions on the emergence of totally drug resistant TB (TDR-TB), e.g. in Iran and India.3 Because 
only a minority of MDR-TB cases can currently be treated according to the guidelines of the 
wHO, resistant TB may increasingly become an untreatable disease, although there is hope 
that new drugs may force a major improvement in this situation within some years.4
There are multiple factors known that underlie the development of resistance to anti-TB drugs, 
like unregulated availability of anti-TB drugs, poor quality of drugs, unprofessional prescrip-
tion, non-compliance, malabsorption in certain subpopulations and large inter-individual 
variability in pharmacokinetics of anti-TB drugs, and host genetic factors. The combination 
and/or relative impact of factors that eventually lead to resistance emergence are not well 
understood. However, non-compliance is generally considered to be the most relevant factor 
leading to resistance in TB treatment.1, 5-6 a recent addition to the determinants of resistance 
is a bacterial one. Particular strains seem more prone to develop resistance and/or be trans-
mitted as MDR-TB. For instance, at multiple geographical sites, the Beijing genotype has been 
correlated with MDR and XDR-TB.7-8 In Europe Beijing strains are significantly associated with 
transmission of resistance.9-10 But also in Vietnam, Beijing strains have been correlated with 
MDR-TB, treatment failures and relapses after initially curative treatment in multiple stud-
ies.11-13 whereas the East-african/Indian (EaI) genotype strains are not associated with these 
problems. Still both Beijing and EaI genotypes are predominant in Vietnam, both lineages 
cause about 40% of the TB cases. For this reason, in a recent study we selected strains of 
these both lineages and compared their intrinsic in vitro susceptibility and determined 
their mutation frequency regarding the development of resistance to four different anti-TB 
drugs.14 The results revealed that for the Beijing genotype bacteria a much higher dosage 
of rifampicin was required to achieve a 100% killing and that two out of five Beijing strains 
exhibit a remarkably high frequency of mutations conferring rifampicin resistance.14 These 
data underline the importance of the use of different Mtb strains in preclinical experimental 
studies using animal models, as stated by de Groote et al. 15 They recommend the use of 
different Mtb strains in the confirmation of treatment efficacy results of novel drugs in the 
translational phase, in order to strengthen the likelihood of success of novel drug regimens 
that advance forward into clinical trials.15
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In the present paper we studied the impact of non-compliance and the role of Mtb strains as 
risk factors for the emergence of resistance to TB treatment. More specifically, we investigated 
in a well-established mouse TB model 16 whether the consequences of suboptimal treatment, 
simulating non-compliance in patients, would be more pronounced in the outcome of TB 
caused by a Beijing genotype strain in comparison to TB caused by an EaI genotype strain. 
The results obtained may help explanation the large differences in treatment success in 
Vietnam in patients infected by Beijing versus those infected by EaI genotype bacteria.
MATERIAlS AnD METhODS
Bacterial strain  
The two Mtb strains used were clinical isolates obtained from Vietnam one of the Beijing 
genotype and one of the EaI genotype, as described previously.14 The strains were provided 
by the national Tuberculosis Reference laboratory (Bilthoven, the netherlands), where they 
were labelled as Beijing Vn 2002-1585 (Beijing-1585) and EaI Vn 2002-1627 (EaI-1627) and 
were cultured as described previously.17
Infection model  
Specified pathogen-free female BalB/c mice were obtained from Charles River [les Oncins, 
France]. The experimental protocols adhered to the rules specified in the Dutch animal 
Experimentation act (1977) and the published Guidelines on the Protection of Experimental 
animals by the Council of the EC (1986). The Institutional animal Care and use Committee 
of the Erasmus MC Rotterdam approved the present protocols. Mice were infected through 
intratracheal inoculation followed by inhalation, as described previously.16 The inoculum of 
Mtb used for infection contained 1.3x105 cfu [range 1.2 - 1.3x105] of Beijing-1585 and 0.6x105 
cfu [range 0.5 – 0.7x105] of EaI-1627.
Drug dosing and anti-TB treatment  
The mice receiving compliance therapy were treated with dosage and schedules of anti-TB 
drugs derived from current clinical guidelines. Isoniazid (Hospital Pharmacy; Rotterdam, 
The netherlands), rifampicin (Rifadin®, aventis Pharma B.V, Hoevelaken, The netherlands) 
and pyrazinamide [150 mg/kg; P7136, Sigma Chemical Co, St. louis, MO] were administered 
in human pharmacokinetic-equivalent doses, as described previously.16 Treatment was 
started at 2 weeks after infection. The duration of full-compliance treatment was 26 weeks, 
consisting of a 9-week initial phase followed by 17-week continuation phase. During the 
initial phase, animals received a combination of isoniazid [25 mg/kg], rifampicin [10 mg/
kg] and pyrazinamide [150 mg/kg]. In the continuation phase, animals received isoniazid 
and rifampicin. agents were administered subcutaneously once daily, five days per week. In 
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the non-compliance treatment drugs were administered for treatment duration of only 13 
weeks (9 weeks isoniazid, rifampicin and pyrazinamide, followed by 4 weeks of isoniazid and 
rifampicin), simulating premature discontinuation in patients (defaulting). also underdosing 
was simulated by applying a reduced frequency of dosing; mice received treatment either 
five days per week, or three days per week, or once a week. In the non-compliance treatment, 
the daily doses were identical to the compliance treatment.
Therapeutic efficacy  
Parameters for therapeutic efficacy were (1) Mtb load in pulmonary and extra-pulmonary 
organs and emergence of drug resistance, (2) clinical signs of illness of mice, (3) relapse of 
infection during the 3 months post-treatment period, (4) histopathological characterization 
in the infected organs and (5) cytokine concentrations in blood. Treatment success was de-
fined as elimination of the Mtb load from infected organs and prevention of TB relapse after 
13 weeks post-treatment.
Therapeutic efficacy – Mtb load in pulmonary and extra-pulmonary organs and 
emergence of drug resistance  
at indicated time points the Mtb load in infected organs was assessed. Mice (n=4 per time 
point) were sacrificed by CO2 exposure. Subsequently, lung, spleen and liver were removed 
aseptically and homogenized each in 2 ml PBS, samples were centrifuged and washed with 
PBS to prevent carry-over of anti-TB drugs. From the undiluted tissue homogenate and 10-
fold serial dilutions samples of 200 μl were plated onto 7H10 agar. To detect the presence 
of drug-resistant Mtb mutants, subcultures on rifampicin-containing or isoniazid-containing 
plates were also performed. The concentrations of rifampicin and isoniazid in the subculture 
plates were 4-fold the “critical concentration”, i.e. 4 mg/l for rifampicin and 0.8 mg/l for iso-
niazid.18 Colonies of drug-resistant Mtb were characterized using the GenoType® MTBDRplus 
assay (Hain lifescience GmbH, nehren, Germany), to detect the most common mutations.19
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ThERAPEuTIC EffICACY – ClInICAl SIGnS Of IllnESS Of MICE  
The behaviour of mice was monitored daily, as prescribed by the animal ethical committee. 
Clinical parameters were the body weight assessed 3 times per week and evaluation of a 
discomfort score was performed 5 times per week. Mice that displayed severe signs of illness 
were euthanized by CO2 exposure.
Therapeutic efficacy – relapse of infection  
Mtb load in the lung, spleen and liver of mice (n=4) were assessed 13 weeks after termination 
of TB treatment. Relapse was defined as Mtb-positive organ cultures, while immediately after 
termination of treatment organ cultures were Mtb-negative. Emerging drug-resistant Mtb 
mutants were characterized.
Therapeutic efficacy – histopathological changes of infected organs  
lung, spleen and liver from sacrificed animals (n=3) at indicated time points (at weeks 1 and 
2 of the untreated infection, at weeks 3, 5, 7, 15 and 28 during treatment and in weeks 28 
and 41 post-treatment) were processed as described previously.16 In brief, standard 4 µm 
haematoxylin-eosin stained sections were prepared from ethanol fixed, paraffin wax embed-
ded lung, spleen and liver tissues. additionally, a Ziehl-neelsen staining was performed to 
detect acid-fast bacilli. Histopathological analysis was performed on tissues from untreated 
infected mice, from infected mice receiving compliance treatment and from mice receiving 
non-compliance treatment once per week for 13 weeks.
Therapeutic efficacy – cytokine levels in blood  
Blood samples were obtained by cardiac puncture from mice at week 2 (start treatment), 
from compliance treated mice at week 28 and 41 and from non-compliance treated mice 
(treatment once dose a week for 13 weeks) at week 15 and 28. Plasma samples were pre-
pared from EDTa-blood. Quantification of cytokines was performed using a bead-based flow 
cytometry technique (xMap; luminex Corporation, austin, TX, uSa). a milliplex map mouse 
cytokine, 31-plex was used (Millipore Corporation, Billerica, Ma, uSa) consisting of bead-
labelled cytokine receptor against the following biomarkers; Eotaxin, G-CSF, GM-CSF, IFn-γ, 
Il-10, Il-12 (p40), Il-12 (p70), Il-13, Il-15, Il-17, Il-1α, Il-1β, Il-2, Il-2, Il-4, Il-5, Il-6, Il-7, IP-10, 
kC-like, lIF, lIX, M-CSF, MCP-1, MIG, MIP-1α, MIP-1β, MIP-2, RanTES, TnF-α and VEGF. Tests 
were performed according the manufacturers’ protocol. Samples were tested in duplicate. 
Results in median fluorescence intensity (MFI) values were converted to pg/ml using MIl-
lIPlEX analyst software (Millipore) and subsequently averaged.
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figure 1. TB infection and efficacy of compliance treatment in mice infected with Beijing-1585 or EaI-1627. 
The mycobacterial load in lung, spleen and liver of the untreated mice, infected with Beijing-1585 (black 
bars) or EaI-1627 (gray bars). Mice receiving therapy started 2 weeks after infection and continued for 26 
weeks are indicated for the BE-1585 (diagonally stripped bars) and for the EaI-1627 (open bars). Results are 
expressed as median ± range (error bars) of the colony forming units (CFu) per organ, n = 4 per time point. 
numbers above bars are the numbers of culture-positive mice out of total numbers of mice at that time 
point. † = 4 out of 4 untreated mice died due to TB infection before this time point.
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figure 2. Histology. lung tissue from mice infected with Beijing-1585 or EaI-1627. (A-E) mice infected 
with Beijing-1585. (f-J) mice infected with EaI-1627. (A, f) week 2, start of treatment. (B, G) week 28, 
end of compliance treatment. (D, I) week 15, end of non-compliance (once per week) treatment. (C, h) 
week 41, 13 weeks post-compliance treatment. (E, J) week 28, 13 weeks post-non-compliance (once per 
week) treatment. (A) (original magnification 100x): Extensive intra-alveolar accumulation of histiocytes is 
observed, with a peri-bronchiolar lymphocytic component. [Ziehl-neelsen (Zn) staining revealed numerous 
acid-fast bacilli; not shown] (B) (25x): Peri-bronchiolar infiltrates, predominantly composed of lymphocytes 
are seen, admixed with a minor histiocytic component. (C) (50x): Scattered sparse lymphocytic foci are 
observed. (D) (50x): a moderately dense peri-bronchiolar predominantly lymphocytic infiltrate is present, 
no intra-alveolar or interstitial inflammation is seen. (E) (100x): a combination of an intra-alveolar histiocytic 
infiltrate is present with a moderately dense peri-bronchiolar lymphocytic component; the pattern is 
similar, however less extensive to the pattern observed in (A). [Sparse acid-fast bacilli are observed in Zn 
staining]. (f) (50x): Intra-alveolar histiocytes are seen with a centri-lobular distribution, combined with a 
minor lymphocytic component. [Zn staining reveal numerous acid-fast bacilli; not shown]. (G) (50x): a mild 
to moderately dense lymphocyte predominant infiltrate is present; a mild increase in alveolar macrophages 
is also seen. (h) (50x): Moderate to dense peri-bronchiolar infiltrates are present, mainly composed of 
lymphocytes. (I) (50x): a mild to moderately dense peri-bronchiolar lymphocytic infiltrate is present. (J) 
(25x): a dense lympho-histiocytic infiltrate is present. [Sparse acid-fast bacilli are observed in Zn staining].
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RESulTS
Course of untreated TB infection  
as shown in figure 1, progressive TB infection caused by Beijing-1585 or EaI-1627 in untreated 
mice resulted in similar Mtb load in the lung from week 1 after infection, which increased at 
week 2 up to 8.7x107 [0.6 - 1.4x108] cfu Beijng-1585 and 1.2x108 [0.8 - 2.2x108] cfu EaI-1627. 
In the third week of untreated infection caused by either strain all mice died or became 
moribund, as evidenced by their discomfort score and body weight loss (data not shown).
at week 2 histological analysis of lung tissue from untreated mice infected with either strain 
showed predominantly centrilobular inflammatory infiltrates composed of lymphocytes and 
histiocytes. The infiltrates were dense and located within the alveoli, sparing the interstitium 
(figure 2a and 2F). no differences were observed between the Beijing-1585 or EaI-1627-
infected mice at this stage.
Cytokine profile in plasma at week 2 revealed no significant different levels in any of the 
cytokines between mice infected with Beijing-1585 and mice infected with EaI-1627. In both 
infections the levels of Il-17, IP-10, MIG, TnF-α and IFn-γ were elevated compared to unin-
fected mice (data not shown). as untreated mice died in week 3, their cytokine levels could 
not be assessed at later time points. Therefore the dynamics of these cytokines in untreated 
infections could not be assessed further.
Therapeutic efficacy of compliance treatment  
as shown in figure 1, the therapeutic efficacy of compliance treatment as measured by de-
creases in Mtb load was similar for the Beijing-1585-infected mice and the EaI-1627-infected 
mice. The liver was the first organ that became culture-negative, followed by the spleen and 
finally the lung. after 26 weeks of treatment all organs of the Beijing-1585 and EaI-1627 
infected mice were culture-negative. Importantly, drug-resistant Mtb mutants were never 
selected from these mice receiving full compliance treatment.
Relapse assessment after the additional 13 weeks post treatment period, revealed that re-
lapses of infection did not occur. From 2-4 weeks of treatment onwards, the discomfort score 
and weight of the mice in both Beijing-1585 and EaI-1627-infected mice were at the level of 
the uninfected control mice (data not shown).
During full-compliance treatment, lung tissue from the mice infected with Beijing-1585 
initially showed an increase of compact fields of epithelioid histiocytes, which in later stages 
decreased in intensity (figure 2B). almost complete resolution at week 41 (26 weeks therapy 
followed by 13 weeks post-treatment) with only sparse peri-bronchiolar infiltrates was ob-
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figure 3. TB infection and efficacy at non-compliance treatment in mice infected with Beijing-1585 or EaI-
1627. The mycobacterial load in lung, spleen and liver of the untreated mice (black bars). Therapy started 
2 weeks after infection continued for 13 weeks. Mice received treatment five times per week (chequered 
bars), three times per week (open bars) or once per week (diagonally stripped bars). Results are expressed 
as medians ± range (error bars) of the colony forming units (CFu) per organ, n = 4 per time point. numbers 
above bars are the numbers of culture-positive mice out of total numbers of mice at that time point. † = 4 
out of 4 untreated mice died due to TB before this time point.
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served. Mice infected with EaI-1627 (figure 2H) showed essentially similar histopathological 
characteristics as the Beijing-1585-infected mice (figure 2C). During full-compliance treat-
ment the infiltrate diminished to a mild peri-bronchiolar exclusively lymphocytic pattern 
(figure 2G).
Cytokine profile in plasma during the course of Beijing-1585 infection or EaI-1627 infection 
showed elevated levels of Il-17, IP-10, MIG, TnF-α and IFn-γ at week 2, which decreased upon 
start therapy. after 13 weeks of therapy, the levels of these 5 cytokines were back to baseline. 
no differences in cytokine patterns or the height of the cytokine levels were observed when 
comparing the Beijing-1585 with EaI-1627 infected mice (data not shown). In the 13 weeks 
post-treatment period, the cytokines patterns did not change compared to week 28 (end of 
treatment, data not shown).
Therapeutic efficacy at non-compliance treatment  
The non-compliance treatment of mice consisted of only 13 weeks treatment at various 
dosing frequencies. Results are shown in figure 3. Treatment for five days per week resulted 
in relapse of infection in all Beijing-1585-infected and EaI-1627-infected mice at 13 weeks 
post-treatment. at the end of treatment (week 15) half of the mice were Mtb culture-negative 
in the lung (two out of four mice, for both Beijing-1585 and EaI-1627). However, at 13 weeks 
post-treatment all mice relapsed and the Mtb load in the lung was 1.4x103 [1.1x102 – 4.2x105] 
cfu Beijing-1585 and 2.2x103 [0 – 3.7x103] cfu EaI-1627 at week 28. Reduction of treatment fre-
quency to 3 days per week resulted in Mtb culture-positive lungs after 13 weeks of treatment 
in all Beijing-1585-infected and all EaI-1627-infected mice, whereas the spleen- and liver cul-
tures were negative. The Mtb load in the lung at the end of treatment (week 15) was 1.2x102 
[0.6 – 1.4x102] cfu Beijing-1585 and 28 [5 – 4.0x102] cfu EaI-1627. at 13 weeks post-treatment 
all mice showed regrowth of Mtb, resulting in a Mtb load in the lung of 3.9x104 [0.2 – 1.9x105] 
cfu Beijing-1585 and 9.0x103 [0.1– 1.1x104] cfu EaI-1627 at week 28. Finally, treatment of mice 
once per week revealed culture-positive lungs and spleens after 13 weeks in all Beijing-1585-
infected and all EaI-1627-infected mice. The Mtb load in the lung at the end of treatment 
(week 15) was 1.7x103 [0.2 – 4.0x103] cfu Beijing-1585 and 6.5x103 [5.4 – 8.3x103] cfu EaI-1627. 
after the 13 weeks post-treatment period all mice showed relapse of infection, resulting in a 
Mtb load in the lung of 6.2x104 [0.2 – 1.8x105] cfu Beijing-1585 and 2.7x105 [0.5 – 8.6x105] cfu 
EaI-1627 at week 28. Mice receiving the non-compliance treatment once per week showed a 
very high Mtb load throughout the entire course of infection, especially in the spleen. During 
non-compliance treatment significant differences in the efficacy of any treatment modality 
were not observed between the Beijing-1585-infected and EaI-1627-infected mice.
Remarkably, only in the Beijing-1585-infected mice, receiving non-compliance treatment 
once per week for 13 weeks isoniazid-resistant Mtb mutants were selected from lungs and 
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spleens of all mice, at week 20 and week 28. Isoniazid-resistant mutants at week 20 repre-
sented 2.2% [range, 0.3-6.4] of the total Mtb load in the lung, and 1.9% [0.7-2.6] of the Mtb 
load in the spleen. at week 28, isoniazid-resistant Mtb mutants represented, 1.7% [1.2-3.4] 
in the lung and 5.1% [3.4-18.5] in the spleen. In the livers selection of resistant Mtb mutants 
was not observed. The selection of resistance was not observed in Beijing-1585-infected 
mice receiving non-compliance treatment three times per week or five-times per week for 13 
weeks nor in any of the EaI-1627-infected mice receiving non-compliance treatment. Further 
analysis of the isoniazid-resistant Mtb mutants selected from the lung at week 20 and week 
28 showed that the minimal inhibitory concentration of isoniazid was 128 mg/l. Genotypic 
analysis revealed no mutations in the katG or inhA genes.
lung tissue of mice infected with Beijing-1585 and receiving non-compliance treatment 
once per week, initially showed a minor lymphocytic infiltrate (week 15) without epithelioid 
histiocytes (figure 2D), which became more dense at week 28 and was associated with a mild 
histiocytic component (figure 2E). In the EaI-1627-infected mice receiving the same non-
compliance treatment, the infiltrate initially decreased at week 15 (figure 2I) but became 
more widespread and denser at week 28 (figure 2J).
Cytokine levels in plasma from mice during the non-compliance treatment once per week 
showed that the levels were similar to that of the mice receiving full-compliance treatment. 
However, during the relapse of infection the cytokines IP-10, MIG and TnF-α reappeared 
above the base-line level (data not shown). The cytokine levels of Beijing-1585-infected and 
EaI-1627-infected animals were highly similar.
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DISCuSSIOn
From previous studies in Vietnam, it is known that TB patients infected with an Mtb Beijing 
genotype strain have a poorer outcome than patients infected with an EaI genotype strain. 
However, no satisfactory explanation for this observed phenomenon is yet available. Recently, 
we have shown in in vitro studies that Beijing genotype strains have an increased mutation 
frequency for rifampicin, compared to EaI genotype strains.14 also a relatively large window 
of rifampicin concentrations within which rifampicin resistant Mtb mutants were selected, 
was observed in the Beijing genotype. In the present study it is investigated whether the high 
mutation frequency for rifampicin observed in only Beijing genotype strains is associated 
with treatment failure in Beijing infection. we compared the treatment efficacy in a mouse 
model of TB caused by the Beijing-1585 strain or the EaI-1627 strain. The mutation frequency 
for rifampicin in Beijing-1585 and EaI-1627 strain were 3.7x10-3 and 3.5x10-6, respectively.14
The genotype of Mtb may influence different aspects of the infection. One hypothesis is that 
the Beijing genotype strain might exhibit mechanisms that modulate the immune response by 
the host; as such having an advantage over other Mtb strains.20-21 Elaborating on this hypothesis, 
when mass vaccination with the bacillus Calmette-Guérin (BCG) was introduced in TB endemic 
areas, the Beijing genotype could use this advantage over other strains and spread more easily.20 
In the present study in unvaccinated mice, a potential advantage of the Beijing genotype over 
the EaI genotype was not observed. It was shown that both Beijing-1585 and EaI-1627 are equal 
in pathogenic capacity in the progression of TB. In both infections the untreated animals died or 
became moribund within 3 weeks after infection. also a similar increase in Mtb load in infected or-
gans during the first two weeks was observed. In addition, the histopathological damage inflicted 
was equivalent and the changes in cytokine levels during the course of untreated infection were 
similar for both strains. Moreover, the cytokine profile of both strains were in line with previously 
described cytokine levels in our murine TB model caused by the Mtb strain H37Rv.22 The H37Rv 
strain is a clinical isolate and nowadays the strain most commonly used in studies in vitro as well as 
in animal models. nonetheless, the Beijing-1585 and EaI-1627 strains show an increased virulence 
in the course of TB compared to the H37Rv strain. In a previous study, we showed that H37Rv-
infected mice survived for at least 22 weeks.16 The increased virulence of the Beijing genotype is in 
accordance with previously described studies 8, 23-24 The high virulence of the EaI genotype in our 
mouse TB model is consistent with the fact that EaI strains, similar to the Beijing strains, do very 
frequently cause disease in Vietnam (40% of the TB patients).11, 13 In contrast to the Beijing strains, 
the EaI-strains in Vietnam are negatively correlated with resistance, and in the previous studies 14 
and the present study in mice we found clues to explain this.
a very prominent observation is that the treatment efficacy in conditions mimicking compliance 
is similar for Beijing-1585-infected and EaI-1627-infected mice; both Mtb load in infected organs 
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and cytokine levels in blood were equivalent. This finding suggests that if treatment is applied ad-
equately therapy should be successful without differences in causative infecting strain. another 
factor contributing to the emergence of MDR-TB might be variability in pharmacokinetics of anti-
TB drugs among patients. Gumbo et al. predicted in their hollow fiber studies for both bactericidal 
and sterilizing effect, that approximately 1% of TB patients with full-compliance therapy would 
still develop MDR-TB due to interindividual variability in pharmacokinetics of anti-TB drugs, caus-
ing low drug concentrations in a subset of patients.25 The variability in pharmacokinetics is less 
distinct in inbred mice as used in our TB-model. as a consequence differences in pharmacokinet-
ics of anti-TB drugs could not be investigated in the present study.
The consequences of non-compliance were mimicked in the present study to evaluate this 
relevant factor in the emergence of resistance in TB treatment. It was demonstrated that an in-
creasing level of non-compliance led to reduced Mtb killing in the lung, as well as the spleen and 
liver at the end of the 13 weeks treatment period. The compliance-dependent results obtained in 
Beijing-infected and EaI-infected mice are strikingly identical. The only difference found between 
with Beijing-1585 infection and the EaI-1627 infection was the selection of isoniazid-resistant 
Mtb mutants. These resistant mutants were selected only in the Beijing infection and only in mice 
relapsing from the most severe non-compliance condition (once per week treatment). In EaI-
infected mice at non-compliance condition resistant mutants Mtb were never found, although 
treatment response at non-compliance condition was similar in EaI infection and Beijing infec-
tion. Similar observational data are obtained in clinical studies in endemic areas 11-13. as a result 
the present model could serve in future studies to further unravel the mechanism(s) by which 
Beijing genotype strains facilitate the selection of resistant mutants. whereas, in a previous in vitro 
study we showed that the Beijing genotype strains exhibit an increased mutation frequency for 
rifampicin,14 in Beijing infection in vivo no selection of rifampicin-resistant mutants was observed. 
In contrast, isoniazid-resistant mutants were found. Given the fact that in patients isoniazid-
resistance is most often observed and is regarded as precursor for MDR-TB, our in vivo results 
are well in line with clinical reality. Possibly, an increase in isoniazid dosage could prevent the 
selection of isoniazid-resistant Beijing mutants, and thereby prevent the formation of MDR-TB. 
Further studies to explore this hypothesis are needed.
In conclusion, this study shows that the genotypic diversity of Mtb in terms of selection of 
resistant mutants occurred not only in vitro but also in our in vivo mouse TB model. Resistant 
Mtb mutants were selected only in Beijing-infected mice during severe non-compliance 
treatment. This might justify genotype-tailor-made therapy.
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ABSTRACT
The dosage of 10 mg/kg/day rifampicin, as currently used in the treatment of tuberculosis 
(TB), is not (yet) an optimal dose. Shortening of treatment duration might be achievable using
an increased rifampicin dose. The objectives of the current stuy are; determination of the 
optimal rifampicin dosage in mice, resulting in maximum therapeutic effect including 
prevention of relapse of infection, and without adverse effects. Moreover, we assessed 
the pharmacokinetics/pharmacodynamics (Pk/PD) parameters to determine the human 
pharmacokinetic-equivalent dose.
a murine TB infection was established using a Beijing genotype Mycobacterium tuberculosis 
strain for intratracheal bacterial instillation. we assessed dose-dependent activity of rifampi-
cin (R) in single-drug treatment during 3 weeks. also the maximum tolerated dosage (MTD) 
and Pk/PD were determined. Secondly, therapeutic efficacy of a range of rifampicin dosages 
added to a base regimen of isoniazid (H) and pyrazinamide (Z) was assessed.
The MTD of rifampicin in the murine TB was 160 mg/kg/day. Pk/PD measurement in the 
HR(10)Z and HR(160)Z therapy regimens showed for rifampicin a Cmax of 16.2 and 157.3 
mg/l, an au C0-24h of 132 and 1782 h*mg/l and a 24h-au C/MIC ratio of 22 and 297, respec-
tively. a clear dose-effect correlation was observed for rifampicin after 3-weeks single-drug 
treatment. administration of HR(80)Z allowed 9-week treatment duration to be effective 
without relapse of infection.
Our findings indicate that the currently used rifampicin dosage in the therapy of TB is too low. 
In our murine TB model a rifampicin dosage of 80 mg/kg/day enabled a significant reduction 
in therapy duration without adverse effects.
Chapter 11
152
InTRODuCTIOn
The current treatment of TB is long and complex, which may lead to non-adherence, inad-
equate response, and emergence of multidrug-resistant TB (MDR-TB) or extensively drug-
resistant TB (XDR-TB).1 as a consequence there is a need to develop a novel, shorter and 
simpler TB therapy. The use of current drugs can be optimised; alternative combinations can 
be explored possibly involving new drugs.2-3
The role of rifampicin, being the cornerstone drug in TB treatment is believed to be its ability 
to kill actively-growing as well as dormant Mycobacterium tuberculosis (Mtb). unfortunately, 
the 10 mg/kg rifampicin dose (often 450 or 600 mg daily) as determined in the 1960s based 
on pharmacokinetics, toxicity and financial considerations 4, appears to be at the lower end 
of the dose-response curve. Early experiments in mice 5 and clinical trials performed before 
1985 6 already suggested that a higher dose of rifampicin may enhance sterilizing activity and 
shorten therapy duration. Currently observed failure of TB treatment has caused a resurgence 
of interest to increase the dosage of rifampicin in TB treatment, as reflected in an experimen-
tal study in mice, 7 a clinical study on early bactericidal activity (EBa) of high dose (20 mg/
kg) rifampicin administered as single-drug therapy,8 a small trial on pharmacokinetics and 
tolerability of a higher dose of rifampicin 9 and ongoing clinical trials on high dose rifampicin 
in pulmonary TB and in TB meningitis.10 Recently, Rosenthal et al. showed in experimental TB 
in BalB/c mice using the Mtb strain H37Rv, that each rifamycin demonstrates a significant 
increase in sterilizing activity with increasing dose.11 Of note, an increase in rifampicin dose 
may not only result in enhanced killing of mycobacteria and shorter therapy duration, but 
may also result in prevention of drug-resistance.12-13
In view of the apparent potential of a higher dose of rifampicin, and the wide availability and 
affordability of this drug in resource-poor settings, stronger evidence on the utility of higher 
dosage of this potent drug is needed. It is important to know what the MTD for rifampicin 
is and what dose increase is needed to achieve a significant reduction in therapy duration. 
Therefore, the current study assessed the MTD for rifampicin in mice and the effect of incre-
mental increases in rifampicin dosages on treatment response in terms of treatment duration 
needed and prevention of resistance.
we focused on maximizing the rifampicin dosage aiming for reduction of therapy duration 
from 6 months to even 2 months in mice. as the Beijing genotype of Mtb is a major driving 
force in the emergence of MDR-TB in high prevalence areas 14 in which rifampicin resistance 
develops more readily 15, a high-mutator strain of this lineage was tested in our murine TB 
model.16-17
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MATERIAl AnD METhODS
Bacterial strain  
The previously described Mtb genotype strain Beijing Vn 2002-1585 (BE-1585) was used.18 
Susceptibility assays performed according to ClSI guidelines 19, showed MICs for rifampicin 
of 0.25 mg/l and for isoniazid of 0.125 mg/l, and susceptibility for pyrazinamide
Infection model  
Specified pathogen-free female BalB/c mice (13-15 weeks old) were obtained from Charles 
River [les Oncins, France] and infected as previously described 16. In short, mice were exposed 
to intratracheal instillation of a suspension (40 μl) containing 0.7x105 [0.5 – 0.8 x105] cfu of 
BE-1585, followed by proper inhalation.
Anti-tuberculosis treatment  
Dosage and schedules of TB drugs, derived from current clinical guidelines were admin-
istered as described earlier. all treatment schedules started at 2 weeks after infection.16 In 
Study 1 mice received single-drug treatment with rifampicin at various doses (10, 20, 40, 
80, 160 or 320 mg/kg/day po.) for 3 weeks. In study 2 mice received a 9-week or 13-week 
combination therapy: during 9 weeks various doses rifampicin (10, 40, 80 or 160 mg/kg/day 
po.) in combination with isoniazid (25 mg/kg/day sc.) and pyrazinamide (150 mg/kg/day sc.), 
followed by 4 weeks (in case of 13 weeks treatment) various doses of rifampicin (10, 40, 80 or 
160 mg/kg/day po.) in combination with isoniazid (25 mg/kg/day sc.).
Maximum tolerated dose (MTD)  
MTD was assessed in Study 1 and was defined as the highest dose that did not cause 1) local 
damage at the site of injection, 2) liver and/or kidney dysfunction, identified by increase of 
more than 5-times the upper limit of normal (in clinical studies regular considered a measure 
of toxicity) for aspartate aminotransferase (aST), alanine aminotransferase (alT), creatinine 
(CREaT) and blood urea nitrogen (Bun), using a Cobas® modular analyser (Roche Diagnostics, 
Basel, Switzerland), 3) animal death and 4) abnormal animal behavior. Clinical parameters 
were bodyweight (assessed 3x/week) and daily evaluation of a discomfort score.
Pharmacokinetic sampling  
Pharmacokinetic parameters were assessed for rifampicin 10 mg/kg or 160 mg/kg, as single-
drug treatment (Study 1) or in combination with isoniazid and pyrazinamide (Study 2) at the 
end of week 3, when steady-state for anti-TB drugs was expected. Blood was sampled at 5, 15, 
30, 45 min and at 1½, 3, 6 and 12h post dose. at each sampling point, 3 mice were sacrificed, 
blood was obtained by cardiac puncture, collected in heparin tubes (Sarstedt, nümbrecht, 
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Germany), and centrifuged at 11.000xg for 5 min to obtain plasma. Plasma samples were 
immediately frozen at -80oC.
Measurement of TB drugs in plasma  
Total (protein-bound plus protein-unbound) concentrations of rifampicin (Study 1) and of 
rifampicin, isoniazid and pyrazinamide (Study 2) were measured with validated HPlC methods 
for human plasma that were cross validated to murine plasma. The analytical method for rifam-
picin was described before.9 Total concentrations of isoniazid and pyrazinamide were measured 
with liquid-liquid extraction followed by ultra Performance liquid Chromatography (uPlC) 
with ultraviolet (uV) detection. accuracy was between 99.7-119% for isoniazid and between 
96.4-104.9% for pyrazinamide, depending on the concentration level. Intra-assay coefficients of 
variation were less than 4.5 % for isoniazid and less than 4.3% for pyrazinamide (dependent on 
the concentration) over the range of 0.15-15.1 mg/l isoniazid and 0.6-60.6 mg/l pyrazinamide. 
To measure protein-unbound rifampicin, a validated HPlC method was used based on ultrafil-
tration of plasma with Centrifee YM-30 tubes (Millipore, amsterdam, the netherlands).
Pharmacokinetic data analysis 
Based on measurements in 3 mice, a geometric mean plasma concentration was calculated 
for each drug at each sampling point. next pharmacokinetic curves for each drug were 
constructed by combining geometric mean plasma concentrations at the various sampling 
points. Pharmacokinetic parameters including the area under the concentration-time curve 
(auC0-24h ), peak plasma concentration (Cmax), time to peak plasma concentration (Tmax) and 
elimination half-life (T1/2) were assessed with non-compartmental techniques using winnon-
lin, version 5.3 (Pharsight, Mountain View, California, uSa). The concentration at 24 h post 
dose (C24h) was estimated, based on the last measurable concentration (Clast) and elimination 
rate constant β using the formula C24h = Clast * e 
–β * (24-Tlast).
Pharmacokinetic parameters for total (protein-bound plus protein-unbound) rifampicin and 
pyrazinamide and for the protein-unbound (free) fraction of rifampicin in mice were compared 
to data in Indonesian TB patients, assessed with the same analytical methods.9, 20 whereas, 
pharmacokinetic parameters for isoniazid in mice were compared to data from measurements 
in Tanzanian TB patients, which were assessed with the same analytical methods.21
Therapeutic efficacy  
Parameters for therapeutic efficacy were; 1) animal survival; 2) elimination of Mtb in pul-
monary and extra-pulmonary organs; 3) the absence of emergence of drug resistance; 4) 
re-growth of Mtb during 2 weeks post-treatment (Study 1), or relapse of infection during 3 
months post-therapy (Study 2). Relapse was defined as Mtb-positive organ cultures, if organ 
cultures immediately after termination of therapy were Mtb-negative.
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The Mtb load and the presence of rifampicin-resistant and isoniazid-resistant mutants were 
determined as described previously.16 For genotypic characterization of resistant Mtb, the 
GenoType® MTBDRplus assay (Hain lifescience, nehren, Germany) was used.
Therapeutic efficacy - Statistical analysis  
CFu counts of Study 1 were log10 transformed before analysis. Mean CFu counts between 
groups of mice were compared using one-way anOVa (Stata 12, Stata Corporation, TX, uSa).
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RESulTS
Study 1
Maximum tolerated dose (MTD)  
administration of rifampicin at doses of 10, 20, 40, 80 or 160 mg/kg/day po. during 3 weeks 
did not result in changes in behavior of mice or in liver and kidney function tests. a dose of 
320 mg/kg/day showed an increase of aST and alT although below five-times the upper 
limit of normal, whereas CREaT and Bun values were not changed (data not shown). Mice 
receiving a dose of 320 mg/kg/day became hyperactive and unmanageable. Thus, the MTD 
of rifampicin was defined as 160 mg/kg/day.
Pharmacokinetic analysis 
In uninfected mice the 16-fold increase in rifampicin dose from 10 to 160 mg/kg resulted in 
an almost proportional (15-fold) increase in exposure (auC0-24h) from 125.1 to 1854.8 h*mg/l. 
Cmax increased almost 9-fold. T½ of rifampicin at a dose of 160 mg/kg could only be estimated 
very roughly, as decrease in plasma concentrations was small compared to the sampling 
period, and it appeared to be much longer (19.2 h) than the T½ at a dose of 10 mg/kg (4.4 h).
Efficacy of rifampicin administered as single-drug treatment  
a clear dosage-effect correlation was observed for rifampicin after 3 weeks single-drug 
treatment (p = <0.0001, one-way anOVa) (figure 1). administration of 10 mg/kg/day rifam-
picin resulted in a Mtb load in the lung of 7.7x105 [range 5-1.x105] cfu, in the spleen 9.0x102 
[7-25x102] cfu and in the liver 3.1x102 [0.4-20x102] cfu, whereas 160 mg/kg/day rifampicin 
resulted in a Mtb load in the lung of 1.8x102 [0.8 – 6.8x102] cfu and undetectable Mtb loads in 
the spleen and liver. all mice survived.
with respect to regrowth of Mtb, at 2 weeks after termination of treatment with 10 mg/kg 
rifampicin the Mtb load increased up to 8.5x105 [6–20x105] cfu in the lung, 8.0x104 [3–19x104] 
cfu in the spleen and 4.6x103 [0.5–16x103] cfu in the liver. at 2 weeks after termination of 160 
mg/kg rifampicin the Mtb load in the lung had increased to 3.7x103 [2.2–4.7x103] cfu and 
in the spleen to 1.1x102 [0.1–12x102] cfu, but the liver remained culture-negative (figure 1). 
Rifampicin-resistant Mtb mutants were never found.
Study 2
MTD. administration of rifampicin in combination therapy schedules HR(10)Z, HR(40)Z, 
HR(80)Z, and HR(160)Z during 13 or 9 weeks did not result in changes in behaviour of mice or 
liver- or kidney function tests.
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figure 1. Effect of single-drug treatment for 3 weeks with rifampicin at various doses (10, 20, 40, 80, 160 
or 320 mg/kg/day po). The Mtb load in lung, spleen and liver at the start of the treatment (gray bar) and 
at indicated time points (end of 3 weeks treatment and 2 weeks post-treatment). Mice received rifampicin 
either 10 mg/kg/day (black bars), 20 mg/kg/day (chequered bars), 40 mg/kg/day (left high diagonally 
striped bars), 80 mg/kg/day (right high diagonally striped bars), 160 mg/kg/day (horizontally striped bars) 
or 320 mg/kg/day (open bars) for a total of 3 weeks, 5 days a week. Results are expressed as median ± range 
(error bars) of the colony forming units (CFu) per organ, n = 4 per time point. numbers above bars are the 
numbers of culture-positive mice out of total numbers of mice at that time point.
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Pharmacokinetic analysis  
Pharmacokinetic data for rifampicin at a dose of 10 mg/kg and 160 mg/kg in Study 1 and Study 
2 were similar (table 1). This indicates that co-administration of isoniazid and pyrazinamide 
does not affect pharmacokinetics of rifampicin. after administration of 10 mg/kg rifampicin 
combined with isoniazid and pyrazinamide, samples (combined around Tmax) yielded a total 
(protein bound plus protein-unbound) concentration of 15.1 mg/l and a protein-unbound 
concentration of 0.48 mg/l, yielding a protein-unbound (free) fraction of 3.2% (correspond-
ing to 96.8 % protein binding).
after administration of 160 mg/kg rifampicin combined with isoniazid and pyrazinamide, 
the protein-unbound fraction was 2.6% at a total rifampicin concentration of 65 mg/l and 
4.0% at a total concentration of 141 mg/l. This shows that protein-unbound fractions were 
not strongly dependent on the total concentration of rifampicin, i.e. no saturation of protein 
binding occurred at higher doses of rifampicin. Exposure (auC0-24h) and Cmax of isoniazid were 
23-24% lower when combined with 160 mg/kg of rifampicin compared to 10 mg/kg rifam-
picin. This may suggest that a strongly increased dose of rifampicin affects the exposure to 
the other TB drugs to a limited extent. Similarly, auC0-24h and Cmax to pyrazinamide were 24% 
and 10% lower when combined with the high dose of 160 mg/kg rifampicin compared to 10 
mg/kg rifampicin.
Dose
(mg/kg)
AuC0-24h (h*mg/l)
Cmax
(mg/l)
Tmax
(h)
T1/2
(h)
Study 1: rifampicin single-drug treatment
rifampicin 10 125.1 18.5 0.5 4.4
rifampicin 160 1854.8 142.1 0.75 19.2
Study 2: rifampicin (10 mg/kg) combination therapy with isoniazid and pyrazinamide
rifampicin 10 131.9 16.2 0.5 5.4
isoniazid 25 31.9 26.7 0.25 0.90
pyrazinamide 150 256.4 173.8 0.25 0.84
Study 2: rifampicin (160 mg/kg) combination therapy with isoniazid and pyrazinamide
rifampicin 160 1782.3 157.3 0.25 11.1
isoniazid 25 24.2 20.7 0.25 0.61
pyrazinamide 150 194.7 156.2 0.25 0.57
Table 1. Steady-state pharmacokinetics of rifampicin, isoniazid and pyrazinamide. Study 1 (single-drug 
treatment with rifampicin), Study 2 (combination therapy of rifampicin, isoniazid and pyrazinamide). Results 
obtained are based on sampling at 5, 15, 30, 45 min and at 1.5, 3, 6 and 12h post dose. a geometric mean 
plasma concentration based on measurements in 3 mice was calculated for each drug at each sampling 
point. Data refer to total (protein-bound plus protein-unbound) concentrations. For protein-unbound 
(free) plasma concentrations: see text. abbreviations: auC0-24h: area under the concentration-time curve 
from 0-24h post-dose, Cmax: maximum concentration, Tmax: time to maximum concentration, T1/2: elimination 
half-life.
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Pharmacokinetics in mice versus humans  
For rifampicin administered to mice in a dose of 10 mg/kg (table 1) the auC0-24h is much 
(almost 3-fold) higher than that recorded in Indonesian TB patients 9, using the same 
analytical techniques (auC0-24h 132 h* mg/l in mice vs. 48.5 h*mg/l in humans). However, 
protein-unbound fraction for rifampicin in mice (circa 3.2%, see above) is much (also circa 
3-fold) lower than protein-unbound fraction (10.3%) assessed in Indonesian TB patients.20 
implicating that, protein-unbound, active concentrations of rifampicin in mice and men are 
similar at the human pharmacokinetic-equivalent dose of 10 mg/kg.
auC0-24h values of pyrazinamide in mice (256.4 h* mg/l) were lower than those in Indonesian 
patients (472.8 h*mg/l).21 For isoniazid administered to mice in a human pharmacokinetic-
equivalent dose (table 1) the auC0-24h is higher than that in humans (auC0-24h 31.9 h* mg/l in 
mice vs. 11.0 h*mg/l in humans) using the same assays.21 no protein-unbound concentra-
tions of isoniazid or pyrazinamide were measured in the current study.
Therapeutic efficacy of rifampicin administered in combination therapy with 
isoniazid and pyrazinamide  
administration of HR(10)Z, HR(40)Z, HR(80)Z and HR(160)Z during 13 weeks or 9 weeks re-
sulted in undetectable Mtb loads in all organs at the end of therapy (figure 2 and 3), with the 
exception of 9 weeks HR(10)Z therapy, which showed in 3 out of 4 mice positive lung cultures 
with a Mtb load of 46 [0.4–2.3x102] cfu (figure 3).
at 13 weeks after termination of 13 weeks therapy all mice receiving rifampicin 10 mg/kg/day 
relapsed, with a Mtb load of 8.5x103 [0.2–12x103] cfu in the lung, 0.3x104 [0.2–2.9x104] cfu in the 
spleen and 0.0 [0.0–3.6x102] cfu in the liver (figure 2). Treatment with 40 mg/kg/day rifampicin 
resulted in relapse of infection in 1 out of 4 mice, showing a Mtb load of 0.0 [0.0–2.9x105] cfu in 
the lung, 0.0 [0.0–2.1x105] cfu in the spleen and 0.0 [0.0–1.7x104] cfu in the liver.
at 13 weeks after termination of 9 weeks therapy, all mice receiving rifampicin 10 mg/kg/day 
relapsed, with an Mtb load of 5.3x104 [2.0–9.4x104] cfu in the lung, 3.5x104 [0.5–8.6x104] cfu in 
the spleen and 0.6x103 [0.0–2.2x103] cfu in the liver (figure 3). Treatment with 40 mg/kg/day 
rifampicin resulted in relapse of infection in 2 out of 4 mice, showing a Mtb load of 0.1x104 
[0.0–1.1x104] cfu in the lung, 0.0 [0.0–7.4x101] cfu in the spleen and were culture-negative in 
the liver. Mice receiving isoniazid, pyrazinamide and rifampicin in a dose of 80 mg/kg/day or 
higher for 9 or 13 weeks did not show relapse of TB in any of the cultured organs, meaning 
that rifampicin dosed at 80 mg/kg (in combination with the other drugs) was the lowest dose 
that enabled treatment shortening to 9 weeks. Rifampicin-resistant or isoniazid-resistant Mtb 
mutants were never cultured.
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figure 2. Therapeutic efficacy of combination therapy for 13 weeks with rifampicin at various doses (10, 40, 
80 or 160 mg/kg/day po.) in combination with isoniazid (25 mg/kg/day sc. and pyrazinamide (150 mg/kg/
day sc.). The Mtb load in lung, spleen and liver at the start of the therapy (gray bar) and at indicated time 
points (end of 13 weeks therapy and 13 weeks post-therapy). Mice received rifampicin either10 mg/kg/day 
(black bars), 40 mg/kg/day (left high diagonally striped bars), 80 mg/kg/day (right high diagonally striped 
bars) or 160 mg/kg/day (open bars) for a total of 13 weeks, 5 days a week. Results are expressed as median 
± range (error bars) of the colony forming units (CFu) per organ, n = 4 per time point. numbers above bars 
are the numbers of culture-positive mice out of total numbers of mice at that time point.
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figure 3. Therapeutic efficacy of combination therapy for 9 weeks with rifampicin at various doses (10, 40, 
80 or 160 mg/kg/day po.) in combination with isoniazid (25 mg/kg/day sc. and pyrazinamide (150 mg/kg/
day sc.). The Mtb load in lung spleen and liver at the start of the therapy (gray bar) and at indicated time 
points (end of 9 weeks therapy and 13 weeks post-therapy). Mice received either10 mg/kg/day rifampicin 
(black bars), 40 mg/kg/day (left high diagonally striped bars), 80 mg/kg/day (right high diagonally striped 
bars) or 160 mg/kg/day (open bars) for a total of 9 weeks, 5 days a week. Results are expressed as median 
± range (error bars) of the colony forming units (CFu) per organ, n = 4 per time point. numbers above bars 
are the numbers of culture-positive mice out of total numbers of mice at that time point.
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DISCuSSIOn
Sufficient improvement of drug activity in the sterilizing phase of TB therapy is important 
to achieve reduction of treatment duration. Based on previous studies in mice, improving 
the sterilizing activity of rifampicin might be achieved by increasing its dosage.5, 7, 11 Similar 
findings have been shown for rifapentine administered more frequently or in a higher dose 
in mice 11, 22 and for rifabutin.11 However, escalation of the daily dose of rifapentine above 15 
mg/kg in humans did not result in an increase of drug exposure.23 Rifampicin is generally 
available, highly affordable and there is widespread experience with its clinical use; a new 
regimen with higher dose could be implemented quickly.
In a previous in vitro study we have demonstrated that Beijing genotype strains showed 
high rates of mutation towards rifampicin within a wide range of rifampicin concentrations, 
compared to the East-african/Indian genotype strains. Strains of both genotypes are highly 
prevalent in Vietnam, but only the Beijing genotype is associated with MDR-TB, treatment 
failures and relapses after curative treatment.24. Based on our previous studies showing dif-
ferences in emergence of drug-resistant mutants between different Mtb genotypes, in the 
present study we used a selected strain of the endemic Beijing genotype family.17-18
First, a strong dose-dependent activity of rifampicin in single-drug treatment was found 
(Study 1), which is in line with the concentration-dependent activity of rifampicin in vitro 
as we described previously.18, 25 In addition, in combination with isoniazid and pyrazinamide 
(Study 2) the dose-dependency of rifampicin was again clearly visible.
Second, the MTD of rifampicin in the murine model was found to be 160 mg/kg based on 
aberrant behaviour of mice. we did not find gastro-intestinal problems or hepatotoxicity as 
dose limiting adverse events. This MTD can be interpreted as relatively high, as it is 16-fold 
higher than the usual dose, which is promising regarding increasing the dose in humans. In 
the dosage range we investigated, increasing the rifampicin dose resulted in a roughly pro-
portional increase in auC0-24h and Cmax in mice. This was not anticipated, as rifampicin shows 
non-linear pharmacokinetics in humans.9, 26 Preliminary unpublished results of an MTD study 
in TB patients that currently takes place in Cape Town (www.clinicaltrials.gov nCT01392911) 
reveal that rifampicin doses up to 35 mg/kg are tolerated and that the pharmacokinetic pa-
rameters show a similar proportional increase in the higher dose groups (M. Boeree, personal 
communication).
Third, this study determined the efficacy of a range of rifampicin dosages up to the MTD. 
a rifampicin dose of 80 mg/kg/day in combination with isoniazid and pyrazinamide for 
only 9 weeks was sufficient to achieve successful therapy without relapse after 3 months 
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post-treatment. These results are generally in line with the observations of Rosenthal et al. in 
murine TB caused by the H37Rv strain.11 However, results of our study and that of Rosenthal et 
al. differed in the dosage of rifampicin that resulted in relapse-free therapy. Rifampicin at 40 
mg/kg/day rifampicin was sufficient to achieve a relapse-free therapy in the study of Rosen-
thal et al.11, whereas we still observed relapse of TB in 1 out of 4 mice. This might be related to 
the Beijing-1585 strain, being the causative agent in our murine TB. using this strain, which 
is known to be associated with treatment failures, allows a more realistic representation of 
the clinical situation. Importance of using different Mtb strains to assess the in vivo efficacy of 
new drug regimens has been recently emphasized by de Groote et al.27.
Studies on high dose rifampicin in murine TB using different study design and in one EBa 
study in humans 8 suggest that an increased dose of rifampicin is associated with a fast 
decline of Mtb load in the lung. Thereby, one can argue that a patient treated with increased 
dosage of rifampicin would become sputum smear-negative in a shorter time resulting in 
a reduced time or risk of TB transmission. Moreover, the rapid decrease in Mtb load in the 
infected organs in the early stage of therapy will reduce the risk of selection of drug-resistant 
mutants; as we showed in a previous study, the risk of selection of resistance will increase 
with an increasing Mtb load and prolonged time of TB drug exposure to the Mtb popula-
tion.25 The different murine studies on the efficacy of increasing rifampicin dosages should 
be considered as proof-of-concept, paving the road for phase-II clinical trials. In addition, 
there are several studies ongoing: the aforementioned MTD study in Cape Town and a phase 
II study investigating 10, 15 and 20 mg/kg in 150 patients in Tanzania (www.clinicaltrials.gov 
nCT 00760149).
The current study in mice is also informative on the human pharmacokinetic-equivalent dose 
of rifampicin in mice, which is relevant for future studies in the murine TB model. The human 
pharmacokinetic-equivalent dose of rifampicin in mice has been designated as 10 mg/kg, i.e. 
similar to the dose in humans, based on data presented by Grosset et al.28. Our auC0-24h and 
Cmax values in mice following administration of 10 mg/kg rifampicin until steady-state were 
remarkably similar to those recorded by Rosenthal et al.(auC0-24h 131.9 h*mg/l and Cmax 16.2 
mg/l in the current study versus auC0-24h 142.1 h*mg/l and Cmax 13.52 mg/l in their study).
11 
we noted that the auC0-24h at the presumed human pharmacokinetic-equivalent rifampicin 
dose was almost 3-fold higher than that recorded in Indonesian TB patients on 10 mg/kg ri-
fampicin, while using the same bio-analytical techniques for assessment of rifampicin plasma 
concentrations.9 Rosenthal et al. have noticed the same discrepancy and state that rifampicin 
exposures observed in mice overestimate those in humans. In the current study we have 
gone one step further and showed that this is not the case, by measuring protein-unbound 
rifampicin plasma concentrations. The total exposure to rifampicin at a dose of 10 mg/kg 
is higher in mice, but the protein-unbound fraction of rifampicin in mice is lower. Thus 10 
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mg/kg is the human pharmacokinetic-equivalent dose for rifampicin indeed. Importantly, 
increasing the dose of rifampicin up to 160 mg/kg did not result in a relevant change in 
protein-unbound fraction, i.e. no saturation of protein binding did occur. This means that 
interpretation of total auC0-24h and Cmax values in mice is not misled by changes in protein 
binding.
In conclusion, the present study shows that efficacy of rifampicin in the human pharmacoki-
netic-equivalent dose of 10 mg/kg/day can significantly be improved, by increasing the dose 
to 80 mg/kg/day. This increased rifampicin dose showed no adverse effects in our murine 
model and enabled therapy duration of only 9 weeks to be effective. Our use of a clinically 
relevant strain, like the Beijing strain will improve the translational power of animal studies 
to TB patients and may further support the clinical studies on tolerability and efficacy of 
increased rifampicin doses in TB patients, currently ongoing.
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To reduce the high mortality and/or morbidity of TB diagnostics and treatment of this in-
fectious disease need significant of substantial improvement. However, to accomplish this 
enormous task and unravel the puzzle, which might result in eradication of TB, will take time 
and great effort from many different organisations and scientists around the world. The stud-
ies described in this thesis were aimed to add one piece to that puzzle.
The (translational) pathway of TB-drug development needs to be as short a possible without 
giving in on the predictive value for the clinical trials. This is not only needed to reduce the 
costs of TB-drug development, but also to ensure that TB remains a treatable disease. The 
increasing emergence and spreading of drug-resistant TB is currently threatening the status 
of treatable disease. Moreover, there is an increasing number of cases not only of multidrug 
resistant TB (MDR-TB; resistance to rifampicin and isoniazid) but also of extensively-drug 
resistant TB (XDR-TB; besides MDR also resistance to one of the injectable TB-drugs and one 
of the fluoroquinolones). The therapeutic outcome of patients with XDR-TB is very poor, even 
with optimal care and resources. Recently, the anxiety of the emergence of totally-drug resis-
tant TB (TDR-TB) came true in asia and the Middle-East. Here we have an infectious disease 
where medical doctors can only watch the course of infection in their patients. In a way, this 
is like historic time where there were no antibiotics. It is more than clear that novel treatment 
approaches are urgently needed.
Translational studies in animal TB models are needed as they provide the basis for the design 
of therapeutic clinical trials in TB patients. The animal model should be well described in 
histopathological and immunological characteristics, and validated in terms of therapy 
response under treatment compliance and treatment non-compliance conditions. Such 
an animal model using the H37Rv Mtb strain as infectious organism has been described in 
chapter 2
Dependent on the research question and the objectives of a study, the choice of the right 
translational animal model is of high importance. In chapter 3 it is shown in mice using the 
H37Rv Mtb strain that the route of Mtb inoculation applied influences the course of the TB 
infection and the therapeutic response. It is concluded that the comparative therapeutic 
potential of novel anti-TB drugs in translational animal studies can only be established within 
the same animal model.
The diversity of different animal models is also demonstrated in the studies described in 
chapter 6 where we compared the course of primary TB versus relapse of TB in mice, both 
caused by the H37Rv Mtb strain. we showed that the histopathological and immunological 
characteristics of relapse of TB resulting from treatment non-compliance during primary TB, 
were essentially different compared to those in primary TB. The most striking difference is 
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the relatively low Mtb load in the infected organs in relapse TB compared to the primary TB. 
It was observed that in relapse TB memory Th-1 cells were locally and systemically expanded 
and congregated in the lung, permitting an efficient control of Mtb growth. However, this im-
mune response is insufficient to clear the Mtb, thereby leaving a potential infectious reservoir 
within the mice. This is probably also occurring in therapy non-compliant patients. Interest-
ingly, treatment response in relapse of TB is as good as the treatment response in primary TB; 
so no supportive evidence could be given for the recommended longer treatment duration 
in case of relapse of TB.
a small side-step in this thesis is represented in the chapters 4 and 5, within which we 
discussed the difficulties of accurately diagnosing TB. The case report of the congenital TB 
(chapter 4) illustrates that TB can present in a non-specific way and thus can be very difficult 
to diagnose. Missing the diagnosis TB or getting it too late can have fatal implications for 
the patients. Therefore, numerous studies are conducted to explore the possibilities for new 
diagnostic tools. One of these investigated assays is the Interferon Gamma Release assay 
(IGRa). The IGRa took over the field of TB screening in just a couple of years, and is in short 
time implemented in the clinic. Gradually it is being used not only to screen for (latent) TB, 
but also for diagnosing active TB. However, the value of the IGRa for diagnosing active TB 
is still a matter of debate. Therefore we investigated in our murine TB model the value of 
the IGRa during different phases of the TB infection (chapter 5). In murine TB no support 
could be found for the value of IGRa to accurately diagnose active TB or to monitor infection 
progression. nonetheless, IGRa showed to be a useful biomarker to monitor therapy success 
in murine TB.
Besides the studies on animal model design and limitations in diagnosis, the primary research 
question for this thesis was: ‘How can treatment of TB be improved and emergence of drug 
resistance in TB be reduced?’.
The currently-used diagnostic drug susceptibility tests (MGIT, MIC) guiding TB therapy, 
investigate metabolically active Mtb isolates under static conditions and provides an end-
point measurement of only the bacteriostatic activity of the anti-TB drug. In chapter 7 we 
performed Time-kill kinetics assays to investigate the concentration-dependent bactericidal 
activity of the anti-TB drugs over time and the emergence of drug-resistant mutants during 
drug exposure. we included the differences in metabolic state of the mycobacteria by com-
paring actively-growing versus slowly-growing or even dormant Mtb cells. It was observed 
that the anti-TB drugs differed significantly in the Time-kill kinetics analysis and the impact of 
the metabolic state of the mycobacteria to their drug susceptibility. Isoniazid showed rapid 
and high killing capacity towards actively-growing mycobacteria, but due to the emergence 
of resistance isoniazid could not eliminate Mtb. Rifampicin revealed time-dependent kill-
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ing capacity, and did achieve elimination. Ethambutol was not bactericidal at all. amikacin 
showed immediate and rapid killing activity which was not time-dependent.
Better knowing these anti-TB drug characteristics we could further design optimization of 
the dosage of anti-TB drugs in the treatment of infection. It is clear that achievement of 
maximum drug concentrations at the site of infection is of utmost importance in order to 
maximize reduction in Mtb load and in this way to minimize the emergence and selection 
of drug resistance. Depending on the growth phase and thereby the metabolic activity of 
the Mtb population, we observed selection of drug-resistant mutants for different anti-TB 
drugs. For rifampicin we further analysed the drug-resistant mutants by performing a micro-
array analysis. Rifampicin-resistant mutants were compared to their wild type counterpart. 
The microarray results described in chapter 8 have shown that several interesting gene 
clusters associated with molecular efflux, cell membrane transport and virulence are altered 
in the rifampicin-resistant H37Rv mutant compared to the rifampicin-susceptible H37Rv wild 
type strain upon exposure to rifampicin. we identified Rv0559c and Rv0560c being strongly 
rifampicin-inducible, with a high level induction based on microarray analysis and multiple 
qPCR experiments. Evidence was obtained that the induction of both genes is dependent on 
concentration of rifampicin and exposure time. we concluded that the Mtb mutant although 
being rifampicin-resistant, still was influenced by rifampicin exposure at different genetic 
levels. This may open new ways for future treatment improvement.
In chapter 9 and 10 we focus on the mycobacterial side that drives the development of 
drug-resistance in TB. Certain genotype Mtb strains appear to be particularly associated with 
treatment failures. Therefore we investigated different endemic Mtb strains in our in vitro 
assays and in vivo infection, aiming for additional insight and improvement of the predictive 
value of these in vitro and vivo models. In this way the preclinical (translational) value of 
drug-development research might be improved. although the approach of using clinically-
relevant genotype strains in viral disease research is not new, surprisingly in the TB research 
field the use of endemic Mtb strains is very limited.
In chapter 9 we compared the in vitro activity of anti-TB drugs against five endemic Beijing 
genotype strains and five East-african/Indian genotype strains that were all drug-susceptible 
according to the currently-used drug susceptibility tests. The Beijing genotype strains 
showed high rates of mutation towards rifampicin within a wide range of drug concentra-
tions, possibly explaining this genotype’s association with MDR-TB. The increased mutation 
frequency only observed for the Beijing genotype strains showed the relevance of the use of 
different genotype strains, and may contribute to further insight in the mechanisms behind 
the Mtb genotype-associated resistance.
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To further investigate improvement of TB treatment and reduction of drug resistance in our 
TB infection murine model we decided to apply as infecting strains one Beijing genotype 
strain and one East-african Indian genotype strain instead of the in TB research traditionally-
used H37Rv Mtb strain. as described in chapter 10 both Mtb strains showed a high virulence 
in comparison to the H37Rv Mtb strain, resulting in a highly progressive infection with rapid 
lethal outcome in untreated mice. Full-compliance treatment was effective without relapse 
of TB irrespective the infecting strain, showing similar decrease of Mtb load in infected 
organs, and similar histopathological changes. non-compliance treatment, simulated by a 
reduced treatment duration and reduced dosing frequency resulted in relapse of infection. 
Relapse rates were correlated with the level of non-compliance and were identical for Beijing 
infection and East-african/Indian infection. However, in only Beijing-infected mice and not 
in EaI-infected mice isoniazid-resistant mutants were selected at the highest level of non-
compliance. This is in line with the substantial selection of isoniazid-resistant mutants in 
vitro in a wide isoniazid concentration window that we observed for the Beijing strain and 
not for the EaI strain. These results suggest that genotype diversity of Mtb may be involved 
in emergence of drug resistance and indicates that genotype-tailor-made treatment in TB 
should be investigated.
To improve TB treatment and reduce drug resistance there are many different approaches to 
achieve these goals such as the application of newly-developed drugs or novel drug combi-
nations. next, optimization of the dosage regimen of currently-used drugs also deserves full 
attention. For the last approach rifampicin is a good candidate drug, as we have shown for 
rifampicin in vitro a strong concentration- and time-dependent killing activity (chapter 7) 
and a high mutation frequency in the Beijing genotype strains (chapter 9). In chapter 11 we 
determined the optimal rifampicin dosage in mice with Beijing genotype infection, resulting 
in maximum therapeutic effect including prevention of relapse of infection, and without 
adverse effects. we concluded that the dosage of 10 mg/kg/day rifampicin, as currently used 
in the therapy of TB is too low. In Beijing genotype-infected mice a rifampicin dosage of 80 
mg/kg/day is far more effective without adverse effects, and enabled a significant reduction 
in therapy duration from 6 months to only 2 months.
175
Summarizing discussion
MAIn fInDInGS
– a model of TB infection induced through the natural respiratory route in BalB/c mice is 
developed, characterized and validated in terms of therapy response under treatment 
compliance and treatment non-compliance conditions. [chapter 2]
– The evaluation of the comparative therapeutic potential of novel anti-TB drugs in trans-
lational studies in mice should be performed in the same model, as the route of infection 
applied influence the course of infection and therapeutic response. [chapter 3]
– The course of infection in mice with relapse TB is different compared to primary TB in 
terms of a lower Mtb load and different histopathological and immunological character-
istics. However, the therapy response of the infected mice is equal irrespective relapse of 
TB or primary TB. [chapter 6]
– Based on results obtained in a murine TB model, no support can be given that there is 
a value of IGRa to accurately diagnose active TB or to monitor infection progression. 
However, IGRa showed to be a useful biomarker to monitor therapy success. [chapter 5]
– anti-TB drugs differ significantly regarding their concentration-dependent time-kill kinet-
ics. The metabolic state of Mtb significantly affects the drug susceptibility. [chapter 7]
– Optimization of anti-TB drugs dosage is required to achieve optimal drug concentrations 
at the site of infection in order to maximize reduction in Mtb load and to minimize the 
emergence and selection of drug-resistance. [chapter 7]
– Several genes associated with molecular efflux, cell membrane transport and virulence 
are altered in the rifampicin-resistant H37Rv mutant compared to the rifampicin-sensitive 
H37Rv wild type strain after exposure to rifampicin. Mtb mutants although being rifampicin-
resistant, still are influenced by rifampicin exposure at different genetic levels. [chapter 8]
– Beijing genotype Mtb strains show high rates of mutation frequency for rifampicin within 
a wide range of rifampicin concentrations, possibly explaining this genotype’s associa-
tion with multidrug-resistant TB. [chapter 9]
– In mice with a Beijing genotype TB infection and mice with an East-african/Indian TB 
infection relapse of TB is correlated with the level of non-compliance, irrespective the 
infecting strain. [chapter 10]
– Only in Beijing-infected mice at non-compliance treatment isoniazid-resistant mutants are 
selected, which is in line with the selection of isoniazid-resistant mutants in vitro that we 
observe for the Beijing strain only. This suggests that genotype diversity of Mtb is involved 
in emergence of drug resistance and indicates that genotype tailor-made treatment should 
be investigated. [chapter 10]
– The currently used rifampicin dosage in the therapy of TB is too low. In mice with Beijing 
genotype TB infection an 8-fold increased rifampicin dosage is far more effective without 
adverse effects, and enables a significant reduction in therapy duration from 6 months to 
2 months. [chapter 11]
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fuTuRE PERSPECTIvES
The in vitro and in vivo tools described in this thesis, were developed to gain insight in dif-
ferent aspects of Mycobacterium tuberculosis and TB infections, and were designed for stud-
ies to improve TB treatment and reduce drug-resistance in TB. The future perspective is to 
continue the studies by investigating different treatment approaches using new regimens of 
(combinations of ) anti-TB drugs aiming for 1) substantial reduction of treatment duration, 2) 
prevention of selection of resistant Mtb mutants, and 3) therapeutic success in the treatment 
of MDR-TB.
Our recent finding that a substantially increased therapeutic efficacy is achieved by simply 
increasing the dosage of rifampicin opens the door to other and new ways to achieve this 
goal. One approach might be the addition of efflux pump inhibitors or the use of cell wall 
destabilizing agents that increase bacterial cell wall permeability. Both will result in increased 
intracellular and/or intrabacterial concentrations of anti-TB drugs. also drugs relatively new 
in TB treatment like the oxazolidinones and newer fluoroquinolones should be further inves-
tigated. Combining the new drugs with efflux pumps inhibitors and/or cell wall destabilizers 
will possibly even further increase the therapeutic efficacy even in MDR-TB.
next to the application of more potent (combinations of ) drugs, the approach of drug target-
ing to the primary infected organs should be elaborated. In this respect pulmonary delivery 
of anti-TB drugs looks promising as it is expected to result in relatively high concentrations 
of anti-TB drugs in the lung without systemic toxic side effects. High anti-TB drug concentra-
tions in the lung will effect rapid decrease of the Mtb load resulting in reduced transmission 
of disease as well as reduction/prevention of selection of drug-resistant mutants. By using 
nanocarriers containing the most potent drug combinations in pulmonary delivery we ex-
pect to further increase the therapeutic effect.
To accelerate the search for a novel treatment approach and tackle pre-clinical research 
barriers two important initiatives, i.e. the Critical Path to TB Drug Regimens (CPTR) and the 
PreDiCT-TB consortium have been founded, both being consortia of academia and phar-
maceutical companies. In their approach of starting with back-validation of currently-used 
anti-TB drugs using existing in vitro and in vivo models in TB research, these models can be 
evaluated with respect to their prognostic and translational value as the drugs tested already 
have been used in clinical trials or even in large groups of TB patients with the clinical outcome 
known. The in vitro and in vivo models described in this thesis will be part of the PreDiCT-TB 
consortium, and in the novel treatment approaches the new anti-TB drugs developed by the 
pharmaceutical consortium partners will be included.
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Tuberculose (TBC) is een ziekte die bij veel mensen associaties en reacties zal oproepen 
zoals; ‘uit de tijd van mijn grootouders’, ‘de oude kuuroorden in de alpen’ of ‘betaat die ziekte 
nog?’ De keiharde waarheid is dat TBC nog jaarlijks, wereldwijd zo’n 1.6 miljoen slachtoffers 
eist. Daarmee is TBC, na HIV/aids, de op één na dodelijkste infectieziekte van dit moment. 
Volgens schattingen van de wereldgezondheidsorganisatie (wHO) zijn er jaarlijks zo’n 9 
miljoen nieuwe gevallen van TBC, die allemaal een hoge ziektelast met zich meebrengen. De 
bacterie die TBC veroorzaakt is Mycobacterium tuberculosis (Mtb). Het is bekend dat slechts 
een relatief klein deel (5-10%) van de mensen die geïnfecteerd raakt met deze bacterie ook 
daadwerkelijk TBC ontwikkelt. Een heel groot deel van de mensen draagt de bacterie bij zich 
maar wordt er niet ziek van; die mensen ontwikkelen geen actieve TBC; men noemt dit dan 
een latente TBC infectie. De wHO schat dat ongeveer éénderde van de wereldbevolking zo’n 
latente TBC infectie heeft. Er is dus een enorm grote groep van mensen die mogelijk actieve 
TBC kunnen ontwikkelen als hun afweersysteem minder goed wordt. Dysfunctioneren van 
het afweersysteem kan gebeuren bij voorbeeld bij mensen die door hogere leeftijd altijd 
al een minder goed afweersysteem hebben of bij personen met een HIV infectie. Juist die 
laatste groep is in de laatste 25 jaar toegenomen en vormt een probleem voor het in de hand 
houden / verminderen van de wereldwijde TBC epidemie. HIV/aids en TBC gaan (helaas) hand 
in hand en zijn samen een dodelijke combinatie.
naast de schrikbarend hoge cijfers van mortaliteit en morbiditeit (sterfte en ziektelast) van 
TBC, is er de laatste jaren een nieuw probleem bij gekomen: de resistentie voor antibiotica. In 
korte tijd heeft de Mtb zich weten te ontwikkelen tot een bacterie die veel minder gevoelig 
is voor verschillende antibiotica. De bacterie wordt dan resistent genoemd. Hoewel het 
arsenaal aan antibiotica waarover we beschikken groot is, is het aantal antibiotica waarmee 
patiënten met TBC kunnen worden behandeld redelijk beperkt. unieke eigenschappen in de 
celwand van Mtb zorgen ervoor dat veel beschikbare antibiotica niet of nauwelijk werkzaam 
zijn.
De huidige 4 antibiotica die in combinatie als standaard therapie gegeven worden voor TBC 
zijn isoniazide (InH), rifampicine (RIF), pyrazinamide (PZa) en ethambutol (EMB). De duur van 
therapie is bij actieve TBC ten minste 6 maanden, waarbij 2 maanden InH, RIF, PZa en EMB 
gegeven wordt, gevolgd door 4 maanden InH en RIF. Hiermee is het een langdurige en inge-
wikkelde therapie, met als gevolg dat de behandeling vaak niet volledig wordt afgemaakt. 
Het gevolg van deze ‘therapie-ontrouwheid’ is dat patiënten weer ziek worden (relaps TBC) 
en dat de bacterie door de onvolledig gevolgde behandeling minder gevoelig of ongevoelig 
(resistent) voor de antibiotica is geworden.
al met al ziet het er naar uit dat, na de tijd van onze grootouders en de kuuroorden in de 
alpen, we nu staan voor een immens probleem van TBC dat nog lang niet uit de wereld is en 
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waarvan de behandeling door de toenemende antibiotica resistentie wereldwijd ons voor 
grote problemen stelt. Het proefschrift PREDICT TB, beschrijft een aantal studies waarmee 
we hopen onze bijdrage te kunnen leveren aan de wetenschap aangaande TBC, opdat in 
de toekomst deze ziekte effectiever én in een kortere periode te behandelen is, zodat onze 
kleinkinderen met trots kunnen zeggen: TBC was een ziekte uit de tijd van onze grootouders!
In de hoofdstukken 2 en 3 beschrijven we de door ons ontwikkelde TBC modellen in 
proefdieren (muizen). Studies in diermodellen zijn nodig om beter inzicht te krijgen in hoe 
verbetering kan worden verkregen in de TBC diagnostiek in het laboratorium en de behande-
ling van de patiënt. Bij de opzet van onze TBC modellen hebben we beoogd dat het begin en 
het verloop van de ziekte in de muizen zoveel mogelijk lijkt op dat in de mens, opdat we de 
resultaten verkregen in de muis met TBC zo goed mogelijk kunnen vertalen naar verbetering 
in diagnostiek en behandeling van de mens met TBC.
In hoofdstuk 6 gaan we nog een stukje verder. Daar vergelijken we het verloop en de behan-
deling ‘primaire TBC’ (‘voor het eerst verkregen TBC’) met ‘relaps TBC’ (‘het weer terugkrijgen 
van de TBC omdat de behandeling van de primaire TBC niet goed is geweest’). Onze studies 
geven inzicht in de verschillen in karakteristieken van beide vormen van de infectie en in 
effectiviteit van de behandeling.
hoofdstuk 4 en 5 hebben als focus de problemen die er zijn met adequate diagnostiek 
van actieve TBC. kweken van de bacterie uit opgehoest sputum van de patiënt (de gouden 
standaard methode) duurt lang, en de waarde van nieuwe, meer gevoelige en snellere tech-
nieken waarbij je het Dna van de bacterie aantoont (bijvoorbeeld PCR) is nog niet helder. In 
hoofdstuk 4 illustreren we dit aan de hand van een moeilijke patiëntcasus met TBC, die zich 
presenteerde in het Sofia kinderziekenhuis.
Ook voor de diagnostiek van latente TBC zijn er nieuwe tests en technieken in ontwikkeling. 
In hoofdstuk 5 bestuderen we een van de nieuwe tests: de IGRa (Interferon Gamma Release 
assay) in ons TBC diermodel. we concluderen dat in de muis de IGRa niet bruikbaar is om 
actieve TBC aan te tonen. Hiermee is de boodschap voor de kliniek dat de bruikbaarheid van 
de IGRa in de diagnostiek van actieve TBC nog moet worden onderzocht, ook al is de rol van 
deze test in het aantonen van latente TBC bewezen. In de muis bleek de IGRa wel een goede 
maat om het succes van de behandeling van TBC vast te stellen. Een goede basis om dit ook 
in TBC patiënten te onderzoeken.
In hoofdstuk 7 onderzoeken we diepgaand de verschillen in werkzaamheid van de antibio-
tica die op dit moment worden toegepast in de behandeling van TBC. Dit is een belangrijke 
basis om te kunnen nadenken over en werken aan nieuwe en alternatieve vormen van be-
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handeling van TBC. In het diagnostisch laboratorium wordt tot nu toe alleen in een beperkte 
opzet gemeten of de toegepaste antibiotica de Mtb in de groei remmen. In hoofdstuk 7 
hebben wij ons verdiept in de bacteriedodende werking bij meerdere concentraties van an-
tibiotica, en op meerdere tijdstippen gemeten. Daarbij is ook gelet op het mogelijk ontstaan 
van antibioticum-resistente bacteriën, en zo ja onder welke condities van blootstelling aan 
antibiotica dit gemakkelijk kan ontstaan. Grote verschillen worden er gevonden voor de ver-
schillende antibiotica met betrekking tot hun concentratie-afhankelijke en tijd-afhankelijke 
bacteriedodende activiteit. Tevens blijkt er een sterk verschil te zijn tussen de omstandighe-
den waaronder er selectie van resistentie kan optreden. Dit verdiepend inzicht is van belang 
bij het ontwerp van nieuwe alternatieve therapieschema’s.
Studies van anderen, en ook onze eigen studies (hoofdstuk 7 en 9) hebben laten zien dat 
rifampicine, één van de twee hoekstenen van de TBC therapie, een belangrijke rol heeft in 
de resistentie problematiek in TBC. Daarom hebben we ons in hoofdstuk 8 toegespitst op 
rifampicine resistentie en de gevolgen die dat heeft op genetisch niveau. Het blijkt dat naast 
bekende resistentie genen (stukjes Dna die informatie bij zich dragen over de opbouw van 
de bacterie) er ook een aantal genen veranderen die coderen voor cel membraan transport, 
moleculaire efflux en virulentie factoren. we concluderen dat bacteriën, ook al zijn ze resis-
tent voor rifampicine, nog steeds veranderen onder invloed van rifampicine. Mogelijk zijn 
deze veranderingen en de eiwitten die daarvoor verantwoordelijk zijn een doelwit voor het 
ontwikkelen van nieuwe geneesmiddelen.
In hoofdstuk 9, 10 en 11 richten we ons op klinisch-relevante Mtb stammen die veel voorko-
men in TBC endemische gebieden, moeilijk behandelbaar zijn, en gemakkelijk antibioticum 
resistentie ontwikkelen.
In hoofdstuk 9 hebben we bacteriestammen uit de Beijing-groep die veel voorkomen en 
prominent geassocieerd zijn met verkrijgen van antibiotica-resistentie vergeleken met bac-
teriestammen uit de East-african/Indian (EaI) groep, ook veel voorkomend maar niet geas-
socieerd met deze resistentieproblematiek. Een opmerkelijke bevinding is dat vooral in de 
stammen uit de Beijing-groep de genen heel gemakkelijk en snel muteren (veranderen), wat 
gemakkelijk tot resistentie leidt. Het is ook een opmerkelijk brede antibioticum concentratie-
reeks waarbinnen de resistentie vorming blijkt te gebeuren. Met dit laboratorium onderzoek 
kunnen we dus een mogelijke verklaring geven voor de in-de-bacterie gevonden associatie 
met resistentie in de dagelijkse praktijk.
In navolging hebben we in hoofdstuk 10 onderzocht in het muis TBC model of het verloop 
van de infectie, wanneer veroorzaakt door de Beijing stam, anders is dan wanneer veroorzaakt 
door de EaI stam. Er blijkt geen verschil te zijn, evenmin in de effectiviteit van de behandeling 
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mits die volledig wordt gevolgd. Echter, in geval van een niet volwaardige behandeling (te 
korte duur en te weinig doses, als simulatie van een therapie-ontrouwe patient) dient de 
resistentie problematiek zich aan in de Beijing infectie, maar niet in de EaI infectie.
we weten dat therapie-ontrouw bij de TBC patiënt in de endemische gebieden nog altijd 
een realistisch gegeven is en dat nieuwe krachtige middelen (nog) niet beschikbaar zijn voor 
behandeling. Voor ons is het dan ook de ultieme uitdaging om, met onze verkregen kennis 
aangaande rifampicine, in het model van de Beijing infectie te onderzoeken wat de waarde 
is van intensivering van de rifampicine behandeling. Het doel van dit onderzoek, beschreven 
in hoofdstuk 11, was een succesvolle behandeling te verkrijgen met een hogere dosering 
van rifampicine bij een korte behandelingsduur. De resultaten laten zien dat een therapie 
verkorting van 6 naar 2 maanden gepermitteerd is mits een 8-voudige toename van de rifam-
picine dosering gegeven wordt; de behandeling die door de muizen goed wordt verdragen 
is succesvol, er is geen relaps van TBC 3 maanden na beëindigen van de behandeling, en er is 
geen ontwikkeling van resistentie.
we hopen dat met boven beschreven onderzoek we een aantal puzzelstukjes hebben aange-
leverd, en dat de grote puzzel die tot eradicatie van TBC wereldwijd moet leiden verder kan 
worden gelegd.
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